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Aim and outline of this thesis 
 
Despite ongoing efforts to find new drugs and tools in the battle against cancer, it remains 
one of the leading causes of morbidity and death worldwide. A more recent treatment approach, 
cancer immunotherapy, harnesses the patient’s own immune system to fight the tumor. Ever 
since, cancer immunotherapy is booming and various novel therapeutic moieties emerge based 
on the adoptive transfer of ex vivo modified immune cells, or on the delivery of recombinant 
proteins for the induction or blockage of specific pathways involved in immunity. This field is 
moving fast, new targets are virtually being discovered daily, various immunotherapeutics have 
made their way into clinical trials and even some of them have been granted approval for clinical 
use in patients. As a result, immunotherapy was named “Breakthrough of the year 2013” by 
Science Magazine.  
One of these immunotherapeutic strategies is the use of dendritic cell-based vaccines. 
Here, the key initiators of immune responses, the dendritic cells, are modified ex vivo so that 
they start presenting tumor antigens and evoke specific antitumor immunity. Although promising 
results are accumulating, these cellular vaccines face a number of problems which are mainly 
associated with their cumbersome and patient-specific production. In addition, when these 
modified cells are injected as a vaccine, they often experience difficulties to reach their 
anatomical target sites in vivo.  
To address these issues, the aim of this thesis is to design biomaterial solutions to 
overcome these problems associated with current cancer vaccines. More specifically, we will 
develop theranostic strategies that allow the induction of anticancer immunity by targeting 
dendritic cells, while simultaneously providing real-time feedback via non-invasive diagnostic 
imaging techniques.  
Chapter 1 provides a general introduction to the two main topics that are addressed in 
this thesis. Firstly, an overview of current cancer immunotherapy is given, including a summary 
of how dendritic cells can evoke antitumor immune responses. Moreover, the rational design of 
biomaterials that can be used for this purpose will be discussed. Secondly, the concept of 
therapeutic imaging will be introduced. The two key diagnostic imaging techniques employed 
in this thesis, magnetic resonance imaging and ultrasonography, will be highlighted. The 
application of contrast agents for both imaging methods is addressed, as well as how these 
diagnostic agents can be used for therapeutic imaging.  
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Importantly, when novel cancer vaccination strategies are investigated, the initial 
experiments are usually performed on in vitro cultured cells. However, it is crucial to realize that 
the use of in vitro model dendritic cells is associated with a number of limitations. The effects 
of small variations in cell culture circumstances on the way these cells behave in vitro will 
therefore be discussed in Chapter 2.  
Taking these pitfalls into account, we will evaluate two different kinds of therapeutic 
imaging methods for immunotherapy. In Chapter 3, the use of liquid perfluorocarbon droplets 
as imageable antigen-delivery systems is explored. This way, we aim to produce traceable 
dendritic cell vaccines which could allow non-invasive tracking of the migration and faith of the 
injected antigen-laden dendritic cells in vivo using fluorine MRI.  
This strategy, however, still requires the ex vivo modification of dendritic cells, and 
therefore does not solve all the issues associated with cellular vaccines. For that reason, a 
second therapeutic imaging strategy will be implemented for immunotherapy: the use of 
microbubbles for ultrasound-guided, ultrasound-triggered delivery of antigens and immune 
adjuvants to dendritic cells in vivo. Therefore, in Chapter 4, we will develop mRNA-loaded 
microbubbles for the ultrasound-mediated delivery of antigen-coding mRNA, and evaluate their 
potential in dendritic cell cultures in vitro. In Chapter 5, these microbubbles will be further 
modified to carry antigen mRNA as well as adjuvant mRNA for the simultaneous transfection 
and immunomodulation of dendritic cells. Furthermore, we will evaluate whether cells that were 
modified in this way, can indeed trigger antitumor immunity in vivo. Finally, Chapter 6 will 
provide a first step towards the immediate in vivo application of this transfection strategy. For 
this, we aim to investigate if these theranostic mRNA-loaded microbubbles can reach the lymph 
nodes upon subcutaneous injection, and whether their migration can be visualized via contrast-
enhanced ultrasonography.  
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Chapter 1 
 
A general introduction to  
cancer immunotherapy and 
therapeutic imaging 
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ABSTRACT  
Over the years, research in the field of cancer immunotherapy has flourished, bringing 
about crucial breakthroughs, but at the same time revealing the drawbacks of current ex vivo 
approaches that put a break on the successes obtained with cellular vaccines. This chapter 
focuses on how immunotherapy can be induced by targeting dendritic cells, and how nano- and 
micromaterials can be designed for this purpose.  
In addition, an overview of therapeutic imaging is provided, highlighting the strengths of 
imageable and image-guided drug delivery using MRI and ultrasound. The basic principles of 
both imaging techniques are addressed and the evolution in the design of contrast agents and 
relevant therapeutic imaging moieties is described.  
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PART 1: CANCER IMMUNOTHERAPY 
 
 
CANCER IMMUNOTHERAPY ON THE RISE  
Cancer is still one of the leading causes of death in the Western world, and besides the 
enormous impact is has on the patients (both physically, mentally and financially), it is also a 
major challenge for society. For example, for 2008, the American Cancer Society calculated 
the total economic impact of premature death and disability from cancer worldwide was $895 
billion, not including direct medical costs (www.cancer.org)1. In addition, current treatments 
such as surgery, radiotherapy and chemotherapy have their limits. Especially the occurrence 
of metastatic disease has a detrimental impact on the patient’s prognosis. As a result, novel 
treatment strategies are being investigated and explored. One of these new approaches is 
cancer immunotherapy, where the patient’s immune system is enlisted in the battle against the 
tumor. It holds a number of important advantages over current therapies, including its 
selectivity, the fact that it is a systemic approach that can tackle both the primary tumor as well 
as metastatic lesions and the build-up of an immunological memory which could offer long-term 
protection against relapse.  
The initial idea of exploiting the immune system to combat cancer, originated in the early 
1800s, when Dr. Wiliam Coley achieved (limited) antitumor effects by injecting microbe-derived 
toxins2. Since then, the field of cancer immunotherapy has evolved drastically, mainly due to a 
number of crucial breakthroughs in our understanding of the complex function of the immune 
system, a number of which are listed in Figure 1.  
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Figure 1. Timeline overview of important discoveries and milestones that have 
shaped cancer immunotherapy today3-7. 
An essential step forward was the identification of dendritic cells (DCs) as the initiators of 
immunity. These cells form a bridge between innate and adaptive immunity by capturing 
antigens and efficiently presenting them to T cells in specialized molecules called major 
histocompatibility complexes (MHCs). Depending on the intracellular location of the antigenic 
protein, presentation will occur either in MHC-I, for cytoplasmic proteins, or in MHC-II for 
exogenous antigens, which have been endo- or phagocytosed by the cell. Once the antigen-
MHC complexes are translocated to the DC surface, the presented antigen can be recognized 
by CD8+ or CD4+ T cells in case of MHC-I or MHC-II presentation, respectively. Importantly, 
these antigen-presenting cells (APCs) are unmatched in their capacity to activate naïve 
antigen-specific T cells: DCs are the only cell type that can provide the necessary co-stimulatory 
signals (e.g. ligation of CD86 or CD80 on the DC surface to CD28 on the T cell membrane), 
chemokines (e.g. IP-10 and MIG) and cytokines (e.g. type I IFN and IL-12) required for T cell 
stimulation. This way, DCs can initiate proliferation and differentiation of antigen-specific CD8+ 
T cells into cytotoxic T lymphocytes (CTLs), and CD4+ T cells into helper T cells (Th)4. An 
overview of the ways DCs present antigens and induce T cell responses is presented in 
Figure 2. 
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Figure 2. Antigen presentation and T cell activation by DCs.  
Cytoplasmic antigens (e.g. proteins produced within the cell’s cytoplasm) are cleaved into 
peptides which can be presented in MHC-I complexes at the DC surface. There, they can 
be recognized by antigen-specific CD8+ T cells. When these cells receive co-stimulation 
from the DCs, they will become activated and differentiate into CTLs. Engulfed 
extracellular antigens on the other hand, are presented in MHC-II. The antigens can then 
be recognized by the T cell receptors (TCRs) of CD4+ T cells. Upon activation, these 
differentiate into Th1 or Th2 cells, depending on the local cytokine environment. Through 
cross-presentation, a process that exclusively occurs in potent APCs, extracellular 
antigens can be diverted towards MHC-I presentation.  
In the meanwhile, researchers were looking into the Achilles’ heel of tumor cells. For long, 
the existence of tumor-associated antigens (TAAs), which are selectively or preferentially 
expressed by tumor cells, was presumed but not proven. As early as 1905, Clowes and 
Baeslack reported that immunity occurred in mice that spontaneously recovered from their 
tumor burden8. This was further evidenced by Gross’ experiments in 1943, who proved that 
somehow the immune system of mice was capable of recognizing and rejecting implanted 
tumors9. However, it was only in the early 1990s that the first sets of human TAAs against which 
CTL responses could be mounted, were actually identified10, 11.  
Taken together, the weak spots of tumor cells and the strengths of our immune system 
were exposed. By combining these novel insights, the road to the development of new 
therapeutic strategies that exploit the patient’s immune system to selectively recognize and 
destroy tumor cells was paved.  
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DENDRITIC CELL-BASED IMMUNOTHERAPY 
The identification of DCs as the initiators of immunity made them interesting targets in 
cancer immunotherapy. Not so long after their discovery, the first report on DC-based 
vaccination was published12. In DC-based vaccination, DCs are modified to present TAAs to T 
cells, resulting in TAA-specific CTL activation. The production of such cellular vaccines requires 
loading of the DCs with TAAs, after which the cells need to be matured, in order to become 
potent APCs.  
With regards to the antigen-loading of DCs, various strategies have already been 
explored. The earliest studies made use of tumor lysates as a source of antigen. Later on, 
based on the identification and sequencing of TAAs, recombinant antigens or antigen-derived 
peptides were produced and passively pulsed into DCs. More recently, researchers have 
moved on to the use of viral vectors for the delivery of DNA or RNA encoding TAAs13, 14. Due 
to safety issues associated with the use of these pathogen-based delivery systems, the use of 
non-viral carriers for the delivery of DNA and RNA is currently under investigation.  
After antigen-loading, the DCs are exposed to maturation stimuli. These can be pathogen 
or danger-associated molecular patterns (PAMPs and DAMPs respectively), that can bind to 
the DCs’ pathogen recognition receptors (PRRs) and initiate an intracellular cascade resulting 
in the production of pro-inflammatory cytokines, increased antigen-presentation and 
augmented expression of co-stimulatory molecules (e.g. CD40, CD80, CD86) and chemokine 
receptors (e.g. CCR7). The mature antigen-presenting DCs can then be injected as therapeutic 
cancer vaccines. The initial results were promising, and in 2010, years of research in this field 
were rewarded by the food and drug administration (FDA) approval of the first DC-based 
vaccine: Provenge® (Sipuleucel-T, marketed by Dendreon)15. Figure 3 is a schematic 
representation of how these DC-based vaccines are generally produced. 
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Figure 3. Production of ex vivo generated DC-based cancer vaccines.  
Peripheral blood monocytes (PBMCs) are collected from a cancer patient via 
leukapheresis. By culturing these cells with cytokines, they can be differentiated into 
monocyte-derived DCs (MoDCs). These can subsequently be loaded with TAAs and 
maturation stimuli after which the mature antigen-presenting DCs can be reinfused as a 
therapeutic vaccine.  
Although DC vaccine research is flourishing, a number of important drawbacks hinder the 
applicability of current DC-based vaccines. First of all, and this might even be the most limiting 
factor, all the modification steps described above (i.e. antigen-loading and maturation), are 
performed on isolated cells in vitro. This way, the production of these vaccines is labor-
intensive. In addition, working with isolated cells makes these therapeutics patient-specific. For 
every other patient, cell isolation, antigen-loading and maturation needs to be repeated, which 
adds to the production costs of the vaccines. To give an illustration, the costs for a full round of 
Provenge® treatment are currently set at $93,000 (~ €70,000), not including hospital and 
physician fees. Thirdly, it was shown that upon subcutaneous injection of the cellular vaccine, 
DC survival and migration towards the lymph nodes, where T cell activation occurs, is poor. 
Merely 5% of the transferred cells are capable of reaching the lymphatics, requiring the use of 
large numbers of antigen-modified cells in order to establish therapeutic effects16. As a result, 
only cells that can be isolated in sufficient numbers can be employed. For primary plasmacytoid 
or “conventional” DCs, this is a challenge, therefore researchers have chosen for a long time 
to use monocyte-derived DCs (MoDCs). These cells are obtained by isolating a patient’s 
peripheral blood monocytes (PBMCs) and culturing them with cytokines (GM-CSF with or 
without IL-4) to stimulate their differentiation into MoDCs. These cells, however, do not show 
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the same phenotypic properties as most of the lymphoid-resident DCs, but rather correspond 
to “emergency DCs” which are usually only detected at sites of inflammation17. This, together 
with loss of activation of the cells once injected, and insufficient cytokine production by the in 
vitro modulated cells, has sparked interest to find ways of loading antigens into various 
circulating DCs subsets in vivo18, 19.  
ADVANTAGES OF PARTICULATE SYSTEMS FOR DC VACCINATION IN VIVO 
The search for in vivo antigen-delivery techniques promptly resulted in the production of 
nanoparticles (NPs) and microparticles (MPs) to carry antigenic material towards DCs in the 
skin or the lymphatics, since the use of particle structures offers many important benefits over 
the delivery of free antigen. Before describing the advantages of particulate vaccines, it should 
be noted that a number of prerequisites will determine whether these particulate cancer 
vaccines are indeed able to induce potent immune responses in vivo. 
A first important point is that many novel antigen-delivery systems are still entirely 
evaluated in vitro on murine or human DCs that were generated from bone marrow or blood 
precursor cells, respectively. Indeed, a thorough characterization of the materials with respect 
to their capacity to encapsulate antigen and/or adjuvant, their stability, uptake by DCs and 
antigen-transfer to these cells is routinely performed in vitro. However, purely in vitro testing 
comes with a number of pitfalls. First of all, it should be noted that in vitro generated DCs need 
to be considered as models for a complex in vivo situation where numerous types of DCs exist20-
22. In addition, for murine bone marrow-derived DCs, it was reported that slight variations in cell 
culture protocol resulted in large variation in the phenotype of the generated cells, as well as in 
their capacity to respond to particulate antigen23. Moreover, in vitro experiments evaluating the 
particle’s characteristics and uptake by DCs are often exclusively performed in serum-free 
media, making it even more difficult to draw conclusions on their in vivo behavior. Therefore, in 
vitro validation of new carriers should comprise proof of the compatibility of the carrier with 
biological fluids with respect to particle aggregation, size and antigen release kinetics. For 
example, cationic particles are often used for electrostatic binding of antigenic protein or nucleic 
acids encoding antigens. Without additional surface modifications, such as grafting 
polyethylene glycol (PEG) chains on the outer particle surface to provide the particle with a 
hydrophilic shield that reduces the particles’ surface charge, these structures tend to quickly 
aggregate upon contact with serum proteins. This can result in premature antigen release and 
a change in particle size, which leads to different cellular uptake and antigen transfer kinetics24, 
25.  
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Secondly, the aim of antigen-loaded particles is to deliver the antigenic material to APCs 
so they can induce potent antitumor immune responses. Importantly, evidence emerged 
indicating that potent immune responses can only be mounted when antigens are presented to 
T cells by mature DCs. In fact, where mature DCs stimulate antitumor immunity, antigen-
presentation by their immature counterparts will rather lead to tolerance and suppression of 
effector antigen-specific T cells26, 27. The process of DC maturation is complex, finally resulting 
in a complete shift of the cell’s function towards antigen presentation. Thus, fully mature DCs 
are characterized by (a) combined up-regulation of numerous co-stimulatory molecules (e.g. 
CD40, CD80, CD86), (b) cytokine production (e.g. IL-12p70 and IL-6) and (c) increased 
migratory capacities for their translocation to the T cell areas of the lymph nodes. Only when all 
of these processes occur simultaneously, are DCs considered as fully mature and are they 
expected to be able to mount potent antitumor immune responses. Thus, an in vivo applicable 
particulate system for DC vaccination should not only deliver antigen, but also exhibit immune 
adjuvant effects and induce complete maturation of the antigen-loaded DCs. Whether NPs and 
MPs as such possess intrinsic adjuvant activity is a recurring topic of discussion. Thorough 
comparisons of the various reports are difficult to make due to the plethora of confounding 
factors (e.g. particle size, surface charge, production methods, additional surface modifications) 
that prevent unbiased conclusion-drawing. Hence, the opinions on carrier-related auto-
adjuvancy remain divided: cationic liposomes might induce surface charge density-related DC 
activation28-30, others show exactly the opposite, pointing towards enhanced adjuvancy of 
neutral or anionic liposomes 31. Similar debates arose for Poly(lactic-co-glycolic) acid (PLGA) 
capsules, another commonly investigated antigen-carrier. Whereas Sharp et al. pointed out that 
PLGA could induce significant cytokine production32, many other researchers could not observe 
any PLGA-induced DC maturation or cytokine secretion33. For most particles, however, it is 
clear that stimulation of DC maturation by including adjuvants will result in the production of 
more effective particulate vaccines. Of note, it was demonstrated that it is crucial to deliver 
antigen and adjuvant to the same intracellular compartment to obtain both CD4+ and CD8+ T 
cell activation34. Schlosser and colleagues investigated the effect of delivering antigenic protein 
and adjuvant (CpG oligodeoxynucleotides (ODNs), a toll-like receptor 9 (TLR9) agonist or 
Poly(I:C), a known TLR3 agonist) packaged in separate PLGA microspheres, or co-formulated 
within the same microsphere. As expected, co-encapsulation of antigen with a TLR agonist 
significantly improved antigen (cross-)presentation and induction of potent CTL responses in 
vivo35. Similar results demonstrating the need for physical association of antigen, carrier and 
adjuvant were obtained for liposomal NPs by Zaks et al.36. Therefore, particles should be co-
formulated with both antigen and PRR agonists (often TLR agonists). In this way, a three-
component system is produced, containing (a) a target antigen, which will steer the immune 
responses towards the cancer cells, (b) an immune potentiator to enhance the antigen-specific 
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immune responses, and (c) a suitable particulate carrier to deliver antigen and adjuvant to the 
DCs at the site of interest.  
Thirdly, choosing a potent adjuvant is crucial, and this could also become a pitfall in 
particle design. Firstly, it is important to consider that not all TLRs are expressed by all DC 
subsets. Therefore, rational design and adjuvant selection based on the subset of DCs that will 
be targeted by the particulate vaccine in vivo are key. Moreover, the cellular location of the TLR 
which is targeted by the adjuvant-particle composite can also play a role. This is exemplified by 
the work of Bal and colleagues, who evaluated liposomal formulations containing either 
Pam3CSK4 (a TLR2-1 agonist) or CpG ODNs (a TLR9 agonist). They observed that the delivery 
of adjuvants to endosomal TLRs, such as TLR3, 7, 8 and 9 benefit more from the liposomal 
delivery than adjuvants to TLRs that are located on the cell surface. As a result, liposomal 
encapsulation of CpG ODNs resulted in prominently better results over liposomal Pam3CSK437. 
Furthermore, there are differences in TLR expression on mouse and human DC subsets. For 
instance, TLR9, receptor to the popular adjuvant CpG ODNs, is absent on most human DC 
subtypes38. Careful and critical interpretation of immunological effects observed in mouse 
models is therefore warranted. An overview of the TLRs, their cellular location and commonly 
used agonists is given in Figure 4. 
 
Figure 4. Cell membrane and endosomal TLRs can ligate to a variety of agonists.  
By using these agonists as immune adjuvants, DC maturation can be induced and 
antigen-presentation and stimulation of antigen-specific T cells becomes possible.  
(Abbreviations: PAM = Pam3CSK4; MPLA = monophosphoryl lipid A) 
Taking the pitfalls of in vitro-in vivo translation and the requirement for simultaneous 
antigen and adjuvant delivery into account, the following sections will describe the advantages 
of different biomaterials for vaccination purposes, and the different strategies that are used to 
enhance the particulate’s immunogenicity. An overview of different carrier-antigen-adjuvant 
combinations that have been designed and evaluated, is listed in Table 1. 
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Table 1: Particulate carriers for simultaneous antigen and adjuvant delivery to DCs 
in vivo. 
Passive DC targeting and the loophole of cross-presentation.  
  
Carrier  Particle-related advantages 
Antigenic 
cargo 
Combined immune adjuvants 
PLGA 
Antigen release rate can be 
modified by tweaking the ratio 
of glycolic acid to lactic acid 
Protein 
CpG ODNs35, 39, 40 
Poly(I:C)35, 39 
Poly(I:C) combined with resiquimod 
(R848)41 
R84840 
Tumor 
lysate 
CpG ODNs42 
Peptide 
MPLA43 
CpG ODNs44 
pDNA 
GpG + IL-10 siRNA45 
Poly(I:C) + IL-10 siRNA45 
Liposomes 
Easy modification and 
production 
Possible auto-adjuvancy 
(depending on the liposome’s 
physicochemical properties)29, 
37, 46 
Protein 
MPLA47 
non-coding DNA36 
CpG ODNs36, 37, 48, 49 
Poly(I:C)36, 49, 50 
TDB (C-type lectin ligand)49 
PAM3CSK4 (PAM)37 
Cationic lipid (3,5-
didodecycloxybenzamidine, TRX)30 
Peptide 
Non-coding DNA36 
CpG ODNs36, 51 
Poly(I:C)36 
Cubosomes 
Increased encapsulation 
compared to liposomes 
Protein MPLA + imiquimod52 
Gold NPs 
NP size is easy to control 
Tracking via computed 
tomography (CT) imaging 
Protein CpG ODNs53, 54 
Bacterial 
magnetic 
particles 
Enhanced gene delivery by 
magnet application 
Auto-adjuvant effects 
pDNA Auto-adjuvant55 
Polymeric 
micelles 
High protein loading capacity 
Auto-adjuvant effects 
Protein 
Auto-adjuvant56 
Poly(I:C)56 
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A first advantage of formulating antigens in particles, is that by packaging the antigenic 
material in larger constructs, antigens are passively targeted towards phagocytic APCs and can 
be considered for cross-presentation. In general, exogenous antigenic material that is taken up 
by DCs via phagocytosis or endocytosis will end up in the MHC-II presentation pathway, leading 
to the activation of Th cells. Cytoplasmic proteins, on the other hand, can be presented in MHC-
I and result the induction of CTLs. Cross-presentation acts as a loophole in these pathways, 
allowing exogenous antigens to be redirected towards MHC-I (as previously depicted in 
Figure 2). How exactly phagocytosed or endocytosed antigens find their way into MHC-I 
presentation remains vague, although increasing evidence demonstrates the involvement of 
phagosomes, early endosomes and autophagosomes57-59. By formulating antigens into NPs 
and MPs, these cross-presentation-competent organelles can be targeted, resulting in 
activation of both CTLs (via MHC-I) and long-lasting memory T cells (via MHC-II)60. The role of 
particulate delivery systems in governing antigen-presentation can be illustrated by the 
research of Stano et al. They elegantly showed that the use of solid-core NPs where antigen is 
attached to the particle surface, preferentially leads to CD4+ T cell activation, whereas 
administration of NPs that encapsulate the antigen within their watery core primarily results in 
CD8+ responses. As a result, the authors propose co-administration of both antigen-loaded 
particles since these result in superior immune responses with both CD4+ and CD8+ 
properties61. Additional modifications can be made to nanoparticulate vaccines to promote 
cross-presentation. An example is the inclusion of pH-sensitive polymers into liposomes. After 
endocytic uptake, the reduced endosomal pH will activate the fusogenic potential of these 
polymers, causing disruption of the endosomal membrane and cytoplasmatic delivery of the 
antigenic material. In this way, antigen presentation via the MHC-I pathway is stimulated, and 
enhanced CTL induction could be achieved30, 62. Of course, this specifically applies for protein 
antigen delivery. When antigen-encoding DNA or RNA are delivered, this problem completely 
turns upside down, as the cytolpasmatic protein production upon nucleic acid delivery will favor 
the MHC-I presentation pathway. Here, strategies that target the produced antigens to the 
MHC-II pathway (e.g. via attachment of lysosome-targeting sequences) in order to call for T cell 
help can be applied63.  
Protection of antigen integrity and tuning antigen-release kinetics.  
Secondly, encapsulating antigens in particles protects them from premature degradation 
and enables modulation of the antigen delivery kinetics. Antigens that are packaged within NPs 
or MPs are shielded from digestive enzymes (proteases and nucleases) that are ubiquitous in 
blood and interstitial fluid. This is especially important for the delivery of nucleic acids (i.e. DNA 
or RNA encoding tumor antigens) to DCs, which are much more prone to premature 
degradation. The kinetics of antigen presentation were also shown to exert a major effect on 
the strength, duration and memory of the induced immune responses. For example, Johansen 
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and colleagues showed that dose-escalating antigen contact resulted in much stronger CD8+ T 
cell responses compared to single-shot antigen delivery64. Therefore, particles that result in a 
burst release of the antigenic material upon engulfment by DCs, will induce less pronounced 
immune responses compared to sustained release particles. This was evidenced by Demento 
et al., who compared immune response induction by liposomal (fast release) versus slow 
release PLGA-based protein delivery. Indeed, mice vaccinated with liposomes exhibited lower 
and shorter-lived antibody titers and a lower frequency of memory T cells compared to PLGA-
vaccinated mice. Similar observations were made when slow and fast-release PLGA particles 
were compared65. Thus, tweaking the release kinetics of the encapsulated antigen can augment 
antitumor immunity. As a result, clever modifications to basic polymer and liposome structures 
to ensure longer antigen-retention and controllable antigen release have been reported. For 
example, Moon et al. created covalent crosslinks between different bilayers of multilamellar 
liposomes in order to slow down the release of antigen47. Another considerable option to 
achieve longer-term antigen presentation by DCs, is to use nucleic acid-based vaccines instead 
of protein or peptide vaccines. In addition to favoring MHC-I antigen presentation, as discussed 
in the previous section, genetic vaccines can prolong the duration of antigen presentation and 
subsequently the activation of CTLs. This was demonstrated in a comparative study of Liao et 
al. where a sustained period of antigen presentation was measured after RNA transfection, 
whereas peptide pulsed DCs rapidly lost their ability to present the antigen66. Interestingly, the 
delivery of mRNA has been shown to generate more rapid and longer lasting antigen 
presentation compared to DNA, making mRNA an interesting source of antigen67. 
Multifaceted antigen-delivery vehicles.  
In addition, particle design is not limited to the mere creation of an antigen-delivery 
structure. NPs and MPs can be equipped with tracer molecules, or can be constructed from 
materials that allow in vivo imaging of injected antigen-loaded particles. Imaging and tracking 
the migration of these multifaceted particles from the injection site to the draining lymph nodes 
can provide initial feedback on the vaccine efficacy. For instance, Lee et al. described the 
production of gold NPs that could be covalently loaded with a model protein antigen and CpG 
ODNs. Upon injection of the resulting 23 nm particles in the rear footpads of mice, their 
migration to the popliteal and inguinal nodes could be followed using computed tomography 
(CT)53. To date, however, not many research groups have reported on such multimodal 
particulate vaccines yet. The reason for this, is that up to now, traceable particles have been 
mainly designed to determine the fate and migratory capacities of ex vivo modified antigen-
loaded DCs. The focus on in vivo DC targeting is a more recent development in cancer 
immunotherapy, which gives us reason to believe that reports on new multifaceted particles 
aiming for in vivo modification and migration trafficking are expected to follow.  
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Alternative biomaterial-based strategies.  
Another possibility is to target DCs towards the antigens, rather than vice versa. For this, 
Ali and coworkers designed a poly-lactide-co-glycolic (PLG) matrix that releases GM-CSF in 
order to recruit DCs into the scaffold in vivo. Importantly, the authors showed that the number 
of DCs that could be attracted in this way, resembles the amount of ex vivo modified DCs that 
are routinely injected as a cellular vaccine. Upon DC infiltration into the scaffold, the cells can 
come in contact with entrapped tumor lysate as a source of antigen, and CpG ODNs as immune 
stimulants. By fine-tuning the GM-CSF release kinetics from the polymer matrix, the antigen-
loaded mature DCs can be released from the scaffold and migrate to the lymph nodes to allow 
T cell induction68, 69. This discovery has led to the design of alternative immune priming centers 
that aim to attract and in vivo modulate DCs70. 
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PART 2: THERAPEUTIC IMAGING 
 
 
INTRODUCTION 
Therapeutic imaging agents, also called “theranostics” integrate an imageable and a 
therapeutic moiety into a single agent71, 72. This can be interpreted quite broadly. First of all, 
theranostics could be drug or gene delivery systems that can be followed in vivo via one or 
another medical imaging technique. This way, the biodistribution of the drug can be visualized, 
providing feedback on whether or not the therapeutic reaches its target site after administration. 
Such theranostics are especially useful during the development of novel biomaterials, where 
the effect of different modification strategies (e.g. PEGylation, attachment of targeting ligands) 
can be rapidly evaluated in vivo. Secondly, there is the possibility to produce controlled release 
theranostics, where the release of the drug or gene from the particulate carrier can be followed 
in vivo. For example, ThermoDox® (developed by Celsion), a thermosensitive liposomal 
formulation that contains doxorubicin (DOX, a chemotherapeutic) has also been formulated to 
contain a gadolinium-based magnetic resonance imaging (MRI) contrast agent. After 
intravenous injection of these theranostic liposomes, heat was applied locally at the tumor site 
to trigger DOX release. As in addition to the DOX, the MRI contrast agents are also let out of 
the liposomes, the drug release kinetics could be monitored non-invasively using MRI73. A third 
option is to develop a theranostic that provides visual information on the stage of the disease 
(e.g. characterization of a tumor mass) and treats it at the same time. Lastly, and related to the 
previous possibility, theranostics could allow treatment and at the same time visual follow-up of 
the treatment effects. In other words, the imaging moiety could allow real-time feedback on the 
effects of the co-delivered therapeutic.  
Medical imaging techniques 
Thus, in addition to delivering therapeutics, theranostic compounds act as contrast agents 
which can be detected via a non-invasive biomedical imaging technique. An overview of 
different diagnostic imaging techniques and their most common contrast agents is provided in 
Table 274. Although each technique has its advantages and disadvantages, it is important to 
note that computed tomography (CT), positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) require the use of ionizing radiation. In contrast, MRI 
and ultrasonography make use of electromagnetism and high-frequency acoustic waves, 
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respectively. Hence, these two imaging techniques are associated with improved patient and 
operator safety and they do not produce radioactive waste.  
Table 2. Overview of the clinically used diagnostic imaging techniques.  
Imaging 
Technique 
Principle Costs 
Spatial 
resolution 
Temporal 
resolution 
Contrast agents 
Computed 
Tomography 
(CT) 
Ionizing 
radiation  
(X-rays) 
Moderate + +/- Iodine, Barium  
Positron 
Emission 
Tomography 
(PET) 
Ionizing 
radiation  
(γ-rays) 
High - +/- 
Radioactive tracers 
(e.g. 18F, 11C, 13N, 15O, 68Ga) 
Single-Photon 
Emission 
Computed 
Tomography 
(SPECT) 
Ionizing 
radiation  
(γ-rays) 
High - - 
Radioactive tracers  
(99mTc, 131I, 123I, 111In) 
Magnetic 
Resonance 
Imaging  
(MRI) 
Electro-
magnetism 
High + - 
Paramagnetic metal 
chelates (e.g. gadolinium 
complexes or 
tetraazacycloalkanes) or 
superparamagnetic 
nanoparticles (iron oxide, 
1H), perfluoro-carbons (19F) 
Ultra-
sonography 
Acoustic 
waves 
Low +/- + Microbubbles 
 
As this thesis focuses on the use of non-ionizing diagnostic imaging techniques, the 
following sections will elaborate on the principles behind MRI and ultrasonography, and which 
theranostics can be designed for these imaging methods.  
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THERAPEUTIC IMAGING WITH MRI 
The principles behind MRI 
The first principle that lies at the basis of MRI is the concept of nuclear magnetism. In 
1925, Uhlenbeck and Goudsmit hypothesized that as protons and neutrons rotate over their 
axis, they have an intrinsic angular momentum or “spin”75. Since pairs of spins tend to cancel 
out, only atoms that consist of an odd number of protons and neutrons will have a net spin (e.g. 
1H1, 19F6, 31P15). Since protons have an electrical charge, their continuous rotation will create a 
current loop and thus, a magnetic moment (µ). Thus, when spinning nuclei are influenced by 
an external magnetic field, they will act like little magnets. As an example, for the 1H nucleus, 
which only consists of 1 proton, the application of an external external magnetic field (B) will 
cause the spinning protons to attempt to align either parallel (spin up) or antiparallel (spin down) 
to the applied magnetic field, as shown in Figure 5A. Just like the Zeeman effect in atomic 
energy levels, both states have different energy levels, with the parallel state being a low energy 
level, and the antiparallel state a high energy level.  
 
Figure 5. The orientation of spinning nuclei in an external magnetic field.  
(A) Spinning nuclei will attempt to align their magnetic moments, µ, parallel or antiparallel 
to an externally applied magnetic field, B. (B) In fact, the magnetic moment rather 
precesses around the magnetic field in a certain angle.  
However, this alignment is not complete, causing the nuclei to precess about the axis of 
the applied magnetic field under a certain angle, as shown in Figure 5B. The frequency at 
which this precession occurs, is called the Larmor frequency. Importantly, the Larmor frequency 
depends on both the magnitude of the external magnetic field, as well as on the type of nucleus. 
However, as these nuclei can be part of different molecules, they can be present in 
environments with different electron densities. This will influence their resonance frequency, 
resulting in a chemical shift (expressed in ppm). An example is provided in Figure 6.  
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Figure 6. 1H nuclear magnetic resonance (NMR) spectrum for methyl acetate.  
Methyl acetate contains 6 1H atoms. As these are present in 2 different chemical 
environments (indicated in either green or orange), this results in two separate peaks at 
different chemical shifts in the 1H NMR spectrum. As the number of 1H atoms in each 
environment is the same (3), both peaks have the same area under the curve.  
When applying a radiofrequency (RF) pulse at this Larmor frequency, the spinning nuclei 
will absorb the added energy, causing them to flip from the low parallel to the high antiparallel 
energy state. After switching off the RF emission, the excited atoms will relax back to the more 
energetically favorable parallel state, thereby emitting a RF signal that can be detected by a 
receiver coil. This relaxation occurs gradually. Depending on the chemical environment in which 
the excited nuclei are present, they will require a certain amount of time before they release the 
absorbed energy and return to their ground state. Thus, the T1 relaxation time is the time 
needed for 63% of the excited atoms to return to the parallel state. Depending on the chemical 
environment in which the protons are spinning, this can either be longer or shorter. In addition, 
the RF pulses will cause the atoms to no longer spin randomly, but in phase. The time needed 
for the atoms to return to the random spin state and cause a 63% decrease of the signal, is the 
T2 relaxation time. When protons are very close together, they will cause them to experience a 
slightly higher or lower magnetic field, and hence a slightly different T2 relaxation time.  
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In order to transform these RF signals into an interpretable image, 1H MRI makes use of 
a magnetic field gradient instead of a static magnetic field. An example of the magnetic field 
density generated by different MRI coils is given in Figure 7. As the magnetic field will be 
different at different locations, this can be used to generate differences in the resonance 
frequency and phase, which can then be used to encode for the location of a particular and 
hereby pinpoint the origin of the emitted RF signal. Most of the 1H atoms in the human body are 
present in H2O and lipid molecules. Hence, 1H MRI basically images the distribution of water 
and fat molecules at different anatomical locations.  
 
Figure 7. Magnetic field density around MRI coils.  
Image reproduced from http://www.integratedsoft.com/Applications/Magnetic-
Applications/MRI  
Images can either be T1 or T2 weighted, which means that differences in either one (or 
both) of these relaxation times are used to provide the contrast. Interestingly, for a lot of 
malignancies, different T1 relaxation times were reported for healthy tissue compared to tumor 
tissue. For example, breast tumors have a T1 of 367 ± 79 ms whereas the corresponding healthy 
tissue has a T1 of 1080 ± 8 ms76. This way, T1 weighted MRI is generally used to provide 
anatomical information, and is a powerful tool in the diagnosis of malignancies. Similarly, T2 
relaxation times also differ between tissues, allowing T2 weighted imaging. This usually requires 
longer scanning times compared to T1 weighted imaging, but enables functional imaging. 
Importantly, different contrast agents need to be selected when using T1 or T2 weighted MRI.   
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1H MRI contrast agents 
In 1H MRI, contrast agents can be used to either enhance the natural contrast between 
two adjacent tissues, or to provide additional dynamic information. There are two main 
principles on which contrast enhancement could be based. Firstly, contrast agents could 
change the spin density, i.e. the proton density. However, this cannot be modified in 1H MRI. 
Alternatively, agents can change the T1 and T2 relaxation times. Most contrast agents influence 
both relaxation times but may have a predominant effect on one of them. This way, 1H MRI 
contrast agents are subdivided into T1 and T2 weighted agents.  
T1 weighted contrast agents most frequently are paramagnetic substances, such as Gd3+ 
chelates. These contain a large number of unpaired electrons (7 for Gd3+), which will extensively 
influence the chemical environment of neighboring 1H atoms. Hence, their T1 relaxation time is 
reduced. As a result, the shortened relaxation time will allow rapid return to the thermal 
equilibrium in rapid excitation-relaxation sequences, thereby enhancing the total intensity of the 
signal (positive contrast agents)77. This type of contrast agents is often used in MRI 
angiography78 as illustrated in Figure 8, or for the detection of the break-down of natural barriers 
like the blood brain barrier around brain tumors. . 
 
Figure 8. Gd3+ enhanced MR angiography of the head.  
MRI protocols that make use of differences in T2 relaxation time are based on the 
detection of the signal decay. Thus, contrast agents that speed up this signal decay will locally 
reduce the overall signal intensity, as such creating dark spots on the MR images (negative 
contrast agents). Examples are superparamagnetic materials, such as superparamagnetic iron 
oxide particles (SPIO)79. Their superparamagnetic properties will locally disturb the created 
magnetic field, which provokes the signal dephasing of neighboring protons and as such 
accelerates the signal decay.  
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Both T1 and T2 weighted contrast agents have been used for the development of 
theranostics. For example, self-assembled NPs consisting of a SPIO core and a PEI-containing 
shell have been produced to deliver minicircle DNA, whilst allowing MRI imaging of gene 
delivery80. Similarly, various particulates have been developed and evaluated based on SPIO 
or Gd3+ for MRI-imageable delivery of various drugs or nucleic acid therapeutics81-83.  
19F MRI 
As described in the previous sections, 1H MRI, where the distribution of water in the 
different tissues is imaged, is a commonly used technique in diagnostic medicine, as it provides 
detailed information on tissue anatomy, pathology and functionality. However, when it comes 
to specificity when performing contrast-enhanced MRI, there is always the issue of improving 
the contrast-to-tissue ratio. As the human body is filled with 1H atoms, the differences that need 
to be created by the contrast agents are substantial, which often compels clinicians to use high 
doses of these contrast agents. To respond to this, Holland and colleagues shifted their focus 
towards detecting 19F instead of 1H in 196984. In comparison to 1H, the resonance frequency, 
sensitivity and signal-to-noise ratio of 19F are merely slightly lower. However, as almost all the 
fluorine in the human body is immobilized in bone and teeth structures, which makes it invisible 
to MRI detection methods. Thus, 19F MRI allows selective imaging of fluorine-containing 
contrast agents at a negligible tissue background85.  
Following the development of 19F MRI, 5-fluorouracil (5-FU), a widely used cytostatic drug 
was suddenly upgraded from a therapeutic to a theranostic compound86. However, as this 
molecule only comprises 1 single fluorine atom, high tissue concentrations were needed to 
detect this agent at a sufficient signal-to-noise ratio. Thus, to obtain acceptable image quality, 
obtaining high local concentrations of 19F nuclei will be crucial. To achieve this, 
perfluorocarbons (PFCs) proved to be ideal contrast agents. They are metabolically inert, offer 
a high density of 19F nuclei per molecule and have well-defined safety profiles87-91. Some PFCs 
have gained FDA approval as artificial oxygen carriers due to their ability to dissolve high 
amounts of various gases (Fluosol®, marketed by Green cross corporation but taken off the 
market after problems with the storage of the emulsion formulation) or as an aid during eye 
surgery (Vitreon®, marketed by Vitrophage). Due to their very low surface tension, liquid PFCs 
usually remain cohesive, and are therefore difficult to formulate as stable emulsions. In order 
to overcome this hurdle, different lipid and polymer coats have been designed to stabilize the 
PFC droplets in an aqueous environment92-94.  
This has resulted in the marketing of Cell Sense (CS-1000 by Celsense Inc.), a PFC 
formulation designed for cell labeling. This way, it has been used by researchers who are 
developing cellular vaccines (including DC vaccines) and stem cell therapeutics, in order to 
track the fate of the transplanted cells with high specificity in vivo92. Especially for DC-based 
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vaccines, being able to track whether or not the cellular vaccines migrate from the injection site 
to the draining lymph nodes could provide crucial information that could help predict the 
therapeutic outcome. An example of DC vaccine tracking using 19F MRI is shown in Figure 9. 
Thus, PFCs have made it as 19F MRI contrast agents, but to date, their use as theranostics has 
not yet been intensely investigated.  
 
Figure 9. 19F MRI tracking of the migration of PFC-loaded DCs in a mouse model.  
After subcutaneous injection of the PFC-loaded DCs in tip of the hind foot pad, the 
migration of a fraction of these cells to the popliteal lymph node could be observed. Image 
reproduced from Ahrens et al.92  
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THERAPEUTIC IMAGING WITH ULTRASONOGRAPHY 
Another imaging technique that does not require the use of ionizing radiation and has the 
advantages of providing good spatial and temporal resolution at a low cost, is ultrasonography. 
More importantly, recent advances in the development of microbubbles as ultrasound contrast 
agents have initiated the research into microbubble theranostics for ultrasonography. The 
following sections will highlight the principles that lie at the basis of medical imaging and drug 
delivery using ultrasound and microbubbles. First of all, an overview of how ultrasound came 
to be an established value for diagnostic and therapeutic applications in the clinic, will be 
provided. With the rise of microbubbles as FDA-approved ultrasound contrast agents, the last 
sections will elucidate the principles behind microbubble and ultrasound-triggered drug delivery 
and recent progress in microbubble design for this purpose will be reviewed.  
The history of ultrasound 
As is the case for many inventions, the applications for which ultrasound has been used 
evolved over the years, influenced by the spirit of age. The following sections will briefly discuss 
the course of events that has led to the courant use of ultrasound for non-clinical and 
(pre)clinical applications.  
(1) Piezoelectricity and echolocation 
Ultrasound research was set in motion by the brothers Pierre and Jacques Curie, who 
discovered piezoelectricity as early as 1880. The phenomenon of piezoelectricity occurs in 
certain crystals (e.g. quartz and Rochelle salt), which are electrically polarized under 
mechanical stress95. When also the converse effect for these materials was deduced, the 
possibility to transform mechanical pressure into electricity and vice versa opened new 
avenues. Similar to the way that striking a tuning fork will lead to a vibration that is propagated 
through air and can be heard as sound, applying electrical energy to a piezoelectric element 
can cause it to rapidly vibrate. These vibrations have a certain frequency (in Hz) and result in 
the creation of a pressure wave, as shown in Figure 10A. Depending on the frequency of the 
vibrations, the waves are classified as sound (20 Hz-20 kHz, i.e. within the range of human 
hearing), infrasound (<20 Hz) or ultrasound (>20 kHz). When such sound waves propagate, 
the high and low pressure areas they create will displace particles in the medium. Thus, the 
medium is compressed when the pressure is high, and rarefraction occurs when the pressure 
is low (Figure 10B). 
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Figure 10. Features of ultrasound waves. 
By applying electrical energy to a piezoelectric crystal, vibrations are induced that 
propagate through the medium as pressure waves with a specific wavelength and 
amplitude (A). This results in the alternating compression and rarefaction of the medium 
through which the acoustic wave propagates (B).  
This principle saw its first use after the Titanic tragedy in 1912, when researchers 
proposed that by using sound and listening to echoes, distant icebergs could be detected96. 
The physical principles behind echo detection are explained in Box 1. Almost immediately, the 
first patents describing iceberg echolocation were filed. However, it took two years before the 
first SONAR (SOund Navigation And Ranging) system was actually assembled. Reginald 
Fessenden emitted low-frequency sound (~540 Hz) and used a separate receiver to detect 
underwater icebergs at about 3 km distance. The use of ultrasound for echolocation and the 
development of transducers capable of both emitting as well as receiving ultrasound waves, 
was made possible by Paul Langevin, a former student of Pierre Curie. He aligned multiple 
quartz crystals, allowing the generation and detection of ultrasound at a higher frequency of 
40 kHz. Thus, the first ultrasound transducer was a fact.  
In the run-up to the First World War, the application of ultrasound-based echolocation-
technology changed: it became a powerful military tool to detect enemy submarines. This way, 
the first German U-boat sunk after SONAR detection using Langevin’s hydrophone in 1916. 
Further perfection of the transducer design allowed the generation of higher sound frequencies 
which significantly increased the distances at which submarines could be located (to up to 
1300 m). Despite a lot of patent disputes, Paul Langevin is still considered to be one of the 
founders of ultrasonics97.  
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Box 1. The physics behind iceberg echolocation explained. 
When a sound wave travels through a medium, the density of the medium 
() and the speed of sound in that medium (c) will determine the acoustic 
impedance of that medium (Z).  
𝑍 = 𝜌 × 𝑐 
When the wave travels through medium 1 (with an impedance of Z1) and 
then hits medium 2 with a different acoustic impedance (Z2), a part of the 
ultrasound wave is reflected as an echo. The amplitude of the reflected 
echo is determined by the acoustic impedance mismatch between the 
two media as shown in the following formula:  
𝑅 =
𝑍2 −  𝑍1
𝑍2 + 𝑍1
  
With respect to the iceberg localization (see figure below): the amplitude 
reflection coefficient of an ultrasound wave that travels through water 
(Zwater = 1.48 MRayl) before it encounters an iceberg (Zice = 3.5 MRayl), 
is 41%, as calculated below: 
𝑅 =  
3.5𝑀𝑅𝑎𝑦𝑙 − 1.48𝑀𝑅𝑎𝑦𝑙
3.5𝑀𝑅𝑎𝑦𝑙 + 1.48𝑀𝑅𝑎𝑦𝑙
= 0.41 
Depending on the distance between the ship that sent out the echo and 
the iceberg, the time it takes for the echo to return to the ship will be 
longer or shorter, for more or less distant icebergs, respectively.  
 
 
(2) The dawn of ultrasound in diagnostic medicine 
At the cradle of medical ultrasound applications was Karl Theodore Dussik in 1946. He 
developed what he called “hyperphonography”, a transmission-based imaging technique. He 
applied ultrasound waves at one side of the head of a patient, which was partially submerged 
in water (Figure 11A), and recorded the intensities of the waves at the other side of the head. 
When the waves passed through the tissue, depending on the acoustic impedance and the 
speed of sound in the tissues (as listed in Table 3), differences in attenuation (i.e. loss of 
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amplitude due to scattering or absorption of the transmitted wave) were created. This way, 
Dussik could produce 2D black-and-white images as exemplified in Figure 11B. Unfortunately, 
what Dussik thought were the cerebral ventricles and irregularities that he ascribed to the 
presence of brain tumors, he had not taken the attenuation of ultrasound by the skull into 
account. Nevertheless, Dussik’s research did inaugurate the application of ultrasound in 
diagnostic medicine98.  
Table 3. Density and acoustical properties of different tissues and materials. 
Tissue or 
material 
Density 
(g cm-3) 
Speed of Sound 
(m s-1) 
Acoustic impedance 
(MRayls) 
Water 1 1480 1.48 
Blood 1.055 1575 1.66 
Fat 0.95 1450 1.38 
Liver 1.06 1590 1.69 
Kidney 1.05 1570 1.65 
Heart 1.045 1570 1.64 
Bone 1.9 4080 7.75 
Air 0.0001 335 0.0004 
 
 
Figure 11. Ultrasound imaging by Karl Theodore Dussik.  
(A) The ultrasound apparatus developed by Karl Theodore Dussik to detect brain tumors. 
(B) Pathological hyperphonogram of the brain recorded by Dussik. Black areas were 
thought to be enlarged ventricles, exhibiting a low degree of attenuation. (Figure 11B was 
adapted from Edler and Lindström99) 
This concept was later picked up by Douglass Howry and Joseph Holmes who replaced 
the transmission detection by the detection of ultrasound echoes. Similar to the echolocation 
used in SONAR, pulsed ~2.5 MHz ultrasound waves will be reflected at the interface of tissues 
with a difference in acoustic impedance. Resulting echoes were then detected by the same 
transducer and converted into black-and-white images. They even further improved the 
applicability of ultrasound imaging by designing moving transducers that eliminated “false” 
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echoes and by developing more compact transducers for direct-patient contact, no longer 
making it necessary to submerge the patients in water100, 101.  
Since then, we have come a long way: black-and-white turned into grayscale imaging, 2D 
into 3D and even 4D, and the variety in tissues that could be imaged at improved resolution 
increased rapidly. Advances in image analysis, transducer design and the development of small 
transportable devices and the merging of different technologies, made ultrasound imaging – in 
all its forms – one of the standard diagnostic instruments in medicine today.  
(3) The microbubble era 
In 1968, Gramiak and Shah made a remarkable observation. When imaging the aortic 
root, they observed a “cloud of echoes” during the injection of saline102. These echoes were 
later ascribed to the presence of small air bubbles in the saline solution. The large difference in 
acoustic impedance between air (Zair = 0.0001 MRayl) and blood (Zblood = 1.66 MRayl) will 
indeed cause the generation of echoes by each of these small bubbles (at an amplitude 
reflection coefficient of nearly 100%). The potential of using such microbubbles as ultrasound 
contrast agents was almost immediately recognized. Especially for echocardiography, there 
was an unmet need for ways to get better contrast between blood and the heart muscle (which 
both have almost identical acoustic impedances: Zblood = 1.66 MRayl; Zheart = 1.64 MRayl, 
resulting in an amplitude reflection coefficient of merely 0.6%). If one would be able to safely 
inject microbubbles in the bloodstream, thus increasing the echogenicity of blood in comparison 
to heart, contrast-enhanced echocardiography could provide clinicians with a highly potent 
diagnostic tool to non-invasively detect cardiac irregularities. Thus, the use of these small air 
bubbles as ultrasound contrast agents was initiated103.  
The first contrast agents that were used in this way, were solutions like agitated saline or 
glucose, which provided extremely short-lived contrast enhancement. To prolong the lifespan 
of the air bubbles, the dissolution of the gas into the blood needed to be reduced. This was 
done by equipping the gas bubbles with a thin stabilizing shell, which most frequently consisted 
of proteins such as albumin (e.g. Albunex®)104, 105. Additional improvements were made by 
replacing the air by hydrophobic gasses, as these are less soluble in blood and will thus 
generate longer-circulating microbubbles. These second generation microbubble agents were 
based on sulphur hexafluoride or PFC gas cores, stabilized by lipid (soft-shelled agents) or 
polymer (hard-shelled agents) shells106-108. Moreover, shielding microbubble uptake by 
phagocytic cells, which is commonly done by including a polyethylene glycol (PEG) corona, 
resulted in even longer contrast agent circulation times109. The overall size of microbubble 
contrast agents ranges from 0.5 to 10 µm, as this allows sufficient echogenicity (which improves 
with increasing microbubble size) as well as safety. Below the maximum size of 10 µm 
microbubbles will be small enough to pass through the microvasculature without causing 
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embolisms. In addition, the use of inert gasses for the microbubble core and biodegradable, 
biocompatible shell materials makes microbubbles safe for intravenous applications. A short 
overview of the composition of some commercially available microbubbles that are approved 
for clinical use, can be found in Table 4. 
Table 4. Commercially available microbubbles approved for diagnostic use. 
Contrast agent Manufacturer Gas core Shell composition 
Definity® Bristol-Myers Squibb Perfluorobutane 
Phospholipids, 
PEG5000 
Optison® GE Healthcare Perfluoropropane Human serum albumin 
Sonazoid® GE Healthcare Perfluorobutane 
Egg 
phosphatidylserine 
SonoVue®  
(LumasonTM in the 
USA)  
Bracco Sulfur Hexafluoride 
Phospholipids, 
PEG4000 
 
Interestingly, besides their echogenicity, microbubbles also exhibit other features that 
make them particularly appealing for medicinal purposes. Most prominently, the microbubble 
gas cores will respond to the ultrasound pressure waves by linearly oscillating in response to 
the high and low pressure peaks of the passing ultrasound waves. As shown in Figure 12, in 
this linear behavior, the amplitude of compression and rarefaction are equal. The way these 
microbubbles behave, depends on a number of ultrasound- and microbubble-related 
parameters: ultrasound power (related to the acoustic pressure) and frequency, and 
microbubble type (gas core and shell elasticity) and size. If the frequency of the transmitted 
ultrasound wave matches the eigenfrequency of the microbubble, the amplitude of the 
oscillations reaches a maximum. When this is the case, the microbubbles oscillate nonlinearly, 
resulting in relatively larger microbubble expansion compared to compression, which heavily 
impacts the echoes they generate upon ultrasound exposure110.  
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Figure 12. Linear and non-linear microbubble behavior.  
Ultrasound-exposed microbubbles will oscillate. Depending on the frequency and the acoustical 
pressure, the microbubbles can exhibit linear (left panel) and nonlinear (right panel) behavior, resulting 
in the generation of different echoes.  
More specifically, nonlinear movements will result in the generation of second-order 
harmonic echoes111, 112. This means that when an ultrasound pulse is emitted at a certain 
frequency (f0), the reflected microbubble echo will not only be at this fundamental frequency, 
but also at a second harmonic frequency (i.e. twice the fundamental frequency, 2f0) as depicted 
in Figure 13. Thus, microbubble echoes will be mainly nonlinear, whereas biological tissues 
rather behave linearly. As a result, selectively looking at nonlinear echo signals allows specific 
detection of microbubbles while cancelling out tissue-derived echoes. Thus, strategies such as 
pulse-inversion or amplitude-modulation allow selective harmonic contrast imaging, thereby 
significantly augmenting the contrast-to-tissue ratio of ultrasound images111.  
 
Figure 13. Microbubble harmonic signal generation.  
Microbubbles that oscillate in response to a 4 MHz ultrasound wave will produce echoes 
at various frequencies, including an intense echo at the fundamental frequency (f0) and 
second harmonic frequencies (2f0). Image adapted from Lindner et al.110 
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Taken together, contrast-enhanced ultrasound imaging (CEUS) became an established 
diagnostic moiety in echocardiography. Even though the number of applications approved by 
the FDA is still limited, research indicates that it could be particularly useful for imaging liver 
disease as well as for the characterization of tumors. An overview of courant clinically applied 
ultrasound imaging techniques is provided in Table 4. 
Table 4. Clinically used ultrasound imaging techniques. 
Technique Principle Example 
B-mode  
imaging 
Echoes from different tissue interfaces are collected 
and brought together as a 2D image. Each pixel 
represents one echo, where the brightness of the 
pixel is directly proportional to the echo intensity.  
 
Doppler  
imaging 
Echoes derived from moving structures (often 
blood) are detected at different frequencies than the 
frequency of the transmitted wave, depending on 
the direction (towards or away from the transducer) 
and speed of movement. This information is 
converted into color images showing movement 
towards the transducer in red, and movement away 
from the transducer in blue. Intensity mapping is 
used to point out the flow velocity. Microbubbles 
can be used to enhance the signal.  
 
Contrast-
enhanced 
ultrasound 
imaging (CEUS) 
Microbubbles enhance blood echogenicity to 
improve contrast between e.g. heart muscle and 
blood. Tissue signal cancellation can be done to 
allow harmonic imaging and improve the contrast-
to-tissue ratio.  
 
 
Currently, microbubble contrast agents are moving beyond their exclusive use as 
vascular contrast agents. Recent studies revealed that when these contrast agents are injected 
subcutaneously or intradermally, they migrate away from the injection site via the lymphatics113, 
114. More importantly, when microbubbles were injected around the tumor, they could be tracked 
all the way to the sentinel lymph node. This is the first lymph node that drains material coming 
from the tumor tissue, and hence this is the first location at risk to harbor metastasis115-121. As 
a result, staging the sentinel lymph node to determine whether or not it contains disseminated 
cancer cells is a routinely performed procedure in oncology122. Using CEUS to determine which 
node is the sentinel node could be an improvement over the currently used methods, as these 
are either not patient-friendly (e.g. the injection of a blue dye) or require the use of radioactive 
tracers.  
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Assessing and utilizing ultrasound-mediated bio-effects 
It is important to keep in mind that ultrasound waves are energy waves. Therefore the risk 
of inducing bio-effects should always be taken into consideration. For ultrasound, these bio-
effects can be subdivided into two main categories, namely mechanical and thermal bio-
effects123.  
(1) Mechanical bio-effects  
Mechanical bio-effects are classified based on the mechanical index (MI), a safety 
parameter derived by Apfel and Holland124. It is calculated using the following formula, where 
PnP is the peak negative pressure and Fc is the center frequency of the applied ultrasound 
wave.  
𝑀𝐼 =  
𝑃𝑛𝑃
√𝐹𝑐
 
Mechanical bio-effects are mainly related to cavitation of injected microbubble contrast 
agents, but also of spontaneously occurring microbubbles125, 126. Firstly, when microbubble 
contrast agents are injected and ultrasound is applied (e.g. for CEUS imaging), microbubbles 
act as artificial cavitation nuclei. This means that already at relatively low MIs, microbubbles will 
oscillate, as previously described. As long as the MI is low (<0.5), the cavitation will remain 
stable, which means that the microbubbles will keep shrinking and expanding whilst generating 
linear and harmonic echoes (Figure 14A). However, when the MI is higher, the microbubble 
movements become unstable, and the inertia of the fluid that surrounds the cavitating 
microbubble will eventually cause it to collapse and fragment into smaller microbubbles 
(Figure 14B). Microbubble implosion is a rather violent phenomenon that can be associated 
with tissue damage and haemorrhage.  
When no microbubbles are used, cavitation will only occur at higher MIs. At an MI >1.9, 
the large peak negative pressures will cause oscillation of naturally occurring gas nuclei. 
Continuous ultrasound exposure might then result in additional gas influx into the oscillating 
bubble, causing it to grow in size (Figure 14C). Once more, depending on the size of the 
expanding bubble, the cavitation can rapidly become unstable, eventually leading to 
microbubble implosion and local bio-effects. Overall, to prevent this mechanical tissue-damage, 
the FDA limited the MI output of clinical ultrasound scanners to 1.9, although caution is already 
warranted at lower MI (starting from MI >1), since gas-rich tissues such as the liver and kidney 
will exhibit nucleation and cavitation already at lower acoustical pressures.  
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Figure 14. Mechanical bio-effects of ultrasound.  
Microbubble contrast agents cavitate in response to ultrasound waves. When the MI is 
low, the cavitation is stable (A) but when the MI increases, the microbubble oscillations 
become unstable, and the microbubbles can collapse (B). At even higher MI, these effects 
can occur without the injection of microbubble contrast agents. Then, natural cavitation 
nuclei can give rise to oscillating bubbles in ultrasound-exposed tissue (C).  
(2) Thermal bio-effects 
In addition to mechanical effects, ultrasound energy can partly be absorbed by the 
exposed tissue, and is converted into heat. As a result, the temperature can locally rise, leading 
to thermal bio-effects. The risk of these effects can be estimated using the thermal index (TI)127. 
This value is calculated as the ratio between the total acoustic power (Wp) to the estimated 
power needed to raise the tissue temperature by 1°C (Wdeg, depends on the tissue type). 
Overall, procedures that limit the rise in temperature to 1.5°C are generally considered as 
safe128.  
𝑇𝐼 =  
𝑊𝑝
𝑊𝑑𝑒𝑔
 
(3) Utilizing ultrasound-mediated bio-effects for therapy 
The described mechanical and thermal bio-effects encompass safety risks. To avoid 
tissue damage, clinicians are therefore advised to keep ultrasound exposure as low as 
reasonably achievable (ALARA), even though there have not been concrete indications that 
adverse events due to mechanical damage occur during ultrasound imaging (that is without the 
presence of microbubble contrast agents) in humans123, 128  
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On the other hand, the occurrence of these bio-effects can be used to our advantage in 
both diagnostic and therapeutic medicine. Ultrasound has not only proven its benefit in imaging 
as explained in the previous sections, it also lies at the basis of a number of other treatments 
which are currently used in the clinic. This way, mechanical bio-effects are used for lithotripsy 
and root canal cleaning, whereas thermal bio-effects are applied for physiotherapy and thermal 
tissue ablation.  
Lithotripsy. Low frequency ultrasound shock waves can induce mechanical disruption of 
kidney and gallbladder stones, as first demonstrated by Chaussy in 1980129. By using 
ultrasound to fragment larger stones into smaller ones that can easily pass through the urinary 
tract or the bile duct, surgical intervention can be avoided. However, severe side effects have 
been associated with this technique, as the high intensity non-focused shockwaves can also 
cause rupture of blood vessels and inflammation130.  
Sonothrombolysis. Blood clots that occlude blood vessels can have sever effects such 
as ischemic stroke. To avoid morbidity and mortality, it is crucial to dissolve the thrombus as 
soon as possible, which is mainly done by intravenous injection of thrombolytic drugs (e.g. 
tissue plasminogen activator (tPA)). It was shown that the use of ultrasound-mediated cavitation 
can improve enzymatic fibrinolysis by enhancing tPA penetration into the thrombi, thus allowing 
a reduction of the tPA dose. Several clinical studies using intravascular or transcranial 
transducers have shown that sonothrombolysis has a good safety profile and a significant 
therapeutic benefit. Moreover, the use of microbubbles to lower the cavitation threshold and 
increase cavitation-induced damage to the clot, is currently under investigation131-133.  
Root canal cleaning. For successful endodontic treatment, it is crucial to remove 
necrotic material, debris and micro-organisms from the tooth’s root canal before filling it. 
Therefore, the root canal is thoroughly irrigated and cleaned. Quite often, this tedious task 
needs to be repeated due to the incomplete bacteria removal. By inserting a small ultrasound 
needle tip into the root canal during irrigation, acoustic streaming and cavitation can be induced, 
resulting in “activation” of the irrigant. This way, significant improvements in root canal 
cleanliness were observed134, 135.  
Physiotherapy. Soft tissue injuries such as tendon and muscle wounds, often benefit 
from local heat application. Thus, non-focused ultrasound has been used since the early 1950s 
for the treatment of sports injuries.  
Sonophoresis/Phonophoresis. The ultrasound gel that is used to conduct the 
ultrasound between the transducer and the patient, can be supplied with anti-inflammatory or 
analgesic drugs. Ultrasound application can then promote transdermal drug delivery136.  
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High Intensity Focused Ultrasound (HIFU). By using focused transducers to locally 
deposit high amounts of energy in a small volume, tissue can be ablated via either mechanical 
or thermal bio-effects depending on the ultrasound settings used. Generally, HIFU makes use 
of lower frequency ultrasound (0.8-3.5 MHz) focused to a volume of 1-3 x 8-15 mm. By moving 
the focal point over the tissue, larger areas can be ablated, often under MRI guidance137. The 
working principle can either be thermal or mechanic. For most therapeutic applications in the 
clinic, thermal HIFU is used. Here, longer ultrasound pulses result in the accumulation of energy 
and local heating to over 80°C, causing tissue necrosis and coagulation. Thermal HIFU has 
been clinically used as an alternative to surgery and other thermal ablation techniques (e.g. 
cryoablation and RF ablation) for the treatment of breast cancer legions, uterine fibroids and 
prostate cancer138. Alternatively, when shorter pulses and higher frequencies are used, the local 
heating will be less pronounced and cavitation will become the most prominent phenomenon. 
This is called mechanical HIFU. Although it is less capable of completely destroying the target 
tissue, it has been reported to result in immunogenic cell death, accompanied by the release of 
amongst others heat shock proteins (HSPs) and the infiltration of antigen-presenting cells. 
Thus, mechanical HIFU could spark immune responses against malignancies139. Here too, 
microbubbles are being explored to lower the threshold for these mechanical effects and to 
increase the extent of tissue damage140. In addition to the use of HIFU for tissue ablation, it is 
also under investigation to locally trigger the release of chemotherapeutics which are packaged 
in thermosensitive liposomes. For example, ThermoDox® (thermoliposomal doxorubicin, 
developed by Celsion) and HIFU are currently being investigated for the treatment of metastatic 
liver cancer141, 142. 
Opening the blood brain barrier. Another application for microbubbles and ultrasound, which 
is still in its preclinical phase, is the temporary disruption of the blood brain barrier (BBB). The 
BBB is one of the hardest barriers to conquer, as it is designed to sustain the brain homeostasis. 
The tight connections between brain endothelial cells therefore form a strong impediment for 
the action of drugs that have their target in the brain (e.g. chemotherapeutics for brain tumors, 
or therapeutics against schizophrenia or Alzheimer’s disease)143. One of the strategies to 
temporarily overcome this barrier, is the application of low frequency ultrasound that can be 
delivered non-invasively and under MRI-guidance, through the skull144. Here too, microbubbles 
can be used to promote cavitation, resulting in the disruption of the BBB for about 4h, allowing 
passage of small molecule drugs145, 146, genes147 and even cell therapeutics (e.g. neural stem 
cells and immune cells)148-150.  
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Microbubbles and ultrasound for drug and gene delivery 
(1) Sonoporation 
As previously described, microbubbles respond to transmitted ultrasound waves by 
oscillating, and this can cause mechanical bio-effects. Importantly, stable as well as unstable 
microbubble movements, can affect the integrity of neighboring cell membranes. As shown in 
Figure 15, stably cavitating microbubbles can (A) push or pull at the cell membrane during their 
expansion or compression, respectively. In addition, (B) the acoustic radiation force can drive 
microbubble transport towards or even through the cell membrane, or (C) fluid microstreams 
generated during microbubble oscillations create shear stress that can disrupt the plasma 
membrane. In addition, and even more pronounced, imploding microbubbles can also affect 
cell membranes by (D) creating shockwaves or (E) liquid jets. All these bio-effects can create 
pores in adjacent cell membranes. This phenomenon is called sonoporation151.  
 
Figure 15. Bio-effects of microbubbles on neighboring cell membranes.  
Stably cavitating microbubbles can temporarily permeate cell membranes via pushing or 
pulling (A), acoustic radiation force microbubble displacement (B) or by creating 
microstreamings in the surrounding fluid (C). Unstable cavitation and resulting 
microbubble collapse can create shock waves (D) or fluid jets (E). This figure was 
reproduced from Lentacker et al.151.  
These pores are small and short-lived: if moderate acoustic pressures are used, pore 
sizes are generally between a few tens to a few hundreds of nanometers, and they are sealed 
within milliseconds to seconds152, 153. The mechanisms through which this membrane repair 
occurs are not yet fully elucidated. Current theories include patching of the lipid membrane 
using membrane components derived from intracellular vesicles that are exocytosed, or the 
stimulation of endocytosis, which results in the removal of the pores from the cell membrane154, 
155.  
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(2) Implications for drug and gene delivery 
Since microbubbles in combination with ultrasound can lead to spatio-temporally 
controlled cell membrane poration, this could present advantages for ultrasound-triggered drug 
delivery. By allowing drugs or genes to enter the cell via the created pores, direct cytoplasmic 
entry of the compounds is allowed, circumventing the normal endocytic pathway, as shown in 
Figure 16. This is particularly interesting since one of the problems with passive drug uptake 
by cells is that endosomes fuse with lysosomes, resulting in the digestion of the endocytosed 
components156. Therefore, methods that allow drugs to directly enter the cytosplasm will avoid 
premature degradation and increase the therapeutic effect of the delivered drugs. As a 
consequence, sonoporation is currently under investigation as a strategy to improve drug and 
gene delivery. Indeed, it was shown that when drugs or genes were co-injected with 
commercially available microbubbles, enhanced uptake and therapeutic effects could be 
observed in vitro and in vivo157, 158.  
 
Figure 16. Endocytosis and sonoporation-mediated uptake of drugs.  
When drugs are taken up by cells, this normally occurs via endocytosis, where the cell 
membrane invaginates and forms endosomes, which contain extracellular material. These 
endosomes will fuse with lysosomes, resulting in the digestion of the engulfed components 
(left panel). When microbubbles and ultrasound induce sonoporation, drugs can enter the 
cell through the created pores and immediately end up in the cytoplasm, thus avoiding 
endolysosomal degradation (right panel).  
The effects of sonoporation-mediated drug delivery can even be enhanced by loading the 
drugs or genes onto the microbubbles, as this offers various advantages. First of all, by 
physically coupling the active components to the microbubbles, ultrasound-induced 
microbubble implosion will not only locally permeate cell membranes, it will at the same time 
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result in a local drug release. This has a double benefit: (1) before microbubble implosion, the 
microbubble-bound drugs or genes are protected against degradation by digestive enzymes 
(e.g. proteases or nucleases) in the blood, and (2) the coupled drugs or genes are shielded 
from unwanted uptake in other regions than the target site. Thus, the risk of adverse events 
can be reduced. What is more, by locally releasing the drug at the exact same location where 
the cell membranes are perforated, the local high drug concentrations at the pore sites will 
result in an even better drug uptake. This was evidenced by the work of Lentacker et al., who 
proved that transfection using pDNA-loaded microbubbles and ultrasound resulted in a 10-fold 
improvement over the use of naked DNA together with microbubbles and ultrasound in vitro159. 
In this way, selectively improving drug uptake at the region of interest could allow a reduction 
of the total drug dose, which could improve the therapeutic window of the delivered therapeutic 
agent. Lastly, drug-loaded microbubbles could allow image-guided drug delivery. This way, low 
MI CEUS could be used to visualize the drugs after injection, and when they reach the target 
site, higher MI ultrasound pulses can be delivered to locally burst the bubbles, cause 
sonoporation and promote intracellular drug delivery. Hence, ultrasound-guided, ultrasound-
triggered drug and gene delivery could be possible160.  
(3) Loading microbubbles with therapeutics 
Loading microbubbles with drugs or nucleic acids can be done in different ways, as 
summarized for lipid microbubbles in Figure 17. First of all, drugs can be incorporated inside 
the microbubble shell, either by dissolving the drug in an oil layer within the microbubble, or by 
formulating it in the lipid or polymer shell161, 162. The amount of drug that can be loaded in this 
way, however, is limited as the microbubble coating is generally quite thin (a few nanometers 
for lipid bubbles and 2-500 nm for polymer bubbles). Secondly, cationic microbubbles have 
been formulated, which can be electrostatically loaded with nucleic acids (mainly plasmid 
DNA)163-165. Here, the loading capacity is determined by the charge of the microbubble, which 
is driven by the number of cationic lipids which can be incorporated without impacting lipid 
packing and microbubble stability166. Lastly, and most interestingly, NPs containing drugs or 
genes can be attached to the surface of microbubbles via avidin-biotin bridges or via covalent 
thiol-linkages. This technique has the advantage of a relatively high loading capacity, as 
demonstrated by Geers et al. who estimated that about 600-1300 drug-loaded liposomes could 
be covalently coupled to a single lipid-coated microbubble167. Moreover, a wide range of 
therapeutic agents have been linked to microbubbles in this way, including liposomes 
containing cytostatic drugs (e.g. doxorubicin)167-169 and nucleic-acid containing NPs (e.g. pDNA 
or siRNA lipoplexes)159, 170, 171.  
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Figure 17. Strategies for drug and gene loading of (lipid) microbubbles.  
Drugs can be loaded by (a) dissolving the drug in an oil layer within the microbubble; (b) 
incorporating drugs within the microbubble shell; (c) electrostatically binding anionic 
components such as nucleic acids to cationic microbubbles; (d) attaching drug- or gene-
containing nanoparticles to the surface of functionalized microbubbles.  
Image reproduced from Lentacker et al.172 
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CONCLUSIONS 
With respect to immunotherapy, we have come a long way from beginning to understand 
how the immune system can protect us from danger to realizing how we can harness it in the 
battle against cancer. By the day, our knowledge on effector cells, stimulatory and suppressive 
cytokine signaling pathways and potential therapeutic targets expands. However, the number 
of reports where particles are described that deliver both tumor antigens and immunostimulants 
to DCs in vivo is still limited. To gap the bridge between what we already know about the 
induction of immunity, and the development of suitable biomaterials, close collaboration 
between material scientists and immunologists is probably key.  
From the therapeutic imaging point of view, theranostics are multifunctional agents that 
merge imageable and therapeutic moieties. The ability to image drug distribution and release, 
or to be able to simultaneously treat and follow-up treatment have made them trending topics 
of investigation. Especially the development of theranostics for imaging techniques that do not 
require the use of ionizing radiation, such as MRI (1H and 19F) and ultrasonography, could be 
clinically relevant for visual treatment feedback. How exactly these can be implemented and 
lifted from theranostics to immunotheranostics will be investigated in the following chapters.  
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ABSTRACT 
Dendritic cell (DC)-based cancer vaccination has shown great potential in cancer 
immunotherapy. As a result, novel nanoparticles that aim to load DCs with tumor antigens 
are being developed and are evaluated in vitro. For this, murine bone marrow-derived 
DCs (BM-DCs) are most commonly used as model DCs. However, many different 
protocols exist to generate these cells. Therefore, we investigated to what extent different 
BM-DC culture protocols impact on the immunobiology of the cells, as well as their 
response to particulate antigens. We evaluated four different BM-DC protocols with two 
main variables: bovine serum and cytokine combinations. Our results show distinct 
differences in yield, phenotypical maturation status and the production of immune 
stimulatory and immune suppressive cytokines by the different BM-DCs. Importantly, we 
demonstrate that the antigen-loading of these different BM-DCs via transfection with 
mRNA lipoplexes results in large differences in transfection efficiency as well as in the 
capacity of mRNA-transfected BM-DCs to stimulate antigen-specific T cells. Thus, it is 
clear that the BM-DC model can have significant confounding effects on the evaluation of 
novel nanoparticulate vaccines. To take this into account when testing novel particulate 
antigen-delivery systems in BM-DC models, we propose to (1) perform a thorough 
immunological characterization of the BM-DCs and to (2) not only judge a particle’s 
potential in cancer vaccination based on transfection efficiency, but to include an 
evaluation of functional end-points such as T cell activation. 
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INTRODUCTION 
As discussed in Chapter 1, novel nanoparticulate vaccines are being developed to deliver 
tumor associated antigens (TAAs) and immune adjuvants to dendritic cells (DCs) in vivo. In 
search of novel strategies for effective TAA-loading of DCs to combat cancer or viral infections, 
experiments are generally performed on in vitro generated DCs. The main reason for this is the 
low number of in vivo DCs that can be isolated from different tissues1-3. As a result, different 
protocols were established for the in vitro production of DCs, generated from murine bone 
marrow precursors or from the peripheral blood monocytes found in human blood4-7. By 
culturing these murine and human monocytic precursors for a number of days in the presence 
of appropriate cytokines, their differentiation into murine bone marrow-derived DCs (BM-DCs), 
and human monocyte-derived DCs (MoDCs) will be induced. This way, convenient DC models 
for in vivo studies of the DC functionality, phenotype, immunogenic potential and antigen-
presentation capacity were established. Importantly, these models gained in popularity among 
researchers who are developing novel particulate systems for the delivery of protein or nucleic 
acid antigens to DCs. However, it should be noted that even though these methods result in 
the generation of large numbers of cells with DC-like properties, they do not seem to correspond 
to any of the DC subsets that under normal circumstances populate the mouse lymph nodes. 
Instead, they rather, but not completely, resemble “emergency” or “inflammatory” DCs that only 
occur in inflamed lymph nodes8-10. Therefore, in vitro generated monocyte-derived DCs need 
to be considered as simplified models for a complex in vivo situation, and conclusions from 
experiments using these cells should be drawn with the necessary caution.  
An additional critical factor that complicates the use of DCs in vitro, is the plethora of 
protocols that are available for the generation of these cells. The differentiation of bone marrow 
into BM-DCs can be achieved with either GM-CSF (granulocyte-macrophage colony-
stimulating factor) alone or in combination with IL-4 (interleukin-4), but also other factors, 
including Flt3L (FMS-related tyrosine kinase 3 ligand) or IL-3 have been employed at different 
concentration ratios8, 11, 12. Changing the cocktail and concentrations of cytokines can result in 
major differences in DC phenotype. In addition, other factors such as cell culture medium, the 
timeframe for DC generation from bone marrow precursors, additional purification steps, mouse 
age and especially growth factors that are present in the sera that are routinely added to the 
culture medium may decide the type of BM-DCs that are produced. Obviously, these differences 
make it difficult to compare results obtained in different in vitro models. For one, the variability 
of BM-DCs generated via different protocols has already lead to substantial debate on an 
immunological level. For instance, Lutz et al. observed major differences in the immune 
stimulating properties of BM-DCs based on the serum and cytokine cocktails used during their 
differentiation from bone marrow cells13, 14.  
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Importantly, this variability in BM-DC protocols can also be observed in research on novel 
antigen-delivery systems. In recent years, numerous reports on the design of novel biomaterial 
systems to deliver antigenic material to DCs, packaged in nano- and microparticles have been 
published. These delivery vehicles are becoming increasingly complex, often packaging 
antigen-coding nucleic acid sequences (plasmid DNA and mRNA) instead of proteins or peptide 
antigens and aiming for controlled or triggered antigen-delivery to antigen-presenting cells15-17. 
In the initial evaluation of these particles, BM-DCs are often used as model DCs. And here as 
well, a vast diversity in the BM-DC generation protocols is observed. We hypothesize that these 
changes in the culture protocols for BM-DCs in vitro have important repercussions for their 
response to particulate antigens, and that a careful choice of the BM-DC protocol is warranted 
in order to give newly designed delivery systems a full chance of success.  
In this chapter, we aim to investigate the effect of using four differently generated model 
DCs on their immunological properties, as well as their response to particulate antigen. More 
specifically, we chose to use lipoplexes containing antigen-coding mRNA. mRNA is particularly 
interesting for the delivery of antigens to DCs, as it offers several advantages: (a) by introducing 
antigen mRNA, the antigenic protein will end up in the DC cytoplasm and will therefore 
preferentially be presented in MHC-I which results in de induction of CD8+ T cells; (b) by 
introducing the nucleic acid sequence encoding an entire protein, immune responses against 
multiple epitopes can be induced; (c) mRNA is translated in the cytoplasm and therefore does 
not need to cross the nuclear membrane, in contrast to plasmid DNA and (d) mRNA is not 
considered as a gene therapeutic, as it does not encompass the risk of genomic integration18. 
For these reasons, we used particles consisting of mRNA complexed to cationic lipids, and 
evaluated their use in different BM-DC models.  
MATERIALS AND METHODS 
Dendritic cell culture 
Primary murine BM-DC cultures were generated from C57BL/6 mice. Female C57BL/6 
mice were purchased from Harlan Laboratories and housed in an SPF facility according to the 
regulations of the Belgian law and the local Ethical Committee. Mice were euthanized and bone 
marrow was flushed from the hind limbs. The red blood cells in the resulting single cell 
suspension were lysed (Pharm Lyse Buffer, BD Biosciences, Erembodegem, Belgium) and the 
collected cells were seeded in 100 mm Not TC-Treated polystyrene Culture Dishes (Corning®, 
Amsterdam, The Netherlands) at 2x106 cells ml-1 in 15 ml. The cell culture medium used was 
RPMI 1640 (Gibco-Invitrogen, Merelbeke, Belgium) supplemented with 
penicillin/streptomycin/L-glutamine (1%, Gibco-Invitrogen) and β-mercaptoethanol (50 µM, 
Gibco-Invitrogen) and 5% serum. Two different types of serum were used: Fetal Bovine Serum 
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(FBS 5%, Batch n°RSE30013, HyCloneTM, Pierce, Rockford, IL, USA) and FetalClone™ I (FCI 
5%, Batch n°AXD36551, HyCloneTM). To promote differentiation of the monocytes into BM-
DCs, cytokines were added: GM-CSF alone (20 ng ml-1, Peprotech, Rock Hill, NJ) or a 
combination of GM-CSF (10 ng ml-1) with IL-4 (10 ng ml-1, Peprotech). On day 3 of the culture, 
an additional 15 ml complete cytokine-supplemented culture medium containing GM-CSF 
(40 ng ml-1) or GM-CSF and IL-4 (both at 20 ng ml-1) was added. On day 5, all cells were 
collected by centrifugation (5min at 300 g), resuspended in the appropriate culture medium at 
106 cells ml-1 and seeded in 24 well plates for experiments (5x105 cells per well). For every 
experiment, 1 single batch of bone marrow cells was used to generate the 4 different BM-DC 
cultures in order to exclude bias due to animal-related effects.  
Cell yield, viability and purity 
At day 5, when the cells were collected from the petri dishes, cell yield was determined 
by counting the collected cells with trypan blue exclusion of dead cells (Sigma-Aldrich, Bornem, 
Belgium). DC purity and cell viability were evaluated the next day, via anti-CD11c-
allophycocyanin (APC) surface staining (eBiosciences, Vienna, Austria) and a SYTOX® green 
nucleic acid stain (Molecular Probes/Invitrogen, Merelbeke, Belgium), respectively. The cells 
were collected from the wells, washed in FACS buffer (phosphate buffered saline (PBS, Gibco-
invitrogen), supplemented with 5% bovine serum albumin, BSA (Sigma-Aldrich, Bornem, 
Belgium)) and incubated with a staining buffer containing both the antibody and 45 nM SYTOX® 
green for 30min at 4°C. After additional washing steps, the cells were analyzed by flow 
cytometry using a FACSCalibur and CellQuest Pro software (BD Biosciences). 
Microscopy 
Transmission microscopy images of the cells obtained via the different BM-DC generation 
protocols were recorded using a Nikon C1si confocal laser scanning module attached to a 
motorized Nikon TE2000-E inverted microscope (Nikon Benelux, Brussels, Belgium), equipped 
with a Plan APO 40x DIC water immersion objective lens (Nikon) and suitable optical elements 
to obtain differential interference contrast (DIC) transmission images. For this, the cells were 
seeded in 35 mm MatTek glass bottom culture dishes (MatTek Corporation, MA, USA) on day 
5 of the culture, and imaged on day 6.  
BM-DC phenotype analysis 
The effect of different sera or cytokine combinations on the DC phenotype was 
investigated by examining the expression of the maturation markers CD40, CD86 and MHC-II 
on the DC surface. For this, the cells (at day 6 of the culture) were either untreated, or 
supplemented with Escherichia coli-derived lipopolysaccharide (1 µg ml-1 LPS, Sigma-Aldrich) 
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to induce maturation. 24h after LPS addition, the cells were collected, washed with flow buffer 
and surface stained for the DC marker CD11c-APC in combination with staining for either 
CD40-phycoerythrin (PE), CD86-PE or MHC-II-fluorescein isothiocyanate (FITC) (all BD 
Bioscience) for 30min at 4°C. After additional washing steps, the cells were analyzed by flow 
cytometry. 
mRNA 
Luciferase, eGFP, and ovalbumin (OVA) mRNA were produced by in vitro transcription 
from pBlue-Luc-A50, pGEM4Z-GFP-64A and pGEM-Ii80tOVA plasmids19. The plasmids were 
purified using a QIAquick PCR purification kit (Qiagen, Venlo, The Netherlands) and linearized 
using Dra I (for the pBlue plasmid) or Spe I (for the pGEM plasmids) restriction enzymes 
(Promega, Leiden, The Netherlands). Linearized plasmids were used as templates for the in 
vitro transcription reaction using the T7 mMessage mMachine kit (Ambion, Life Technologies, 
Ghent, Belgium). The resulting capped and polyadenylated mRNAs were purified by DNase I 
digestion, LiCl precipitation and washed with 70% ethanol. The mRNA concentration was 
determined by measuring the absorbance at 260 nm. mRNAs were stored in small aliquots at 
-80°C at a concentration of 1 µg µl-1. 
mRNA lipoplexes 
Cationic liposomes, containing 50% DOTAP (1,2-dioleoyl-3-trimethylammonium-
propane) and 50% DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) (both Avanti Polar 
Lipids, Alabaster, AL) were prepared by transferring the appropriate amounts of lipids, 
dissolved in chloroform into a round-bottom flask. To prepare fluorescent mRNA lipoplexes, 
1 mol.% CholEsteryl-BODIPY® FL C12 (Molecular Probes/Invitrogen) was added. The 
chloroform was evaporated under nitrogen and the resulting lipid film was rehydrated in RNase-
free water (Ambion) to obtain a final lipid concentration of 1 mg ml-1. The resulting 
DOTAP/DOPE liposomes were sonicated for 15min in a bath sonicator (Branson Ultrasonics, 
Dansbury, USA), after which they were mixed with mRNA to obtain mRNA lipoplexes at a 
cationic lipid-to-mRNA charge (N/P) ratio of 10 in OptiMem® (Gibco-Invitrogen). The produced 
liposomes and lipoplexes were subjected to a size and zeta potential quality control prior to 
use, using a Malvern Zetasizer nano-ZS (Malvern Instruments Ltd, Worcestershire, UK). 
mRNA lipoplex loading and transfection of DCs 
Uptake and transfection efficiency of mRNA lipoplexes were evaluated in the four 
differently generated BM-DCs. Lipoplex loading was performed on BM-DCs at day 6 in 24 well 
plates. The cell culture medium was removed and the mRNA lipoplexes, dispersed in OptiMem® 
were added for 2h at 37°C (1 µg mRNA per well, N/P=10). For uptake experiments, fluorescent 
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mRNA lipoplexes containing luciferase mRNA were used. After the 2h incubation period, the 
cells were collected, washed with FACS buffer and extracellular fluorescence was quenched 
using trypan blue (1:1 diluted in FACS buffer for 5 min at RT). Then, the cells were washed, 
surface stained for CD11c-APC and the uptake of fluorescent mRNA lipoplexes was evaluated 
by flow cytometry. The transfection efficiency of the lipoplexes was evaluated using eGFP 
mRNA, and after the 2h incubation of the BM-DCs with the particles in OptiMem®, the cells 
were re-cultured in the appropriate cell culture media. After 24h incubation at 37°C, the eGFP-
transfected cells were collected, surface stained for CD11c-APC and expression of eGFP was 
analyzed by flow cytometry. Untreated cells served as a negative control. 
In vitro T cell activation assay 
In order to assess the potential of the BM-DCs to prime antigen-specific CD8+ T cells, an 
in vitro OT-I activation assay was performed. In this assay, OVA lipoplex transfected DCs were 
co-cultured with OT-I cells, which have a transgenic T cell receptor that recognizes the MHC-I 
restricted OVA-peptide SIINFEKL. Untreated and eGFP-transfected DCs served as negative 
controls. As a positive control, DCs loaded with SIINFEKL peptide (1 µg ml-1, Eurogentec, 
Seraing, Belgium) were used. 5h after transfection, the cells were matured for 2h with LPS. 
Then, the DCs were collected, washed, and seeded per 104 DCs in a U-bottom 96 well plate 
(Falcon, BD Bioscience), for co-incubation with 105 OT-I cells (derived from the spleens of OT-
I transgenic mice, Charles River). After 5 days, the cells were collected, surface stained for 
CD8-APC (BD Pharmingen) and the T cell activation marker CD25-PE (MACS Miltenyi, Leiden, 
The Netherlands) and analyzed by flow cytometry.  
ELISA 
Supernatants of untreated and LPS-stimulated DCs were screened for the presence of 
IL-10 and IL-12p70. Supernatants of DC-T-cell co-cultures were assayed for IFNγ and  
IL-2. Cytokine concentrations were measured via ELISA (all Ready-SET-Go!® ELISA kits, 
eBioscience) according to the manufacturer’s instructions. 
Statistical analysis 
All data are presented as mean ± standard deviation (SD). Presented data are 
representative for at least 3 independent experiments performed on cells derived from the bone 
marrow of different donor mice, except for the uptake experiments. Statistical analyses were 
performed using a one-way ANOVA with Bonferroni correction.  
 
62 | C h a p t e r  2  
RESULTS 
DC yield, purity and viability 
We tested a limited number of variations that are commonly encountered in murine BM-
DC generation protocols. Based on previous results, we chose to use BM-DCs at day 6 of the 
culture as this, in our hands, results in the largest cell yield and the lowest percentages of 
mature DCs in untreated samples. A first variable is the cytokine combination that is used to 
induce differentiation into BM-DCs. Initially, co-supplementation with GM-CSF and IL-4 was 
used, whereas more recent studies are performed on cells that were generated with GM-CSF 
alone. In order to investigate the influence of IL-4, we generated BM-DCs with cytokine 
supplementation of GM-CSF in the presence or absence of IL-4. A second important parameter 
is the serum that is added to the BM-DC culture medium as a source of nutritional and growth 
factors. In general, using different batches of fetal bovine serum (FBS) is known to cause 
variation in cell viability and growth rates due to large batch-to-batch variation in the levels of 
both defined and undefined growth factors present. Besides batch differences, varying types of 
serum have been used and tested for BM-DC generation. Therefore, we chose to use two 
different types of sera within the cell culture medium: regular FBS and FetalClone™ I serum 
(FCI). According to the manufacturers’ information, the latter is supplemented with additional 
growth factors, but contains lower levels of certain immunosuppressive growth factors such as 
transforming growth factor beta-1 (TGF-β1). By changing these two parameters, we obtained 
four different protocols for the generation of BM-DCs and first investigated the influence of these 
parameters on cell yield, cell viability and DC purity.  
A first observation after 6 days of culturing murine bone marrow cells in the four different 
culture media, was the difference in cell number. When the growth media are supplemented 
with FCI, expansion of the cell number is observed, with an 80% increase in cell count when 
GM-CSF is used alone, and 40% increase when a combination of GM-CSF and IL-4 is used. 
In the case of FBS-supplementation, on the other hand, the cell number decreases after 6 days 
of culture, resulting in a 40% and even 60% reduction in cell count when cultured when GM-
CSF alone or combined with IL-4, respectively.  
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Figure 1: Morphology, viability and purity of different BM-DC cultures.  
Images show (A) Transmission microscopy images of BM-DCs generated via the four 
different protocols on day 6 of the culture. Red arrows indicate cells with a DC-like 
appearance; (B) Graphic representation of cell viability measured via SYTOX® green 
nucleic acid staining (n=3); (C) Graph showing the purity of the BM-DC cultures based on 
staining for CD11c (n=6), with representative scatterplots shown in (D). There were no 
significant differences between the BM-DC cultures with respect to cell viability (B). 
Regarding the DC purity (C), the observed differences were all statistically significant 
(p<0.001). 
In all cases, the resulting cell population is quite heterogeneous, as can be seen in 
transmission microscopy images in Figure 1A. These show that in all four BM-DC cultures, the 
cells can grow both adherent to the petri dish surface, as well as suspended within the culture 
medium. In addition, the size and shape of the cells can largely vary. In all populations, a fraction 
of the cells display a DC-like appearance, with dendrites protruding from the cell membranes. 
To evaluate the viability of the cells after 6 days of culture, a SYTOX® green nucleic acid stain 
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was performed. As shown in Figure 1B, although there is a trend towards lower cell viability 
when IL-4 is added to the medium, the observed differences were not significant, and for all 
protocols tested, the percentage of viable cells exceeded 80%.  
In order to determine exactly how many BM-DCs can be obtained from each of the four 
culture circumstances, the cells were surface stained for the DC maker CD11c and analyzed 
by flow cytometry. The results in Figure 1C and 1D indeed support the microscopic 
ascertainments, indicating that a portion of the cells in the population expresses CD11c and 
can therefore be identified as BM-DCs. A percentage of CD11c positive cells over 80% can be 
reached when cells are cultured in medium supplemented with FBS and GM-CSF alone, 
whereas the DC purity in the other cultures is limited to 50%. When these purity results are 
combined with the differences in total cell yield at day 6 of the culture, FCI-supplemented 
medium will provide the largest number of DCs, and GM-CSF alone is superior over a 
combination of GM-CSF and IL-4. 
Often, researchers selectively collect either the suspension or the adherent fraction to 
use in their experiments. In our hands, CD11c+ BM-DCs were found at high percentages in both 
suspension and adherent fractions, therefore, we chose to collect and use all cells for further 
experiments. 
DC phenotype 
An important phenotypical parameter that can provide information on the immunological 
properties of BM-DCs, is their maturation status. During maturation, DCs shift in function from 
antigen-uptake to antigen-presentation, a process that is accompanied by increased expression 
of different molecules that are required for effective antigen-presentation. As their presence is 
a crucial prerequisite for DCs to become effective T cell activators, we evaluated to what extent 
well-known maturation markers CD40, CD86 and MHC-II are present on the surface of the BM-
DCs generated via the different protocols. For this, both untreated (blank) and BM-DCs where 
maturation was induced by co-incubating them with bacteria-derived lipopolysaccharide (LPS) 
were surface stained for both the DC marker CD11c and the different maturation markers.  
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Figure 2. Expression of maturation markers by blank and LPS-stimulated DCs.  
Untreated (blank) and LPS-stimulated DCs (LPS) were analyzed for the expression of 
different maturation markers. DCs were gated based on CD11c staining. Images show (A) 
percentages of CD40 expressing DCs with (B) representative histograms; (C) percentages 
of CD86 expressing DCs with (D) representative histograms and (E) percentages of MHC-
II expressing DCs with (F) representative histograms. (n=3) 
The results of flow cytometric analysis can be found in Figure 2. In the case of the blank 
DCs, the same trends could be observed for all maturation markers tested. First of all, BM-DCs 
generated in the presence of IL-4 exhibit a more mature phenotype, which evidences that IL-4 
enhances the maturation process. Secondly, changing the serum in the cell culture media also 
has a significant effect on the phenotype of the generated BM-DCs. In general, supplementation 
with FBS results in increased maturation marker expression compared to FCI. For effective 
activation of effector cytotoxic T lymphocytes by DCs, a fully mature DC phenotype is crucial. 
Even more so, numerous researchers have reported that antigen presentation by immature or 
partially mature DCs will induce antigen-specific tolerance rather than immunity20. Therefore, 
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we studied the phenotypical properties of the different BM-DC cultures after overnight 
incubation with LPS, a known toll-like receptor 4 (TLR4) ligand, which is expected to induce 
complete maturation. Indeed, in all of the BM-DC populations, there is a marked increase in the 
maturation marker expression level. However, these maximal levels vary gravely. Especially for 
of BM-DCs cultured with FCI and GM-CSF alone, the percentage of fully mature CD86 and 
MHC-II expressing cells is limited to 40%, whereas percentages over 90% can be reached 
when FBS is used. For CD40 expression, differences between the different LPS-stimulated BM-
DCs are less pronounced.  
Besides expression of molecules needed for antigen presentation and T cell activation on 
the DC surface, the cells also produce cytokines that can skew T cell responses towards 
immunity or tolerance. We evaluated the production of two different cytokines by means of 
ELISA assays: the inflammatory cytokine IL-12p70, which is crucial for the activity of effector T 
cells and natural killer cells and on the other hand, the immune suppressive cytokine IL-10. As 
shown in Figure 3A, the production of IL-12p70 corresponds nicely to the maturation marker 
expression by the cells. IL-4 addition as well as utilization of FBS for the culture medium will 
enhance the IL-12p70 production. The production of IL-10, which is a mediator of immune 
tolerance, also points towards a preferable situation when FBS and a combination of GM-CSF 
and IL-4 are used, as these both lead to a significant reduction in IL-10 production (Figure 3B).  
 
Figure 3. Cytokine expression by untreated and LPS-stimulated DCs.  
DC culture supernatants were collected after 24h of incubation in blank or LPS-
supplemented culture medium. The supernatants were assayed for the immunostimulatory 
cytokine IL-12p70 (A) as well as the immune suppressive IL-10 (B). Graphs are 
summaries of 2 independent experiments (n=6). 
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mRNA lipoplex uptake and transfection potential  
The previous experiments have exposed large differences in BM-DC yield, phenotype 
and cytokine production, when the cells are cultured via different protocols. Importantly, all of 
these protocols have been used to generate BM-DCs for the evaluation of novel antigen-
delivery systems designed for potential use in DC-based vaccination. Therefore, we wanted to 
investigate to what extent the choice of BM-DC model could influence the results obtained with 
particulate antigens. As a model antigen-delivery system, we chose mRNA lipoplexes, since 
mRNA is becoming increasingly investigated as a source of antigen, and this requires more of 
the DCs’ own machinery for translation and presentation of the antigens, compared to the use 
of protein- or peptide-antigens21. For the evaluation of such nucleic acid vaccines in vitro, 
transfection efficiency is employed as one of the main parameters and this can make or break 
the chance for further success. Therefore, we investigated if changes in the BM-DCs culture 
protocols influence the uptake and transfection potential of mRNA lipoplexes.  
We prepared DOTAP/DOPE-lipoplexes with a cationic lipid-to-mRNA charge (N/P) ratio 
of 10. At this N/P ratio, complete complexation of mRNA is observed. This was supported by 
zeta potential measurements, which exhibited a drop in surface charge, from 64 ± 6 mV for the 
cationic liposomes to 51 ± 7 mV after mRNA complexation to the lipids. mRNA complexation 
resulted in a ~ 1.5 fold increase in mean particle size, as determined by dynamic light scattering 
(DLS) measurements. Mean particle sizes for liposomes and lipoplexes were 177 nm and 
274 nm with a polydispersity index of 0.3 for both particles. 
Overall, DCs exhibiting a more mature phenotype are expected to be less efficient in 
endocytosis and phagocytosis. This can be related to their function: mature DCs focus on 
antigen presentation, rather than antigen uptake22. To evaluate to what extent this affects 
mRNA lipoplex uptake by the cells, we incubated the different BM-DC cultures with fluorescently 
labeled mRNA lipoplexes. After 2h of incubation, we evaluated the internalization of the mRNA 
lipoplexes by means of flow cytometry. We observed an efficient uptake of the nanoparticles by 
the cells: in all BM-DC models tested, the percentage of lipoplex-loaded CD11c-positive cells 
was over 96%. However, when looking at the amount of intracellular mRNA lipoplexes, we 
could observe large differences in the mean fluorescence intensity (MFI) between the different 
BM-DC models, as shown in Figure 4A. As could be expected, the extent of nanoparticle 
uptake nicely correlated to the phenotypical maturation of the cells: more mature cells were 
less efficient in engulfing the fluorescent mRNA lipoplexes.  
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Figure 4. Uptake and transfection efficiency of mRNA lipoplexes.  
(A) MFI of BM-DCs after 2h incubation with fluorescently labeled mRNA lipoplexes. 
Untreated cells served as blanks (n=6). (B) percentages of eGFP transfected DCs 24h 
after incubation with mRNA lipoplexes. Representative flow cytometry scatterplots are 
shown in (C). DCs were gated based on CD11c surface staining.  
Data represent mean ± SD. (n=3, *p<0.05, **p<0.01). 
In order to evaluate and to compare the efficiency of mRNA lipoplexes to transfect the 
different generated BM-DCs, mRNA encoding enhanced green fluorescent protein (eGFP) was 
used. eGFP mRNA lipoplexes were added to the cells as described in the materials and 
methods section. After overnight incubation, DCs were surface stained for CD11c and levels of 
eGFP expression were evaluated by flow cytometry. The results of the flow cytometry analysis 
are presented in Figure 4B-C. Each DC culture was significantly transfected, but transfection 
efficiencies differed greatly from one culture to another, ranging from minimally 10% and 
maximally 37%. Clearly the choice of the BM-DC generation protocol highly influences the 
transfection efficiency of mRNA lipoplexes. Interestingly, for both sera tested the addition of IL-
4 resulted in a significant reduction in transfection. Furthermore, this was more profound in the 
FBS-supplemented culture, which would suggest an additional influence of FBS-supplemented 
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medium compared to FCI-containing medium. When GM-CSF was used alone, no significant 
difference in transfection efficiency was observed between the DCs cultured in FBS or FCI.  
In vitro T-cell activation 
 
Figure 5. Antigen-specific T cell activation by mRNA lipoplex transfected DCs.  
OT-I T cells were co-cultured with DCs transfected with eGFP or OVA mRNA. Blank and 
SIINFEKL-loaded DCs served as negative and positive controls respectively. After 5 days, 
T cell activation was evaluated by measurement of CD25 expression and cytokine 
measurements. Figures show (A) % of CD25 positive OT-I T cells with (B) corresponding 
CD25 mean fluorescence intensity (MFI); (C) IL-2 production and (D) IFNγ production. n=3 
for all experiments. (Statistical analysis is given in Figure 6) 
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The key feature of DCs is their capacity to activate antigen-specific T cells, and to induce 
their differentiation into effector T cells. Since cancer immunotherapy mainly focuses on the 
induction of CTL responses directed against the tumor cells, we wished to evaluate the potential 
of different BM-DCs, loaded with mRNA lipoplexes, to induce antigen-specific CD8+ T cell 
activation. For this, we performed an OT-I T cell activation assay. OT-I cells carry a transgenic 
CD8 T cell receptor which specifically recognizes the MHC-I restricted OVA peptide SIINFEKL. 
Therefore, if these OT-I cells are stimulated by mature DCs that present SIINFEKL in the 
context of MHC-I, these cells will be activated. This activation is accompanied by an increased 
expression of CD25 on the T cell surface.  
As demonstrated in Figure 5A, all BM-DCs that were loaded with SIINFEKL peptide 
(positive control) were capable of inducing expression of CD25 in over 90% of OT-I cells. 
Changing cytokines or serum merely has a slight influence on the percentage of CD25 positive 
OT-I cells after 5 days of co-culture. When antigens were loaded into the DCs via mRNA 
lipoplexes, CD25 expression is comparable to the SIINFEKL positive control, indicating 
extensive antigen presentation in MHC-I by the mRNA-transfected BM-DCs. Only in the BM-
DCs cultured with both GM-CSF and IL-4 in FBS-containing medium, mRNA-transfection 
results in a lower CD25 expression on OT-I T cells. The differences between the different BM-
DC protocols are more prominent when the amount of CD25 expressed by the cells is studied, 
rather than the percentage of CD25-positive cells. For this, we looked at the MFI of the CD25-
PE stain on the OT-I cells. The results in Figure 5B demonstrate that a higher CD25 expression 
could be detected in co-cultures of OT-I cells and OVA transfected BM-DCs either generated 
with FCI and GM-CSF + IL-4 or generated with FBS and GM-CSF alone. The lowest CD25 
expression was observed with FBS and GM-CSF + IL-4 supplemented BM-DCs (Figure 5B).  
Upon activation, the T cells can start proliferating, which often coincides with the 
production of IL-2. Moreover, if CD8+ T cell activation leads to differentiation into CTLs, the cells 
will start secreting IFNγ, a type II interferon that enhances the CTL activity. Therefore, we 
measured the secretion of IL-2 and IFNγ in the DC-T cell co-culture supernatant via ELISA. The 
IL-2 production can be partly linked with the expression of CD25, pointing towards superior T 
cell activation by BM-DCs either cultured with GM-CSF and IL-4 in FCI-supplemented medium 
or with GM-CSF alone in FBS-supplemented medium. Importantly, the most remarkable 
differences were observed in the IFNγ production. Overall, BM-DCs cultured in FCI containing 
medium could double the IFNγ secretion by OT-I T cells compared to BM-DCs cultured with 
FBS. A more detailed statistical analysis of the results in this section can be found in Figure 6. 
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Figure 6. Statistical analysis of T cell activation by transfected DCs.  
The results of the T cell activation experiments in Figure 5 were statistically analyzed with 
a one-way ANOVA followed by Bonferroni correction. Graphs show the mean difference 
with standard errors between the results obtained in different BM-DC cultures for: (A) % 
CD25 positive OT-I cells after stimulation with OVA-lipoplex transfected DCs (A1) or 
SIINFEKL-loaded DCs (A2); (B) the CD25 MFI on OT-I cells after stimulation with OVA-
lipoplex transfected DCs (B1) or SIINFEKL-loaded DCs (B2); the secretion of IL-2 after 
stimulation with OVA-lipoplex transfected BM-DCs (C1) or SIINFEKL-loaded DCs (C2); (D) 
for the secretion of IFNγ after stimulation with OVA-lipoplex transfected DCs (D1) or 
SIINFEKL-loaded DCs (D2).  
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DISCUSSION 
BM-DCs are extensively used as in vitro model systems to investigate DC 
immunobiology, as well as for the evaluation of novel particulate vaccines. Due to large variation 
in protocols to generate BM-DCs from bone marrow precursors23, 24, we hypothesized that the 
validation of novel antigen-delivery nanoparticles might be influenced by the BM-DC culture 
that is used for their evaluation. Several studies reported on a number of crucial factors that 
can impact the yield, purity and phenotype of BM-DCs generated13, 25. Based on the work of 
Lutz et al., main variables are (a) mouse properties, (b) growth factors and (c) serum 
supplementation13. To exclude the first variable, we opted to consistently use female C57BL/6 
mice at 7 weeks of age. With regard to the two other variables, we screened recent literature 
on nanoparticulate vaccines to find out which growth factor combinations and sera are most 
widely used. Most researchers evaluate novel nanoparticles in BM-DCs grown in RPMI medium 
supplemented with GM-CSF alone (20 ng ml-1), or with IL-4 (10 ng ml-1) in addition to GM-CSF 
(10 ng ml-1). As for the serum, Lutz and Rossner described this to be the most important factor 
influencing the type of BM-DCs generated13. Therefore we chose to work with two different 
types of bovine serum: FBS and FCI.  
After 6 days of culturing red blood cell-depleted murine bone marrow cells in the different 
cell culture media, the percentage of CD11c+ DCs ranges from 39 to 80%. The highest BM-DC 
purity can be reached when FBS serum and GM-CSF alone are used. In accordance with 
previous reports, addition of IL-4 to the medium reduces the yield and purity of the BM-DCs25. 
It should be noted that other factors, such as the duration of the BM-DC culture or the 
implementation of additional, and often quite complex, purification steps, can result in cultures 
with larger percentages of CD11c+ cells4, 23, 26. Often, cells growing adherent to the culture 
dishes are excluded in order to increase BM-DC purity. In our hands, however, for all culture 
media tested, the adherent cell fraction contained a substantial portion of CD11c-expressing 
BM-DCs. This confirms previous results obtained by Li and Lu, who showed that there is no 
reason to discard adherent cells in BM-DC cultures as junk cells27. Overall, practically all BM-
DC protocols will finally result in a cell population containing a (large) fraction of CD11c+ BM-
DCs as well as a fraction of non-DCs. These two subpopulations are expected to behave 
differently with regard to e.g. endocytotic capacity, maturation marker expression and cytokine 
production. Therefore, in order to assess the impact of novel nano- and micromaterials on DCs 
in vitro, it is important to selectively investigate the response of CD11c+ cells, rather than the 
total cell population. Assays where no further selection or gating of CD11c-expressing cells is 
possible (e.g. cell counts, many cytotoxicity assays, DC-T cell co-cultures, other assays 
performed on the total population), can be impacted by these large variations in BM-DC purity. 
This should be taken into account in the design and set-up of new experiments. 
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Substantial differences in surface marker expression can also exist within the CD11c-
positive population. This was made obvious by performing antibody staining against maturation 
markers CD40, CD86 and MHC-II, where we demonstrated the presence of both immature as 
well as mature BM-DCs in all cultures. Importantly, addition of IL-4 increases the proportion of 
mature DCs. This can be explained by the induction of “spontaneous” maturation of generated 
BM-DCs, which is known to be enhanced by the presence of IL-423, 28, 29. In addition, replacing 
FBS by FCI induces a significant reduction of maturation marker expression by the BM-DCs. In 
a study of Lutz et al., high serum levels of the liver enzymes glutamic oxaloacetic transaminase 
(GOT) and lactate dehydrogenase (LDH) have been correlated with high percentages of mature 
cells13. For the batches of FBS and FCI we used, this correlation was not observed: the FCI 
used contained high levels of both liver enzymes, whereas merely a small fraction of the DCs 
exhibited a mature phenotype. Even though the effect of the serum compound is prominent, 
the complexity of these bovine products makes it difficult to pinpoint the exact cause of the 
observed maturation-differences. 
In nanoparticle research, a first step towards success is the efficient uptake of the 
nanomaterials by the target cells. In the case of DCs, their internalization capacity is closely 
related to their maturation status: although mature DCs are still capable of performing receptor-
mediated endocytosis, aspecific endocytosis as well as phagocytosis and macropinocytosis are 
markedly reduced in mature DCs compared to their immature counterparts22. This was also 
evidenced by the mRNA lipoplex uptake experiment, showing less extensive mRNA lipoplex 
uptake by BM-DCs that exhibit a more mature phenotype. Therefore, ideally, antigen-containing 
nanoparticles should be evaluated in immature BM-DCs. However, a striking observation was 
the reduced maturation capacity of the more immature BM-DC subsets. For example, BM-DCs 
cultured with FCI and GM-CSF alone, exhibit the lowest portion of mature DCs in untreated 
samples, but upon TLR4 ligation maximally 40% of the BM-DCs will up-regulate CD86 and 
MHC-II. In contrast, well over 80% of BM-DCs generated in the presence of FBS medium, will 
up-regulate these markers upon LPS stimulation. This reduced responsiveness to maturation 
stimuli is nicely confirmed by cytokine measurements, showing that these specific BM-DCs also 
produce low levels of immune stimulatory IL-12p70 and high levels of the immune suppressive 
IL-10. Such phenotypical properties are expected to impact the immune responses that can be 
induced by these specific DCs. In addition, it is important to consider that for DC vaccines to be 
effective, efficient antigen-presentation by fully mature DCs is required. Since different reports 
have made clear that co-formulation of antigens and maturation stimuli will result in superior 
immune responses, the purpose of nanoparticulate vaccines has shifted from mere antigen 
delivery to dual-modality particles that should simultaneously load DCs with antigens and 
induce maturation of DCs30, 31. Therefore, immune stimulants such as the TLR ligands CpG and 
poly(I:C) have been incorporated into nanoparticulate vaccines32. As these dual-modality 
particles aim to induce complete maturation, it would undoubtedly be disadvantageous to 
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evaluate them in a maturation-resistant BM-DC model. Therefore, a careful choice and 
characterization of the BM-DC model for the intended purpose is required.  
In addition to immunological properties, we wished to assess to what extent 
nanoparticulate vaccines can lead to different results when tested in one BM-DC culture versus 
another. For this, we chose to work with mRNA lipoplexes, since mRNA is an increasingly 
investigated source of antigen in novel DC vaccines21. When DCs are loaded with nucleic acid 
sequences encoding tumor antigens, the transfection efficiency is used as a critical measure 
for the amount of antigen delivered, and hence the main criterion to evaluate new 
nanoparticulate vaccines. An assessment of the transfection efficiency of mRNA lipoplexes in 
our 4 different models, revealed large differences, ranging from 10% to 37% mRNA expressing 
BM-DCs, even though the exact same nanoparticles were used. If transfection efficiency is the 
main parameter, it is now clear that the model BM-DC used for transfection experiments is a 
confounding factor. Do we then use the right means of scoring novel transfection-based 
particulate vaccines? First of all, it should at all times be kept in mind that the final end-point of 
the vaccine is to elicit antigen-specific T cell responses. And this is probably not a question of 
numbers. As reviewed by Gilboa et al., high efficiency transfection of DCs with antigen does 
not necessarily correlate with improved immune stimulatory effects33. In addition, it was 
previously suggested that no analytical method can compare to the sensitivity of T cells to 
detect presented antigens34, 35. Therefore, as a concluding experiment, we evaluated to what 
degree the observed transfection efficiencies could lead to activation of antigen-specific CD8+ 
T cells in vitro. After co-culturing naïve OVA-specific CD8+ T cells with mRNA lipoplex-loaded 
BM-DCs, significant antigen-specific T cell activation could be observed in all models. However, 
the differences observed in the extent of T cell activation point towards influences of both 
phenotypical parameters as well as variations in transfection efficiency. For instance, BM-DCs 
grown in FCI and GM-CSF-supplemented medium showed low expression of molecules 
involved in antigen presentation (MHC-II) and T cell activation (CD86 and IL-12p70). As a result, 
even after efficient loading with antigen-mRNA, merely low T cell stimulation could be detected. 
A similar reasoning is valid for phenotypically superior BM-DCs (e.g. BM-DCs resulting from 
culture with FBS in the presence of IL-4), where a markedly low transfection efficiency is the 
likely cause for the deficient activation of T cells.  
CONCLUSIONS 
To conclude, in vitro data obtained with novel nanoparticles are not exclusively the result 
of the nanoparticle’s capacity to load DCs with antigenic material. Although BM-DCs are 
routinely used as a model for in vivo DCs, they should always be considered as simplified 
models for a complex in vivo situation. By screening a limited number of parameters, we were 
able to demonstrate extensive differences in BM-DC yield and immunological properties. 
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Moreover, we showed that the BM-DC model in which novel nanoparticles are tested, acts as 
an important confounding factor in both transfection efficiency and T cell activation assays. This 
not only makes it hard to evaluate the potential of novel nanoparticles for DC vaccination 
purposes, but also renders it difficult to compare results obtained in different research groups 
using different BM-DC models. We wish to stress that our aim was not to identify an optimal 
BM-DC protocol, but to expose the bias of the model on the functional outcome of the 
nanoparticle. Therefore, we propose to: (1) include a thorough immunological characterization 
of the BM-DCs model used; (2) in addition to transfection efficiency, always evaluate functional 
end-points, such as T cell activation. Only if these two criteria are met, can the impact of the 
model’s confounding effect be assessed, and can the true value of a novel particulate vaccine 
be revealed.  
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ABSTRACT 
Perfluorocarbon (PFC) particles are currently on the rise as cell labeling agents for 
19F MRI tracking of dendritic cell (DC)-based vaccines. In this work, we design theranostic PFC 
particles for single-step loading of DCs with both antigenic protein and a liquid PFC for 19F MRI 
detection of the antigen-loaded cells. Upon addition to DCs in vitro, the antigen-loaded PFC 
particles are efficiently internalized, resulting in the intracellular presence of up to 40 pmol 19F 
atoms per cell. At the same time, the DCs become loaded with antigenic proteins that can be 
efficiently processed, without important effects on cell viability or altering the DC’s phenotype 
and the cell’s capacity to respond to danger signals. In addition, DCs containing antigen-loaded 
PFC particles are capable of inducing extensive proliferation of antigen-specific CD8+ T cells in 
vitro. Importantly, the antigen-coated PFC particles allow in vitro 19F MRI-based detection of 
the antigen-containing DCs with detection limits as low as 103 cells µl-1. The dual-modality 
characteristics of the designed particles could assure that only those DCs that have taken up 
the antigen, and hence are responsible for an immune response, are traceable via 19F MRI. 
Taken together, these novel dual-modality particles represent an interesting strategy in the 
development of a traceable DC vaccine.  
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INTRODUCTION 
As described in Chapter 1, for the production of current dendritic cell (DC)-based 
vaccines, DCs are currently modified ex vivo to present tumor associated antigens and initiate 
anti-tumor immune responses1, 2. These cellular vaccines are mostly injected subcutaneously, 
after which the antigen-laden DCs should be capable to reach the lymph nodes in order to 
present their antigens to naïve T cells. However, different studies in both mouse3, 4 and man5, 6 
have demonstrated that upon injection, merely low percentages (in general <5%) of DCs are 
capable of reaching the draining lymph nodes, whereas most of the transplanted cells are 
retained at the injection site3, 6, 7. Even if the DCs are injected intranodally, in this way 
circumventing migratory problems, de Vries et al. discovered that in only half of the cases the 
DCs were correctly injected, despite ultrasound-guided injections by experienced radiologists8.  
Thus, one of the strategies to improve vaccinations with ex vivo generated cellular 
vaccines, would be to make them traceable. Ideally, this would be done by designing a 
theranostic particle that allows simultaneous delivery of tumor antigens and a contrast agent 
for high-resolution tracking of the antigen-loaded cells after administration in vivo. One 
technique that could be particularly interesting for this application, is magnetic resonance 
imaging (MRI), as it allows high-resolution imaging without making use of radioactive labels. In 
clinical 1H MRI imaging, contrast agents based on lanthanide chelates or superparamagnetic 
nanoparticles have been used9-12. However, intrinsic contrast from the host tissue and contrast 
generated by those agents can be mistaken. To overcome this disadvantage, fluorine (19F) MRI 
emerged as a powerful tool to locate transplanted cells, such as ex vivo modified DCs. By using 
the 19F nuclei instead of 1H, MR images can be obtained without background signal from the 
host tissue, enabling unambiguous identification and quantification of contrast agent-labeled 
cells13. In addition, anatomic information can be retained by also acquiring a 1H MR image of 
the same subject.  
As contrast agents for 19F MRI, perfluorocarbons (PFCs) have been proposed. As 
described in Chapter 1, they are metabolically inert, offer a high density of 19F nuclei per 
molecule and have well-defined safety profiles11, 12, 14-16. Due to their very low surface tension, 
liquid PFCs usually remain cohesive, and are therefore difficult to formulate into stable 
emulsions. To overcome this hurdle, different lipid and polymer coats have been designed to 
stabilize the PFC droplets in an aqueous environment17-19. 
However, the application of such particles has remained limited to mere imaging, which 
implies that besides the regular antigen-loading of the cells, a separate modification of the DCs 
with 19F MRI contrast agents is required. In this way, the vaccine production becomes more 
labor-intensive, and there is no guarantee that the cells that are detected in vivo are in fact 
loaded with antigens and thus capable of inducing antigen-specific immune responses. 
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Therefore, we aim to design theranostic particles that can be applied in DC vaccination. 
Theranostics are multimodal particles that combine the delivery of therapeutic agents and a 
diagnostic functionality20, 21. In the case of DC vaccines, such particles would ideally modify the 
cells with antigens and at the same time, allow in vivo tracing of the antigen-loaded cells during 
their migration to the lymph nodes. This would assure that exclusively those DCs that have 
taken up the antigen and hence are responsible for an immunologic response are detected. 
Evidence of efficient migration could then be used as a first predictor of the vaccine efficacy. 
The present study aims to design and evaluate layer-by-layer antigen-coated PFC particles for 
single-step delivery of antigenic protein and 19F MRI contrast agents to DCs. 
MATERIALS AND METHODS 
Preparation and characterization of PFC particles 
Cationic PFC particles were prepared by mixing 63.7% DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane) (Avanti Polar Lipids, Alabaster, AL, USA), 24.5% DOPE (1,2-
Dioleoyl-sn-Glycero-3-Phosphoethanolamine) (Lipoid, Ludwigshafen, Germany), 2% DSPE-
PEG(2000) (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino polyethyl-ene glycol)-
2000]) (Avanti Polar Lipids) and 9.8% cholesterol (Sigma-Aldrich, Bornem, Belgium), all 
dissolved in chloroform, in a round-bottom flask. After evaporation of the chloroform under 
nitrogen, the resulting lipid film was hydrated in a 1:2:7 mixture of glycerol, propanediol and 
distilled water to obtain a clear solution with a final lipid concentration of 1.4x10-3 mmol ml-1. For 
fluorescent labeling of the lipids, CholEsteryl BODIPY® FL C12 (1%, Molecular Probes, 
Invitrogen, Merelbeke, Belgium) was added to the chloroform lipid mixture. To prepare PFC 
particles, 40 µl of either perfluorohexane (PFH, F2 chemicals, Preston, UK) or perfluoro-15-
crown-5-ether (PFCE, Exfluor Research Corporation, Round Rock, Tx, USA) was emulsified in 
the presence of excess lipid solution by means of high-frequency shaking in a CapMixTM device 
(3M-ESPE, Diegem, Belgium). The produced particles were then centrifuged for 1min at 1000g 
in order to spin down the largest particles. Particle size was evaluated on the smaller particle 
fraction, using a Beckman-coulter Multisizer 4 (Beckman-coulter, Brea, CA, USA) equipped with 
a 20 µm aperture tube.  
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Antigen-loading of PFC particles 
Cationic PFC particles were washed three times with dH2O to remove unincorporated 
lipids. Then, particles were electrostatically loaded with negatively charged ovalbumin (OVA, a 
routinely used model antigen) by adding an aqueous OVA solution (1 mg ml-1, Sigma-Aldrich). 
Repeated washing steps were performed to remove excess OVA before adsorbing an 
additional lipid layer. This process was repeated to load multiple layers of alternating cationic 
lipids and anionic protein onto the particles. The efficiency of this loading process was assessed 
via zeta potential measurements using a Malvern Zetasizer nano-ZS (Malvern Instruments Ltd, 
Worcestershire, UK). To determine the amount of OVA that could be adsorbed onto the PFH 
particles, the liquid PFH was first evaporated by placing the particles into a water bath at 90°C 
for 20min. Then, the OVA content of the resulting OVA solution was measured using a micro 
BCA assay (Thermo Fisher Scientific, Rockford, USA) according to the manufacturer’s 
specifications. By loading the PFC particles with Alexa Fluor® 647-labeled OVA (Molecular 
Probes), the loaded PFC particles could be visualized by confocal microscopy.  
Dendritic cell culture 
Primary murine bone marrow-derived DC (BM-DC) cultures were generated from 
C57BL/6 mice. Female C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, 
France) and housed in an SPF facility according to the regulations of the Belgian law and the 
local Ethical Committee. Mice were euthanized and bone marrow was flushed from the hind 
limbs. Red blood cells were lysed (Pharm Lyse Buffer, BD Biosciences) and the collected cells 
were seeded in bacteriological petri dishes (Falcon, VWR, Haasrode, Belgium) at 2x106 cells ml-
1 in 10 ml. The cell culture medium used was RPMI 1640 (Gibco-Invitrogen, Merelbeke, 
Belgium) supplemented with FBS (5%, Hyclone, Pierce, Rockford, IL, USA), 
penicillin/streptomycin/L-glutamine (1%, Gibco-Invitrogen), β-mercaptoethanol (50 µM, Gibco-
Invitrogen) and GM-CSF (20 ng ml-1, Peprotech, Rock Hill, NJ). On day 3 of the culture, an 
additional 10 ml complete culture medium containing GM-CSF (40 ng ml-1) was added. On day 
6, all cells were collected by centrifugation (7min at 400g) and resuspended in fresh culture 
medium at 106 cells ml-1. Next, the cells were seeded in well plates allowing them sufficient time 
to loosely adhere to the well surface before treatment on day 7 after the start of the culture.  
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Microscopy 
Confocal microscopy images of OVA-loaded PFC particles, their uptake by DCs and 
subsequent OVA processing into peptides were recorded using a Nikon C1si confocal laser 
scanning module attached to a motorized Nikon TE2000-E inverted microscope (Nikon 
Benelux, Brussels, Belgium). For cell experiments, day 6 DCs were seeded in 35 mm MatTek 
glass bottom culture dishes (MatTek Corporation, MA, USA) 1 day before addition of PFC 
particles and confocal imaging using an oil immersion objective lens (Plan Apo 60X 1.4 NA oil 
immersion objective lens). For PFC particle uptake experiments, the cytoplasm of live cells was 
stained by incubating the cells for 15min in culture medium supplemented with CellTrackerTM 
Green (50 µM, Molecular Probes). DC nuclei were stained using Hoechst 3342 (Molecular 
Probes).  
Sample preparation for transmission electron microscopy (TEM) was performed as 
follows: After 1 h incubation of DCs with OVA-loaded PFC particles, the cells were pelleted in 
BEEM® capsules (Structure probe, Inc., West Chester, USA) and fixated in glutaraldehyde (2%, 
Sigma Chemical Co., St. Louis, MO). Subsequently, the cells were postfixated in 
osmiumtetraoxide (2%, Laborimpex, Brussels, Belgium) after which the cells were dehydrated 
in an ascending series of ethanol and finally embedded in epoxyresin at 60°C. The resulting 
blocks were cut into 60 nm sections and stained with uranyl acetate and lead citrate (both 
Laborimpex). TEM images were recorded using the TEM JEM 1200 EX II (JEOL, Tokyo, 
Japan). 
Cytotoxicity assay 
Cell viability was evaluated 24h after addition of OVA-PFC particles to DCs using an MTT 
assay (Cell Proliferation Kit I, Roche Diagnostics, Vilvoorde, Belgium) according to the 
manufacturer’s specifications.  
19F NMR spectroscopy 
The produced particles were suspended in deuterated water (0.5 ml total volume) and 
transferred to a 5 mm NMR tube (Wilmad, Vineland, NJ, USA). 5-Fluorocytosine or sodium 
fluoride (4-10 mM final concentration) were added as an internal chemical shift and 
concentration reference. NMR spectroscopy experiments were carried out using a 400 MHz 
Bruker Avance II NMR spectrometer (Bruker Biospin, Rheinstetten, Germany) equipped with a 
5 mm broadband probe operating at 376.50 MHz for 19F NMR spectroscopy. The following 
acquisition parameters were used: spectral width 200 ppm, relaxation delay 5s, number of 
acquisitions 128 to 1024, and acquisition of 64k data points. Chemical shift was referenced to 
5-fluorocytosine at -172.4 ppm. The temperature was maintained at 37ºC for all measurements. 
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19F NMR signals were quantified relative to 5-fluorocytosine or NaF by integration after phase 
and baseline correction using the manufacturer’s software (Topsin, Bruker Biospin, 
Rheinstetten, Germany). T1 relaxation times were calculated from inversion recovery 
experiments. T2 relaxation times were determined from Carr-Purcell-Meiboom-Gill (CPMG) 
experiments. Other parameters were as described previously22, 23.  
19F MRI detection of OVA-PFC particle loaded DCs 
For in vitro detection of DCs containing OVA-loaded PFCE particles, phantoms were used 
that consist of Eppendorf tubes filled with 104 to 107 cells ml-1 suspended in agar (1% in saline, 
Invitrogen). In addition to the tubes of interest, Eppendorf tubes filled with NaF (25-100 mM 
solutions) were used as concentration and chemical shift references for 19F MRI and 19F NMR 
spectroscopy. All MR images were acquired using a Bruker Biospec 9.4 Tesla small animal MR 
scanner (Bruker Biospin, Ettlingen, Germany; horizontal bore, 20 cm) equipped with actively 
shielded gradients (600 mT m-1). A purpose-built radio-frequency transmit-receive coil tunable 
to the 1H (400.34 MHz) and 19F (376.64 MHz) frequencies was used for all phantom 
experiments. After acquisition of a positioning scan, 2D multi-slice or 3D 1H and 19F gradient 
echo MR images (FLASH) were acquired using identical parameters (except for the frequency) 
for both nuclei. Acquisition parameters were as following for 3D MRI: isotropic resolution of 
600 µm3, repetition time (TR)=100 ms, echo time (TE)=5.9 ms, FLASH sequence (30° flip 
angle), field-of-view (FOV) 60x60x60 mm, number of averages 1 to 120; for 2D MRI: slices of 
1-2 mm thickness, 600 µm in plane resolution, TR=100 ms, TE=5.8 ms, number of averages 8 
to 64, matrix 96x96 data points, FOV 60x60 mm, FLASH sequence (30° flip angle). Acquisition 
frequencies were 376.652 MHz (19F) and 400.325 MHz (1H). The effective spectral bandwidth 
for 19F MRI was 50 kHz. Images were analyzed using Paravision 5.1 (Bruker Biospin, Ettlingen, 
Germany). 
Proteolytic processing of OVA by DCs 
To investigate to what extent the uptake of OVA-loaded particles leads to effective OVA 
processing by the DCs, PFC particles were loaded with DQTM OVA (Molecular Probes). Due to 
the extensive loading of the protein with BODIPY® dyes, the fluorescence of intact DQTM OVA 
is highly quenched. Upon proteolytic digestion of the protein, the green fluorescence drastically 
increases, making it possible to visualize its intracellular degradation. Analysis of the green 
fluorescent signal upon DQTM OVA proteolysis was performed 24h after particle addition to the 
DCs, using both confocal microscopy and flow cytometry. For FACS analysis, DCs were 
washed with Flow buffer (PBS (Gibco, Invitrogen) supplemented with BSA (1%) and azide 
(0.1%, Sigma-Aldrich) and surface stained for the DC marker CD11c-APC (eBioscience, 
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Vienna, Austria) for 30min at 4°C. FACS analysis was performed using a FACSCaliburTM (BD 
Pharmingen, Erembodegem, Belgium) and data were analyzed with CellQuestTM software.  
Phenotype of OVA-PFC-particle loaded DCs 
The influence of uptake of OVA-loaded PFC particles on the DC phenotype was 
investigated by quantifying up-regulation of the maturation markers CD40 and CD86 on the DC 
surface. 24h after particle uptake, DCs were washed with flow buffer. Then, the cells were 
surface stained for the DC marker CD11c-APC in combination with staining for either CD40-
FITC or CD86-FITC (both BD Pharmingen) for 30min at 4°C. Untreated DCs and DCs cultured 
in the presence of Escherichia coli-derived lipopolysaccharide (1 µg ml-1 LPS, Sigma-Aldrich) 
served as negative and positive controls respectively.  
T cell proliferation assay 
In order to assess the efficiency of OVA-PFC-particle loaded DCs to prime antigen-
specific CD8+ T cells, an in vitro OT-I proliferation assay was performed. In this assay, OVA-
PFCE-particle-loaded DCs were co-cultured with carboxyfluorescein succinimidyl ester 
(CFSE)-labeled naïve OT-I cells, which have a transgenic T cell receptor that recognizes the 
MHC-I restricted OVA-peptide SIINFEKL. The DCs were first incubated for 2h with either OVA-
loaded PFCE particles, unloaded PFCE particles (as a negative control), or the SIINFEKL 
peptide as a positive control (Eurogentec, Seraing, Belgium). Then, the cells were matured for 
4h with LPS, washed, and seeded per 104 DCs in a U-bottom 96 well plate, for co-incubation 
with 105 CFSE-labeled OT-I cells (derived from the spleens of OT-I transgenic mice, Charles 
River). After 5 days, the cells were collected, surface stained for CD8-APC (BD Pharmingen) 
and analyzed by flow cytometry.  
Statistical analysis 
Statistical analysis was performed using GraphPad software (la Jolla, CA, USA). All data 
are presented as mean ± standard deviation (SD). A one-way ANOVA followed by Bonferroni 
multiple comparison was performed to determine statistically significant differences between 
datasets. p-values <0.05 were regarded significant. 
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RESULTS 
Characterization and antigen-loading of PFC particles 
 
Figure 1. Size distribution of PFH and PFCE particles.  
The size of PFC and PFCE particles was measured by coulter counter both immediately 
after production (PFH and PFCE) and after removal of the largest particles by 
centrifugation (PFH small fraction and PFCE small fraction). As a result, the mean volume 
diameter decreased from 2.96 ± 1.38 µm to 1.21 ± 1.28 µm for PFH particles and from 
2.96 ± 1.40 µm to 1.42 ± 1.84 µm for PFCE particles. 
As described in the materials and methods section, PFH and PFCE particles with a net 
positive surface charge could be prepared by high-frequency mixing of the liquid PFC with a 
cationic lipid mixture. By including 2% polyethylene glycol (PEG) modified lipids in the particle 
coat, formation of particle aggregates could be avoided. In order to remove the largest particles, 
the samples were briefly centrifuged (1min at 1000g). The average volume diameters of the 
remaining particles, as determined by coulter counter measurements, was 1.21 ± 1.28 µm for 
PFH particles and 1.42 ± 1.84 µm for PFCE particles (Figure 1). The presence of the stabilizing 
cationic lipid layer around the particles resulted in a positive zeta potential of 50.3 ± 3.80 mV 
for PFH particles and 67.5 ± 4.84 mV for PFCE particles. 
These cationic particles were loaded with OVA via electrostatic interactions, as 
schematically depicted in Figure 2A. Effective antigen loading could be demonstrated by 
means of confocal microscopy (Figure 2B), where Alexa Fluor® 647-labeled OVA (red) is 
clearly present around PFC particles of which the lipid membrane was labeled with CholEsteryl 
BODIPY® FL C12 (green).  
88 | C h a p t e r  3  
 
Figure 2. OVA loading of PFC particles.  
(A) Schematic representation of a particle with a liquid PFC core, surrounded by 
alternating layers of cationic lipids and anionic OVA. (B) Confocal images of PFC particles 
stabilized by a green fluorescent lipid layer and loaded with red fluorescent OVA: (1) 
fluorescently labeled cationic PFC particles, (2) red fluorescent OVA, (3) merged image, 
(4) transmission. 
To increase the amount of protein that could be loaded onto the particles, a layer-
by-layer principle was applied24, adsorbing alternating layers of cationic lipids and anionic 
protein around the liquid particle core. The effective presence of each of these additional 
layers was confirmed by zeta potential measurements demonstrating alternating positive 
and negative surface charges of the particle, as represented for PFH particles in Figure 3. 
The amount of OVA that could be loaded onto these PFH particles was 1.87 ± 0.26 µg 
per layer of OVA for 100 µl particles. 
 
Figure 3. Zeta-potential measurements of OVA-loaded PFH particles.  
PFH particles coated with cationic lipids show a positive zeta potential. Upon adsorption of 
negatively charged OVA, the zeta potential reverses. This can be repeated to produce 
particles coated with multiple layers of alternating lipids and OVA (n=3). 
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19F NMR spectroscopic evaluation of OVA-loaded PFC particles 
19F NMR spectroscopy of the produced PFH and PFCE particles confirmed the integrity 
of the fluorinated compounds. For quantification purposes, 5-fluorocytosine or NaF of known 
concentration was added. The determined concentration of the stock solutions was 100 mM for 
the PFCE particles (the concentration of equivalent fluorine atoms was 2 M), and 80 mM for the 
PFH particles (the concentration of equivalent fluorine atoms was 0.48 mM for the two 
equivalent CF3-groups). Furthermore, the chemical shift as well as the T1 and T2 relaxation 
times for both types of particles were determined and can be found in Table 1.  
Table 1. 19F NMR parameters of the prepared PFH and PFCE particles. 
Incorporated 
PFC 
19F chemical shift  
(ppm) 
T1 relaxation time  
(ms) 
T2 relaxation time 
(ms) 
PFH 
-85ppm, -125ppm, -
129ppm 
1450 ± 150 400 ± 50 
PFCE -96ppm 1000 ± 100 350 ± 50 
 
These data already imply the advantages of using PFCE particles over PFH particles. 
First of all, in PFH the fluorine is distributed over three signals, representing the chemically 
equivalent CF2/CF3 groups. This results in a maximum of six 19F atoms for the two equivalent 
CF3 groups that contribute to the signal at 85 ppm. In contrast, for PFCE twenty equivalent 
fluorine atoms make up the signal at 96 ppm which results in a higher sensitivity per molecule. 
In addition, the presence of multiple fluorine frequencies in PFH can lead to ghosting artifacts 
in MR images, depending on the selected 19F MRI frequency and bandwidth.  
Uptake of OVA-loaded PFC particles by DCs 
Confocal microscopy was used to determine the intracellular presence of OVA-loaded 
PFC particles in murine BM-DCs after particle addition in vitro. Within merely 30min, all of the 
adherent DCs showed clear internalization of large numbers of red fluorescent OVA-loaded 
PFCE particles (Figure 4). Images also indicate that upon particle ingestion, OVA is released 
from the particles and is distributed over the entire DC cytoplasm.  
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Figure 4. Uptake of OVA-loaded PFC particles by DCs.  
OVA-loaded PFCE particles were added to murine BM-DCs. After 1h, particle uptake was 
evaluated via confocal microscopy. Images show (A) merged image,  
(B) CellTrackerTM green cytoplasmic stain, (C) Hoechst nucleus stain, (D) red fluorescent 
OVA and (E) transmission. 
More detailed information on the intracellular distribution of OVA-loaded PFC 
particles was obtained through TEM analysis of DC samples after 1h of PFCE particle 
loading. The images confirm the intracellular presence of spherical particles, as depicted 
in Figure 5. Non-loaded cells served as negative controls.  
 
Figure 5. Transmission electron microscopy.  
DCs were either (A) unloaded or (B) incubated with OVA-loaded PFCE particles for 1h 
prior to fixation and preparation for TEM imaging. In the latter image, both internalized and 
external PFCE particles can be observed (indicated with white arrows). 
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DC viability after addition of OVA-loaded PFC particles 
In order to use these particles in DC vaccination, particle uptake by the cells should not 
compromise their viability. To determine the potential toxic effects of the OVA-loaded PFC 
particles on DCs, an MTT assay was performed 24h after addition of different PFC particles at 
different concentrations to the cells. The data, as shown in Figure 6, demonstrate a limited 
dose-dependent cytotoxic effect that occurs starting from a dose of 240 particles per cell when 
the particles are loaded with OVA. For the highest particle load (300 particles per DC), cell 
viability was 86.0 ± 5.2% for OVA-loaded PFCE particles and 79.9 ± 5.3% for OVA-loaded PFH 
particles. In general, cell viability is lower when unloaded particles are used compared to OVA-
loaded particles, which can likely be attributed to the cationic surface charge of these unloaded 
particles.  
 
Figure 6. Viability of DCs after uptake of OVA-loaded PFCE and PFH particles.  
Viability of DCs 24h after uptake of either unloaded or OVA-loaded PFCE and PFH 
particles was assessed using an MTT assay. Untreated cells served as a blank. Asterisks 
indicate statistically significant differences compared to blank.  
(n=4, * p<0.05, ** p<0.01, ***p<0.005) 
19F MRI on OVA-PFC-particle loaded DCs 
After uptake of OVA-loaded PFC particles by DCs, the detectability limits for the PFC-
containing cells were determined by 19F MRI. For this, DCs were cultured in the presence of 
PFC particles overnight and suspended in 1% agarose at different cell densities. Vials 
containing different cell densities and a control vial containing 100 mM NaF were put in a sample 
holder. Intracellular fluorine concentrations were estimated by using 19F NMR spectroscopy of 
the different vials and the reference tubes (see Figure 7). For the PFCE-containing particles, 
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the intracellular fluorine concentration was estimated to be 40 pmol per cell. The 
detectability limit for PFCE-particle loaded DCs was estimated at 1000 cells µl-1 and 250 
cells µl-1 for a 40min and 3h acquisition, respectively. Cells loaded with PFH particles 
were more difficult to detect. This could be attributed to the presence of three peaks in 
the 19F NMR spectrum, each representing a lower number of chemically equivalent 
fluorine atoms. This resulted in a merely low concentration of 1 pmol of equivalent 19F 
atoms per cell for the two CF3-groups of PFH particles and a substantially higher detection 
limit of 104 cells µl-1, which required a 9h acquisition time. It goes without saying that such 
long acquisition times will not be clinically applicable. Taken together, PFCE particles 
allow higher sensitivity detection of antigen-loaded DCs, at shorter acquisition times, 
which makes them preferable for the intended use. 
 
Figure 7. 19F MR on PFCE particle-loaded DCs.  
After 24h loading of DCs with PFCE particles, the cells were collected and suspended in 
1% agarose at different concentrations. (A) 19F NMR spectrum of PFCE particle-loaded 
cells compared to 100 mM NaF. (B) 1H MRI and corresponding 19F MRI of tubes filled with 
labeled cells suspended in agar. Top row: tubes with (a) 10 000 cells µl-1; (b) 1000 cells µl-
1 and (c) 100 cells µl-1, acquired for 40min (number of averages = 10). Bottom row: tubes 
containing (a) 10 000 cells µl-1; (b) 1000 cells µl-1; (d) 500 cells µl-1 and (e) 250 cells µl-1 
were put in an agar block (hyperintense background on 1H MRI) and acquired for 
approximately 3h (number of averages = 32). 
OVA processing upon uptake of OVA-loaded PFC particles by DCs 
Besides introducing liquid PFCs for 19F MRI imaging, we aimed to simultaneously 
load DCs with antigens for vaccination purposes. This means that the particle-mediated 
uptake of the antigenic protein should result in presentation of antigenic peptides in 
specialized molecules, called major histocompatibility complexes (MHCs) at the DC 
surface. This requires intracellular processing of the delivered antigen. To test if this 
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occurs using this method, cationic PFC particles were loaded with DQTM OVA. Due to the 
extensive labeling of this OVA with BODIPY® dyes, the fluorescence of the intact protein is 
quenched. Upon intracellular proteolysis of DQTM OVA, the quenching is relieved, causing a 
drastic increase in green fluorescence intensity. The intracellular green fluorescence due to 
processed DQTM OVA was evaluated 24h after particle uptake by the DCs via both confocal 
microscopy and flow cytometry. Given that exploratory experiments revealed a significant 
increase in DC granularity after particle uptake, DCs incubated with unloaded PFC particles 
served as negative controls.  
 
Figure 8. DQTM OVA processing upon particle uptake by DCs.  
24h after uptake of DQTM OVA loaded PFC particles by DCs, antigen processing was 
evaluated by means of flow cytometry and confocal microscopy. (A) shows a 
representative histogram for the detection of green fluorescence in CD11c+ DCs after 
uptake of unloaded or DQTM OVA-loaded particles. The confocal images in (B) represent 
(1) overlay, (2) green fluorescence due to intracellular processing of DQTM OVA, (3) 
Hoechst nucleus stain and (4) transmission. 
Flow cytometric analysis, as seen in Figure 8A, revealed a 30-fold increase in mean 
green fluorescence intensity upon ingestion of DQTM OVA particles, compared to unloaded 
particles. Further analysis demonstrated that the portion of cells that exhibit low green 
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fluorescence were also low in granularity, and did most likely not contain PFC particles. 
These data were confirmed by confocal images (Figure 8B), showing clear intracellular 
presence of green fluorescence due to processed DQTM OVA in DCs with internalized 
particles. This provides a proof of concept that the OVA introduced into DCs via OVA-
loaded PFC particles can still be released from the particles and enter the natural pathway 
of intracellular antigen processing.  
Phenotype of OVA-PFC-particle loaded DCs  
When using materials for modification of DCs, it is crucial to consider the effects on 
the DC phenotype. Upon encounter of danger signals, such as pathogen-associated 
molecular patterns (PAMPs), the DCs mature, which results in a shift in function from 
antigen-sampling to antigen-presentation25. Since mature DCs are responsible for 
induction of immune responses, whereas immature and semi-mature DCs are mainly 
linked to suppression of immune responses and immune tolerance, it is essential that the 
ability of immature DCs to respond to maturation-stimuli and undergo such a phenotypic 
switch should not be hampered by the materials used in the vaccine development26. 
To evaluate the effect of particle uptake on the DC maturation status, immature DCs 
were incubated with OVA-loaded PFC particles. Additionally, a part of these samples was 
exposed to lipopolysaccharide (LPS), a known PAMP and maturation stimulus, 2h after 
particle addition. In this way, the influence of particle loading on the capacity of the cells 
to respond to maturation stimuli was assessed. After 24h incubation at 37°C, the cells 
were surface stained for the DC marker CD11c and the maturation markers CD40 and 
CD86. The samples were then analyzed by means of flow cytometry.  
The results in Figure 9 show that the uptake of OVA-loaded PFC particles by DCs 
does not induce an increase in expression of both maturation markers tested, indicating 
that the DCs do not recognize any danger signals associated with particle uptake. 
Moreover, DCs that were exposed to LPS 2h after particle uptake, showed up-regulation 
of both surface markers in a similar way to unloaded LPS-treated DCs. This demonstrates 
that the particle-loaded DCs are not phenotypically altered due to the intracellular 
presence of the particles, and preserve their capacity to respond to maturation-stimuli.  
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Figure 9. Maturation status of DCs after uptake of OVA-loaded PFC particles.  
24h after uptake of OVA-loaded PFC particles by DCs, the cells were surface stained for 
the DC marker CD11c in addition to the maturation markers CD40 and CD86. (A) Graphic 
representation of CD40 mean fluorescence intensity (MFI) with (B) a representative 
histogram. (C) Graphic representation of CD86 MFI with (D) a representative histogram. 
(n=3, **** p<0.001). 
T cell activation and proliferation by OVA-PFC-particle loaded DCs 
In order to assess the potential of OVA-PFC-particle loaded DCs to efficiently present 
OVA-derived peptides in MHC-I to CD8+ T cells, an in vitro OT-I proliferation assay was 
performed. OT-I cells carry a transgenic CD8 T cell receptor which specifically recognizes the 
MHC-I restricted OVA peptide SIINFEKL. If these naïve CFSE-labeled T cells are activated by 
mature DCs that present SIINFEKL in the context of MHC-I, these cells will become activated 
and start to proliferate, resulting in daughter cells that contain less CFSE and therefore exhibit 
lower green fluorescence intensities compared to non-proliferated cells. The results, as shown 
in Figure 10, demonstrate that DCs that were incubated with different amounts of OVA-loaded 
PFCE particles are capable of inducing up to 86.5% proliferation of antigen-specific CD8+ T 
cells, compared to merely 8.9% proliferation when unloaded PFCE-loaded particles (at 60 
particles per DC) were used. Interestingly, no statistically significant differences in OT-I 
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proliferation could be detected between the highest particle concentration and the 
SIINFEKL positive control. These data prove that uptake of OVA-loaded PFCE particles 
by DCs results in efficient antigen presentation, resulting in activation and extensive 
proliferation of antigen-specific CD8+ T cells.  
 
Figure 10. Induction of OT-I proliferation by OVA-PFCE particle loaded DCs.  
(A) Graphic representation of the percentage of proliferating OT-I cells after 5 days of co-
incubation with DCs. (B) Representative histograms for (1) OT-I cells that were not co-
cultured with DCs, OT-I cells co-cultured with (2) DCs containing 60 unloaded PFCE 
particles per cell, (3) 30 OVA-loaded PFCE particles per cell, (4) 60 OVA-loaded PFCE 
particles per cell, (5) 120 OVA-loaded PFCE particles per cell or (6) DCs that were loaded 
with the SIINFEKL peptide, as a positive control. (n=4, n.s. = p>0.05) 
DISCUSSION 
Previous research has shown that the effectiveness of DC vaccines has been partially 
linked to their in vivo localization and the cells’ migratory capacities3, 5, 27, 28. Therefore we 
intended to design a theranostic particle for single-step antigen- and PFC-loading of DCs, to 
allow specific tracing of antigen-containing DCs via 19F MRI. This way, detection of these 
antigen-presenting cells in the lymph nodes, could be a first feedback on vaccine efficacy. We 
were able to demonstrate the efficient production of cationic PFC particles, with mean diameters 
around 0.9 µm that can be electrostatically loaded with multiple layers of OVA. Upon addition 
of these antigen-loaded particles to in vitro cultured BM-DCs, fast and extensive internalization 
was observed. This efficient uptake makes the use of additional transfection agents, as 
suggested in previous reports on PFC particles for DC labelling, redundant and consequently 
simplifies the DC modification11. The mild dose-independent cytotoxic effects that were 
observed 24h after particle uptake can presumably be attributed to the incorporation of a 
cationic lipid in the particle coating, since liquid PFCs, the other main particle compounds, are 
well-known to be inert, non-allergenic and non-toxic as they have already been intensively used 
as artificial oxygen carriers in the clinic16. Importantly, the OVA-PFC particle loaded DCs proved 
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to be very efficient in activating antigen-specific CD8+ T cells, and inducing their proliferation in 
vitro. This indicates that both the antigen dose as well as the means of antigen delivery result 
in effective T cell priming. Moreover, these results show that the antigen-particle modified DCs 
are still capable of exerting their crucial role in the induction of immune responses.  
It should be noted that in literature, most PFC particles used for cell labelling are nano-
sized, with mean particle diameters ranging from 100 to 560 nm11, 29, 30. The presented particles 
were purposefully designed with larger average diameters as this offers several advantages 
regarding both the antigen-presenting as well as the 19F MRI imaging of the particle-loaded 
cells. First of all, it was shown that phagosomes are competent organelles in antigen cross-
presentation. In this process, phagocytosed exogenous antigens can escape from the 
phagosomes through a phagosome-to-cytosol pathway and can, as a result, be presented in 
MHC class I instead of class II on the DC surface. In this way, presentation of exogenous 
peptides to CD8+ T cells (via MHC-I) can occur, resulting in activation and proliferation of anti-
tumor cytotoxic T lymphocytes31, 32. In order to promote phagocytic uptake of the antigens, they 
can be coupled to larger-size particles, seeing as phagocytosis is generally accepted to be the 
main uptake mechanism for particles >0.5 µm. Therefore, the 0.9 µm antigen-coated PFC 
particles are expected to be an ideal antigen-delivery vehicle for induction of effective anti-tumor 
immune responses. Secondly, Tran and Shen recently investigated the effect of particle size 
and phagosomal pH on cross-presentation efficiency. They found that larger antigen-containing 
particles (e.g. antigens bound to 0.5 µm and 3 µm beads) resulted in a more neutral 
phagosomal pH, preventing complete intraphagosomal degradation of the immunogenic 
peptides, and hence promoting cross-presentation33. This is also confirmed by the results of 
the in vitro T cell proliferation assay, where efficient antigen processing and presentation in 
MHC-I was shown to lead to extensive proliferation of antigen-specific CD8+ T cells. In addition, 
PFC particle size was also reported to influence the 19F signal. By increasing the particle size 
by a factor 4.3, a 26.8-fold augmentation of the 19F MR signal amplitude could be detected30. 
As a result, the larger diameter we used for these theranostic particles, is expected to positively 
influence both antigen-delivery and immunogenicity, as well as 19F MRI traceability. This was 
also demonstrated by the acquired data showing the fast particle uptake, antigen distribution 
and proteolytic processing as well as sensitive detection of the particle-loaded cells via 19F MRI. 
With regards to this imaging modality, particles containing a PFCE core are preferable 
over PFH-containing particles. Indeed, PFCE particles exhibit one single 19F NMR signal, 
representing 20 equivalent fluorine atoms which allows particle detection at high sensitivity and 
without potential chemical shift artefacts29. The number of fluorine spins that could be detected 
per PFCE-particle-loaded DC was estimated at 2.4x1013 (corresponding to 40 pmol 19F spins 
per cell), which is comparable to previous reports on lipid-coated and PLGA-coated PFCE 
particles for cell tracking11, 29, 34. For applications in DC vaccines, the detectability threshold of 
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1000 cells µl-1 for a 40min acquisition is sufficient for future in vivo studies, since current 
protocols make use of intradermal or intranodal injections of at least 105 DCs in both mice and 
man. Even low percentages of migrating cells should then still be detectable by the presented 
method. Especially in case of intranodal vaccination strategies, unambiguous pinpointing of the 
injected antigen-loaded cells in an anatomical context should be feasible. In addition, the 
development in synthesis of new PFCs and the improvement of 19F MRI methods is still 
ongoing.  
To be applicable in DC vaccination, the effects of OVA-loaded PFC particle uptake on the 
DC phenotype are of key importance. We discovered that OVA-loaded PFC particle uptake did 
not induce up-regulation of DC maturation markers CD40 or CD86, nor did particle uptake 
interfere with the ability of the cells to undergo maturation upon stimulation with PAMPs. 
Previous literature regarding this DC maturation topic has been contradictory. The commercial 
agent CS-1000 (Celsense Inc., USA) was tested and found to have no influence on the 
expression of the maturation markers CD80, CD86 and CD83 on human monocyte-derived 
DCs,14 nor on CD80 and MHC-II expression on murine BM-DCs11. Waiczies et al. on the other 
hand, reported a significant increase in the expression of both CD80 and CD86 when murine 
BM-DCs were loaded with larger (560 nm) surfactant-coated PFCE particles compared to 
smaller (130 nm to 365 nm) particles30. In contrast, our layer-by-layer antigen-coated PFC 
particles do not induce any changes in the DC phenotype. Moreover, complete maturation of 
DCs after particle uptake is not hindered, and the OVA-PFC-particle loaded DCs can induce 
extensive proliferation of antigen-specific CD8+ T cells in vitro. This represents a major 
advantage, as it allows complete control over the DC maturation process during the further 
development of an effective DC vaccine based on these OVA-loaded PFC particles. Maturation 
could then be provoked by either providing a separate potent maturation stimulus after particle 
ingestion by the DCs, or the OVA-loaded PFC particles could be equipped with a layer of 
adsorbed anionic PAMPs (e.g. CpG DNA). Such a particle could make it possible to, in one 
single step, deliver antigen, a maturation stimulus and a 19F MRI contrast agent to DCs.  
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CONCLUSIONS 
Although PFC particles have been designed in many different forms, equipped with 
targeting ligands or drugs and were produced to serve various purposes, to our knowledge, this 
is the first report on a theranostic PFC particle for single-step loading of DCs with both antigenic 
protein and a 19F MRI contrast agent. The particle consists of a liquid PFC core and can be 
equipped with multiple adsorbed layers of antigen. Upon in vitro modification of DCs with these 
particles, the antigen-loaded cells can be imaged via 19F MRI and are capable of processing 
the particle-associated antigen which results in efficient activation and proliferation of antigen-
specific CD8+ T cells. Importantly, particle uptake does not compromise cell viability and does 
not temper with the cell’s phenotypical properties.  
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ABSTRACT 
Cancer immunotherapy aims to selectively recognize and eliminate cancer cells. One way 
to achieve this, is by loading dendritic cells (DCs) with tumor-associated antigens (TAAs), for 
example by transfecting the DCs with mRNA encoding a TAA. Here we demonstrate transient 
transfection of DCs in vitro using mRNA-loaded microbubbles in combination with ultrasound. 
We were able to attach mRNA-lipoplexes (i.e. complexes of mRNA with cationic lipids) to the 
surface of lipid microbubbles. When adding these mRNA-loaded microbubbles to primary 
murine DCs in vitro and exposing them to ultrasound, we observed fast-onset ultrasound-
triggered transfection in up to 24% of the DCs, with maximal expression levels around 8h after 
ultrasound application. Interestingly, when looking at the DC maturation status, transfection with 
mRNA-loaded microbubbles and ultrasound induced a slight but significant shift in the 
expression level of maturation markers (CD40 and CD86). However, further maturation in the 
presence of additional maturation stimuli was not affected. Thus, our results demonstrate that 
mRNA-loaded microbubbles can serve as an applicable and safe tool for efficient mRNA-
transfection of cultured DCs.  
  
105 | C h a p t e r  4  
INTRODUCTION 
In Chapter 3, we showed that theranostic perfluorocarbon particles could be used for 
simultaneous loading of dendritic cells (DCs) with antigens and 19F MRI contrast agents. This 
way, cellular vaccines based on these particle-loaded DCs can allow high-resolution tracking 
of the injected antigen-presenting cells in vivo. However, this strategy still focuses on the 
generation of ex vivo DC vaccines. As described in Chapter 1, several important drawbacks 
limit the effectiveness of these ex vivo generated vaccines, such as patient-specificity, the fact 
that “artificial” DCs are used and the high costs associated with the cumbersome vaccine 
production steps. Hence, there is a growing interest in delivery systems that can target antigens 
to DCs in vivo. 
To address this issue, we propose the use of theranostic microbubbles for ultrasound-
guided and ultrasound-triggered antigen delivery to DCs. As introduced in Chapter 1, it is 
without doubt that the combination of microbubbles with ultrasound has become an established 
value in diagnostic medicine. Moreover, their emerging use as theranostics for image-guided 
and ultrasound-triggered delivery of a plethora of small and large molecules adds to their 
versatility. New microbubble designs, improved transducers, novel in vivo targets, and diverse 
therapeutic approaches are currently under investigation, so we are only at the beginning of 
exploring their full potential.  
Importantly, when translating the mechanisms of action and current knowledge on 
microbubbles and ultrasound to the requirements for delivery systems to target DCs in vivo, 
three important facts point towards the potential use of microbubbles and ultrasound for this 
purpose. First of all, drug- and gene-loaded microbubbles can be used for sonoporation-
mediated delivery to various targets in vivo and in vivo1-4. Thus, maybe it could be possible to 
design a loaded microbubble that could deliver tumor antigens antigen and immune adjuvants 
to DCs in vivo. Secondly, there is convincing evidence that commercially available 
microbubbles can drain to the lymphatics and end up in the lymph nodes after interstitial 
injection5-11. This implies that these microbubbles can reach the core location of immune 
response induction, and one of the main homing regions of DCs in vivo. Thus, microbubbles 
can reach their target cells in vivo. Thirdly, microbubbles can be imaged via contrast-enhanced 
ultrasound (CEUS) and have potential as theranostics. This way, the vaccination could become 
an image-guided therapy where the antigen-loaded microbubbles are followed during their 
migration to the lymph nodes. Moreover, their disappearance after delivery of the high-intensity 
ultrasound bursts required for microbubble implosion and antigen transfer, can also be 
visualized using CEUS12, 13. Bundling these concepts gave rise to the idea of using 
microbubbles as a potential means of locally delivering antigens and adjuvants to DCs in the 
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lymph nodes under ultrasound-guidance. Whether or not this has potential, will be the topic of 
investigation in the chapters to follow.  
Once the delivery vehicle is chosen, the next step is to select the source of tumor antigens 
that will be introduced into the DCs. In recent years, the focus of research has shifted from 
peptide and protein loading of DCs towards genetic approaches, where DNA or RNA is 
delivered into isolated DCs14-16. Translation of the proteins by the DC itself is attractive as it 
paves the way to antigen presentation in both MHC-II and MHC-I. Moreover, these strategies 
hold the potential to introduce multiple epitopes, ultimately yielding an immune response 
against the broad antigenic repertoire of the tumor. As compared to DNA-based approaches, 
RNA-based vaccination presents several advantages. Firstly, RNA does not integrate into the 
genome, rendering its application much safer. Secondly, while in non-dividing cells, the nuclear 
envelope represents a serious obstacle for the delivery of DNA into the nucleus, this obviously 
does not apply to RNA17. Finally, although RNA generates only transient protein expression, 
this should be adequate for antigen processing and presentation by DCs. 
 
Figure 1. Schematic image of ultrasound-triggered mRNA-transfection of DCs.  
When mRNA-loaded microbubbles are exposed to ultrasound in the presence of DCs, the 
microbubbles will implode, leading to the local formation of pores in the DC membrane, as 
well as in local release of mRNA-lipoplexes from the surface of the imploding microbubble. 
As a result, the mRNA-lipoplexes can be taken up through the created pores and 
immediately enter into the DC cytoplasm. Upon mRNA translation, antigenic protein is 
produced, and processed into peptide fragments which can be loaded onto MHC 
molecules and presented to T cells.  
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Thus, the specific aims of this study were (a) to evaluate the potential of ultrasound-
responsive microbubbles loaded with mRNA-complexes to transfect DCs, (b) to measure the 
levels and kinetics of marker protein production following transfection, and (c) to reveal the 
impact of ultrasound treatment on the viability and maturation status of DCs. A schematic 
overview of the concept of mRNA-loaded microbubbles and ultrasound for mRNA delivery to 
DCs in light of cancer immunotherapy, is presented in Figure 1. 
MATERIALS AND METHODS 
Cell culture 
Primary DC cultures were generated from the bone marrow of C57BL/6 mice. Female 
C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, France) and housed in a 
specified pathogen-free facility according to the regulations of the Belgian law and the local 
Ethical Committee. Mice were sacrificed and bone marrow was flushed out of the femur and 
tibia. After red blood cell lysis (Pharm Lyse Buffer, BD Biosciences), cells were seeded at a 
density of 5x105 cells ml-1 in OptiCellsTM (Nunc, Thermo Scientific, Aalst, Belgium) and 
incubated at 37°C in 5% CO2. The cell culture medium was RPMI-1640 (Gibco-Invitrogen, 
Merelbeke, Belgium) supplemented with 5 % FCS (Hyclone, Pierce, Rockford, IL, USA), 1% 
penicillin / streptomycin (Gibco-Invitrogen, Merelbeke, Belgium), 1% L-glutamine (Gibco-
Invitrogen, Merelbeke, Belgium) and 50 µM β-mercaptoethanol (Gibco-Invitrogen, Merelbeke, 
Belgium) and contained also 10 ng ml-1 IL-4 (Peprotech, Rock Hill, NJ) and 10 ng ml-1 
granulocyte macrophage colony-stimulating factor (GM-CSF, Peprotech, Rock Hill, NJ). At day 
2 and 6 of culture, the non-adherent cells were collected by centrifugation, resuspended in fresh 
culture medium and seeded to the same OptiCellTM. The cells were treated 7 days after seeding.  
Messenger RNA 
To produce mRNA by in vitro transcription, plasmids encoding luciferase and enhanced 
green fluorescent protein (eGFP) were purified using a QIAquick PCR purification kit (Qiagen) 
and linearized using Dra I restriction enzyme (plasmid encoding firefly luciferase) or Spe I 
(plasmid encoding eGFP). Linearized plasmids were used as templates for the in vitro 
transcription reaction using the T7 mMessage mMachine kit (Ambion). mRNAs were purified 
by DNase I digestion and precipitated with LiCl. This was followed by washing with 70% ethanol. 
The produced mRNAs were both capped and polyadenylated. The mRNA concentration was 
determined by measuring the absorbance at 260 nm. mRNAs were stored in small aliquots at 
-80°C at a concentration of 1 µg µl-1. 
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Bioluminescence assay 
All cells were removed from OptiCellsTM and collected by centrifugation. After removing 
the culture medium, the cells were washed once with PBS (Gibco/Invitrogen, Merelbeke, 
Belgium). Subsequently, 100 µl of Cell Culture Lysis Reagent (Promega, Leiden, The 
Netherlands) was added. After incubation for 30min, the samples were centrifuged (12,000 rpm 
at 4°C for 5min) and 40 µl aliquots of the supernatants were transferred to a 96-well plate. 
Luciferase activity of each sample was assayed in a GloMaxTM 96 Luminometer (Promega, 
Leiden, The Netherlands). 100 µl of the substrate solution was added to each well and the 
emitted light was measured over a 10s period. A standard Bradford assay was employed to 
determine the protein content of each sample (Biorad, Nazareth Eke, Belgium). The results are 
expressed as relative light units (RLU) per milligram of protein. 
Lipoplexes 
If not indicated differently, liposomes were composed of 42.5 % DOTAP (1,2-dioleoyl-3-
trimethylammonium-propane), 42.5% DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) 
and 15% DSPE-PEG-2000-biotin [1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-
[biotinyl(polyethylene glycol)-2000] (all from Avanti Polar Lipids, Alabaster, AL). This was done 
by transferring the appropriate amounts of lipids, dissolved in CHCl3 into a round-bottom flask. 
The CHCl3 was evaporated under nitrogen and the resulting lipid film was rehydrated in RNase-
free water (Ambion, Lennik, Belgium). The resulting DOTAP/DOPE/PEG liposomes were 
sonicated. The total lipid concentration in these liposomes was 1 mg ml-1. Fluorescently labeled 
liposomes were obtained by incorporation of 1% NBD-PE (phosphatidylethanolamine-N-(7-
nitro-1,3-benzoxadiol-4-yl)) (Avanti Polar Lipids, Alabaster, AL). 
Preparation and characterization of biotinylated microbubbles  
Microbubbles were prepared starting from a solution of a mixture of DPPC (1,2-
dipalmitoyl-sn-glycero-3-phosphocholine) (Lipoid, Ludwigshafen, Germany) and DSPE-PEG-
biotin [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotin(polyethylene glycol)-2000] 
(Avanti Polar Lipids, Alabaster, AL) in a 1:2:7 glycerol-propyleneglycol-H2O solvent (Sigma-
Aldrich, Bornem, Belgium). The molar ratio of the lipids in the lipid solutions was 85:15. The 
lipid solution was prepared as follows. Appropriate aliquots of both lipids, dissolved in CHCl3, 
were transferred to a round bottom flask. After CHCl3 evaporation, the lipid film was dissolved 
in a 1:2:7 glycerol-propyleneglycol-H2O mixture to obtain a clear solution with a final lipid 
concentration of 4.6x10-4 mmol ml-1. Aliquots of this lipid solution were transferred to 2.5 ml 
chromatography vials, the headspace of which was filled with C4F10 gas (F2 chemicals, Preston, 
UK). Finally, microbubbles were obtained by high-frequency shaking of the lipid solution in a 
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Capmix™ device (3M-ESPE, Diegem, Belgium) during 15s. The size and the concentration of 
the microbubbles in the dispersion (i.e. number of microbubbles per ml) were determined with 
a Beckman-coulter Multisizer 4 (Beckman-coulter, Brea, CA). 
Transfection 
mRNA encoding luciferase or eGFP was complexed with cationic liposomes and the 
resulting complexes were attached to the microbubble surface via avidin-biotin interaction, as 
shown in Fig. 2A. The cells were transfected 7 days after seeding. Different amounts of 
DOTAP/DOPE/PEG liposomes were dispersed in 50 µl of OptiMem® (Invitrogen, Merelbeke, 
Belgium). This solution was mixed with 50 µl of mRNA solution in OptiMem®. After 10min of 
incubation at RT, 900 µl of OptiMem® was added. Subsequently, the mixture was added to the 
microbubble solution in OptiMem®. After a short incubation of the cells with mRNA-loaded 
microbubbles, ultrasound was applied (Sonitron 2000, Artison, Inola, OK, USA) (1 MHz, 
2 W cm-² corresponding to a peak negative pressure of 800 kPa, 20% duty cycle (2ms on, 8ms 
off), 30s total insonation time per OptiCellTM). 
BM-DC staining for flow cytometric analysis and confocal microscopy 
Transfected cells were surface stained for CD11c following the manufacturer’s protocols 
and instructions (BD Pharmingen, Erembodegem, Belgium). Briefly, cells were surface stained 
for CD11c-APC or CD11c-FITC (both BD Pharmingen) for 1h at 4°C. Cells were washed twice 
and resuspended in flow buffer (PBS containing 1% BSA and 0.1% azide) for flow cytometric 
analysis or confocal microscopy.  
Dendritic cell maturation 
The effect of the mRNA-lipoplex loaded microbubbles and ultrasound application on the 
DC maturation status was assessed by evaluating up-regulation of the maturation surface 
markers CD40 and CD86. Briefly, following transfection the cells were transferred to 24 well 
plates and cultured with or without addition of Escherichia coli-derived lipopolysaccharide (LPS, 
1 µg ml-1, Sigma Aldrich, Bornem, Belgium) to the culture medium. 24h after exposure of DCs 
to mRNA-lipoplexes, microbubbles and/or ultrasound, the cells were washed with flow buffer 
and incubated on ice for 30min with 5% goat serum in PBS. Then cells were stained for CD11c-
FITC in combination with staining for CD40-PE or CD86-PE (all BD Pharmingen) for 1h on ice, 
followed by washings with flow buffer. Untreated and LPS stimulated cells were used as 
negative and positive controls respectively.  
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Flow cytometric analysis 
Flow cytometric data were acquired using a FACSCaliburTM flow cytometer (BD 
Pharmingen) and data were analyzed using CellQuestTM software. In all experiments, DCs were 
identified based on their CD11c-APC or CD11c-FITC surface staining. Intracellular localization 
of mRNA-lipoplexes was determined by using fluorescently labeled liposomes. Transfection 
efficiency was evaluated by measuring eGFP expression in gated DCs.  
Confocal Microscopy 
Confocal microscopy images of mRNA-loaded microbubbles and transfected DCs were 
recorded using a Nikon C1si confocal laser scanning microscopy module (CLSM) attached to 
a motorized Nikon TE2000-E inverted microscope (Nikon Benelux, Brussels, Belgium). A 
sample of microbubbles or cell suspension was placed on a cover glass and analyzed with 
CLSM using a water immersion objective lens (Plan Apo 60X, NA 1.2, collar rim correction, 
Nikon).  
Toxicity assay 
Cytotoxicity was evaluated 24h after transfection of DCs in OptiCellsTM using a SYTOX® 
green nucleic acid stain (Molecular Probes/Invitrogen, Merelbeke, Belgium). 24h after 
treatment, the cells were washed in HEPES buffer and nuclei of non-viable cells were stained 
with a 45 nM SYTOX® green solution for 30min on ice. Prior to flow cytometric analysis, samples 
were diluted in flow buffer.  
RESULTS 
Characterization of microbubbles loaded with mRNA-lipoplexes 
To avoid degradation by nucleases and to achieve sustained circulation time in vivo 
nucleic acids-based drugs are often complexed with cationic lipids and modified with 
polyethylene glycol (PEG). The latter also serves to prevent complex clearance by the 
reticuloendothelial system18 thus enhancing the chance of uptake by the target cells.  
As described in the material and methods section, mRNA-lipoplexes were prepared by 
mixing mRNA with DOTAP/DOPE liposomes. The resulting lipoplexes were attached to 
microbubbles via biotin-avidin-biotin bridges as schematically depicted in Figure 2A. To be 
responsive to ultrasound frequencies used for diagnostic imaging (1-5 MHz) and enable 
microbubble implosion, microbubbles should ideally have a diameter between 1 and 7 µm19. 
We determined the size of microbubbles by coulter counter measurements. The mean volume 
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diameter of microbubbles employed in this study was 4.4 ± 1.6 µm (consistent with a mean 
number diameter of 2.3 ± 1.2 µm), which meets these requirements. The effective binding of 
mRNA-lipoplexes to microbubbles was demonstrated by confocal microscopy. As shown in 
Figure 2B fluorescently labelled mRNA-lipoplexes clearly mark the bubble surface.  
 
Figure 2. mRNA-lipoplex-loaded microbubbles.  
(A) Schematic representation of an mRNA-loaded microbubble. To generate mRNA-
loaded microbubbles, mRNA was complexed with cationic liposomes consisting of 
DOTAP, DOPE and DSPE-PEG-biotin. The resulting mRNA-lipoplexes were loaded onto 
the microbubble surface via avidin-biotin interactions. (B) Confocal micrographs of 
avidinylated microbubbles after incubation with fluorescently labelled biotinylated mRNA-
lipoplexes: (1) overlay; (2) fluorescently labelled mRNA-lipoplexes; (3) transmission. 
Ultrasound-triggered delivery of mRNA-lipoplexes 
To investigate whether mRNA-loaded microbubbles could be used for the intracellular 
delivery of mRNA-lipoplexes to DCs, DCs were incubated with microbubbles loaded with 
fluorescently labelled mRNA-lipoplexes and exposed to ultrasound. 15min after ultrasound 
application, the cells were collected, surface stained for CD11c and analyzed by flow cytometry. 
As shown in Figure 3, over 50% of DCs contained fluorescently labelled mRNA-lipoplexes. By 
contrast, negligible uptake of complexes (<1%) was observed if cells were incubated with free 
mRNA-lipoplexes or lipoplex-loaded microbubbles without application of ultrasound. 
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Figure 3. Intracellular localisation of fluorescently labelled mRNA-lipoplexes.  
Fluorescently labeled mRNA-lipoplexes, containing 1% NBD-PE, were attached to the 
microbubbles (MBs) and added to DCs. 15min after ultrasound exposure, the cells were 
thoroughly washed to remove non-internalized complexes, which was followed by anti-
CD11c-APC surface staining and flow cytometric analysis.  
The insignificant uptake of free mRNA-lipoplexes by DCs can be explained by the high 
degree of PEGylation (15-20%) of the complexes used in this study. It is known that such a 
hydrophilic coating reduces uptake of the complexes because it shields their positive charge 
thereby preventing interactions with the negatively charged cell surface20. Moreover, it has been 
demonstrated that PEGylated particles, taken up by the cells via endocytosis, get trapped in 
the endo-lysosomal compartment, which impedes their release into the cytosol21. One possible 
way to overcome this problem, is to deliver PEGylated particles directly into the cytosol as 
achieved by ultrasound-assisted delivery. Our group has shown that microbubble implosion 
creates temporary cell membrane perforations and at the same time pushes the complexes 
through such pores22. 
Transfection efficiency of mRNA-lipoplex loaded microbubbles 
To assess the ability of mRNA-lipoplex loaded microbubbles to transfect DCs, an mRNA 
encoding luciferase was employed. The expression kinetics were characterized by determining 
the levels of luciferase at different time points. For this reason we used firefly luciferase mRNA 
as this is known to have a very rapid intracellular turnover with a half-life of 3h23. As shown in 
Figure 4, significant protein expression occurs as early as 30min after mRNA-delivery. Maximal 
levels of luciferase were detected 8h after ultrasound application. Upon longer incubation, 
protein levels gradually declined. Furthermore, no luciferase activity was detected when only 
mRNA-lipoplexes were added to the cells, consistent with the insignificant uptake of mRNA-
lipoplexes by the DCs if neither microbubbles nor ultrasound were applied. This proves that 
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mRNA transfection of DCs can indeed be triggered by means of ultrasound and thus opens 
possibilities towards an image-guided spatiotemporally controlled vaccination system, as will 
be discussed later on.  
 
Figure 4. Transfection efficiency of mRNA lipoplex-loaded microbubbles.  
mRNA encoding luciferase was complexed with DOTAP/DOPE/PEG lipoplexes and added 
to microbubbles after which ultrasound was applied. Levels of luciferase activity in DCs at 
different time points after ultrasound exposure were assayed by measuring 
bioluminescence. Graphs are summaries of two independent experiments at n=3. 
Transfection efficiency of free PEGylated mRNA lipoplexes was assayed 2h after addition 
to the cells.  
In addition to measuring total levels of protein expression, we evaluated the number of 
transfected cells. To that end, DCs were transfected with complexes carrying eGFP mRNA. 
The percentage of DCs expressing eGFP was evaluated 24h after transfection by means of 
flow cytometry. The influence of the transfection protocol on the background fluorescence 
signal of the DCs was verified by using mRNA encoding luciferase. Application of ultrasound in 
combination with mRNA-loaded microbubbles resulted in transfection of up to 24% of the DCs 
(Figure 5A). Ultrasound-assisted transfection of DCs with free mRNA-lipoplexes did not result 
in transfection (<1%; data not shown). These results were confirmed by confocal analysis of 
transfected DCs. Figure 5B shows surface stained DCs (anti-CD11c-APC) expressing eGFP. 
These transfection data provide proof of concept for the use of mRNA-loaded 
microbubbles to transfect DCs. Although 50% of DCs were shown to contain mRNA-complexes 
after this treatment (Figure 3), only 24% of the cells expressed eGFP (Figure 5A). This may be 
due to the incomplete release of the mRNA from the lipoplexes.  
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Figure 5. Transfection efficiency of mRNA-loaded microbubbles.  
(A) mRNA encoding eGFP was complexed with DOTAP/DOPE/PEG liposomes (15% or 
20% PEG) and added to microbubbles (MBs) and ultrasound was applied. As a control, 
DCs were transfected with luciferase mRNA. CD11c+ DCs were analyzed for eGFP 
expression by flow cytometry 24h after transfection. (B) Confocal images of DCs after 
transfection with mRNA lipoplex-loaded microbubbles and ultrasound. (1) overlay; (2) 
CD11c-APC stain; (3) eGFP expression; (4) transmission. 
mRNA electroporation has been shown to achieve transfection efficiencies of up to 70% 
for DCs24. However, Grünebach et al. proved that high transfection efficiencies are not essential 
to elicit effective T cell responses. They even succeeded in eliciting antigen-specific cytotoxic 
T cell (CTL) responses with low to hardly detectable (<1%) transfection efficiencies25. Several 
suggestions explaining this phenomenon were brought forward. Firstly, the CTL assay is 
possibly more sensitive than flow cytometry in detecting low levels of antigen. Secondly, not all 
antigenic peptides that are recognized by CTLs are necessarily derived from biologically 
functional proteins. Even protein fragments translated from damaged mRNA could be 
processed into antigenic peptides that can elicit CD8+ T cells. Taking all this together, we may 
conclude that the transfection results obtained with mRNA-loaded microbubbles and ultrasound 
are likely to be sufficient for effective stimulation of the immune system.  
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Cell viability of DCs following ultrasound exposure 
The potential of mRNA delivery by means of ultrasound can be properly evaluated only if 
potentially toxic effects on the cells are taken into consideration. To assess the effect of the 
mRNA-complexes, microbubbles and ultrasound on DC viability, we utilized a SYTOX® green 
nucleic acid stain. Flow cytometric analysis indicated a survival of 84% of the cells after 
exposure to mRNA-lipoplex loaded microbubbles, 85% after exposure to unloaded 
microbubbles combined with ultrasound and 79% after addition of mRNA-loaded microbubbles 
with ultrasound application (Figure 6). This corresponds with data reported by Suzuki et al. and 
indicates that most of the DCs are indeed able to completely restore the ultrasound-induced 
cell membrane damage within 24h26. The percentage of dead cells after sonoporation is 
comparable to that resulting from electroporation, where 80-90% viability has been reported for 
human monocyte-derived DCs, depending on the physical parameters used25, 27. Moreover, the 
85% toxicity observed when unloaded bubbles were used in combination with ultrasound 
correlates with prior results of our group on other cell types28. This indicates that DCs are not 
particularly sensitive to sonoporation-induced damage.  
 
Figure 6. Cell viability.  
DCs were exposed to mRNA-loaded microbubbles or microbubbles (MBs) and ultrasound 
(US) or mRNA-loaded microbubbles and ultrasound. After treatment, cells were stained 
with SYTOX® green nucleic acid stain to identify dead cells. (n=3) 
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Maturation status of transfected DCs 
In the context of DC-based vaccination strategies, the DC maturation status should be 
taken into consideration. This is a series of changes in the DC phenotype, shifting DC function 
from antigen-sampling to antigen-presentation. As a result, this maturation process is crucial 
for the ability of DCs to prime naive T cells29, 30. We determined whether the mRNA-loaded 
microbubbles and the ultrasound treatment have an influence on DC maturation. To that end, 
DCs were evaluated with respect to the expression of the co-stimulatory markers (CD40 and 
CD86) 24h after transfection. Moreover, we investigated the susceptibility of treated DCs to 
additional maturation stimuli. Therefore, DCs were cultured in the absence or presence of a 
maturation stimulus (lipopolysaccharide, LPS), added immediately after transfection.  
 
Figure 7. Maturation of DCs.  
Representative histograms illustrating phenotypic maturation of DCs in response to 
mRNA-loaded microbubbles (MBs) and ultrasound (US). 24h after transfection, DCs were 
stained for the DC marker CD11c and maturation markers CD40 or CD86 and assessed 
by flow cytometry. Untreated DCs and LPS-stimulated DCs served as negative and 
positive controls, respectively.  
An overview of the phenotypic maturation of DCs in response to mRNA-loaded 
microbubbles and ultrasound is given in Figure 7. In the absence of additional maturation 
signals, transfection of immature DCs with mRNA-loaded microbubbles and ultrasound 
application induced only a minor shift in the expression level of CD40 and a slightly higher 
increase of CD86, compared to that in the untreated cells. However, in the presence of the 
activation stimulus LPS, cells were able to further mature as shown by a significant up-
regulation of CD40 expression. We take this to indicate that the transfection procedure did not 
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negatively affect the capacity of DCs to respond to pathogen-associated molecular patterns 
(PAMPs) and to become activated. Immature DCs exposed to either ultrasound or 
microbubbles did not express higher levels of CD40 and CD86, while LPS stimulation of these 
cells induced expression of these markers. Taken together, these observations indicate that 
the slight phenotypical changes in DC maturation status were solely due to the mRNA-
complexes which had been delivered and that the transfection procedure itself did not induce 
phenotypical changes in the treated DCs. 
DISCUSSION 
We were able to show that mRNA-lipoplexes can be attached to the surface of ultrasound-
responsive microbubbles via biotin-avidin-biotin bridges. Secondly, we demonstrated an 
effective uptake of mRNA-lipoplexes by DCs resulting in a significant expression of luciferase 
and eGFP by DCs after ultrasound-triggered transfection with mRNA-loaded microbubbles, 
without compromising DC viability and maturation capacities. In 2009 Suzuki and colleagues 
reported on the use of microbubbles and ultrasound to pulse DCs with ovalbumine26. They 
showed that this resulted in MHC-I presentation and the development of a strong CD8+ T cell 
response. These results are very encouraging as this indicates that the combination of 
microbubbles and ultrasound can be a powerful vaccination tool. We believe that, compared to 
the system proposed by Suzuki et al. for vaccination purposes, the development of an mRNA-
loaded microbubble offers several advantages. Firstly, when considering the use of autologous 
tumor-derived antigens, even small tumor samples may yield sufficient amounts of mRNA, while 
for protein extraction relatively large tumor samples are required. Moreover, co-transfection with 
mRNA encoding maturation stimuli could be possible, leading to enhanced cytokine signaling, 
thus strengthening the desired immune response31.  
The most important outcome of our findings is that ultrasound-assisted transfection of 
DCs might eliminate the need of ex vivo procedures in the development of a DC vaccine, as 
we will elaborate below. This is important because besides the problems of costs and labor-
intensiveness of current DC vaccination procedures, it has been suggested that the capacity of 
the in vitro cultured and transfected DCs to migrate to the lymph nodes is sub-optimal32. To 
address this drawback, the DC vaccine has been injected intranodally33, 34. Alternatively, in vivo 
transfection of DCs could be considered. The latter is particularly interesting, considering that 
currently used ex vivo generated monocyte-derived DCs are subject to debate. It has become 
more and more clear that this type of DCs merely represents one of the many subsets that can 
be found in vivo. As it remains unclear which particular DC subtypes are responsible for the 
most efficient CTL priming, it would be advantageous to transfect several of these DC subtypes 
in an in vivo setting30, 35. For this purpose, the ideal location would be the lymph nodes, as these 
organs are populated by large numbers of both resident and migratory DCs. In this connection, 
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it has been reported that intranodal delivery of naked pDNA resulted in an important increase 
of vaccine immunogenicity36, 37. Although this is a promising observation, the unprotected DNA 
is rapidly cleared and still has to make its way across the plasma membrane, avoid lysosomal 
degradation and cross the barrier of the nuclear membrane before it can be transcribed and 
translated into an antigenic protein. Therefore, this approach is obviously amenable to 
substantial improvement.  
Microbubbles and ultrasound could provide a possible solution, allowing an increase in 
transfection efficiency of intranodally located DCs. We care to stress here that besides the in 
vitro proof presented in the present work, satisfactory transfection efficiencies with 
microbubbles and ultrasound have been shown also in vivo38, 39. Furthermore, our suggestion 
to use microbubbles for intranodal DC transfection is supported by the consideration that 
microbubbles have already been used clinically as ultrasound contrast agents in the lymphatics, 
and more specifically, as means to visualize sentinel lymph node metastases7, 10. This would 
imply that a non-invasive intradermal injection of the mRNA-loaded microbubbles would be 
sufficient to obtain intranodal localization of the nucleic acids. Intranodal location of the 
microbubbles – and hence of the mRNA – can easily be visualized as the presence of the 
bubbles will be revealed by enhanced ultrasound contrast. This way, the complete vaccination 
procedure could be divided into a first phase of low intensity ultrasound, allowing microbubble 
visualization and a second phase, where the ultrasound intensity is increased to cause 
microbubble collapse and subsequent DC transfection.  
CONCLUSIONS 
Our results demonstrate that mRNA-loaded microbubbles can be used as an efficient 
ultrasound-triggered transfection tool for DCs, without compromising cell viability or DC 
maturation capacities. These findings are especially important in the context of a possible in 
vivo use of this technique. Needless to say that direct in vivo transfection of DCs would not only 
eliminate the need for costly ex vivo DC handling and transfection, but it could also allow 
transfection of several DC subsets which would broaden the generated immune response. The 
feasibility of this approach will further be explored in the following chapters. 
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ABSTRACT 
Dendritic cell (DC)-based cancer vaccines, where the patient’s own immune system is 
harnessed to target and destroy tumor tissue, has emerged as a potent therapeutic strategy. In 
the development of such DC vaccines, it is crucial to load the DCs with tumor antigens, and to 
simultaneously activate them to become more potent antigen-presenting cells. For this, we 
report on microbubbles, loaded with both antigen mRNA as well as immunomodulating TriMix 
mRNA, which can be used for the ultrasound-triggered transfection of DCs. In vivo experiments 
with in vitro sonoporated DCs, show the effective induction of antigen-specific T cells, resulting 
in specific lysis of antigen-expressing cells. Especially in a therapeutic setting, sonoporation 
with TriMix has an important added value, resulting in a significant reduction of tumor outgrowth 
and a marked increase in overall survival. What is more, complete tumor regression was 
observed in 30% of the antigen+TriMix DC vaccinated animals, which also displayed long-term 
antigen-specific immunological memory. As a result, DC sonoporation using microbubbles 
loaded with a combination of antigen and TriMix mRNA can elicit powerful immune responses 
in vivo, and might serve as a potential tool for further in vivo DC vaccination applications.  
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INTRODUCTION 
Since its discovery in the early 70s by Noble Prize winner Ralph M. Steinman, the 
dendritic cell (DC) came to be known as nature’s adjuvant1 (Chapter 1). Its unique capacity to 
present antigens and initiate antigen-specific T cell responses, makes the DC an interesting 
target in cancer immunotherapy. In order to produce effective DC-based vaccines, two major 
requirements need to be satisfied. Firstly, the immune system should be able to discriminate 
between healthy tissue and cancer cells. For this, it is crucial to load DCs with cancer-specific 
tumor associated antigens (TAAs)2, 3. Upon presentation of these TAAs in major 
histocompatibility complexes (MHCs) on the DC surface, TAA-specific immune responses can 
be mounted. Secondly, DCs should receive additional stimulation to become fully mature 
antigen-presenting cells that can provide the necessary co-stimulatory signals to activate 
antigen-specific T cells.  
In Chapter 4, we showed that by using mRNA-loaded microbubbles, we could induce fast 
and efficient, ultrasound-triggered mRNA-loading of murine bone marrow-derived DCs in vitro, 
without important negative repercussions on the DC viability and capacity to respond to 
maturation stimuli4. Thus, this strategy uses mRNA as a source of antigen, and microbubbles 
for ultrasound-triggered antigen delivery.  
With respect to the second requirement, it is essential that the DCs undergo a process 
called “maturation” in order for antigen-presentation to effectively result in T cell activation. 
Maturation is initiated when DCs encounter “danger” signals, such as toll like receptor (TLR) 
agonists, causing them to shift in phenotype and function from antigen-capturing to antigen-
presenting cells5. This is an absolute necessity for a DC-based cancer vaccine to be successful, 
as it is now clear that mature DCs are capable of inducing immunity against the presented 
antigens (i.e. stimulation of effector T cells), whereas their immature counterparts will rather 
induce tolerance (i.e. T cell anergy and regulatory T cells)6. The main reason for this is that 
immature DCs lack co-stimulatory molecules required for effective T cell activation7. Therefore, 
it is crucial to deliver not only antigens to DCs, but also maturation stimuli to ensure optimal 
immune activation by the DC vaccine.  
In this study, we aimed to evaluate the capacity of mRNA-sonoporated DCs to induce 
immune responses in vivo. Moreover, to address the second DC vaccine requirement, we 
aimed to obtain both antigen-loading and stimulation of maturation by a single step 
sonoporation. This is important, as we previously reported that mRNA sonoporation without 
inclusion of additional immune stimulants merely induces partial maturation of the DCs. 
Therefore, we performed sonoporations with antigen mRNA and TriMix mRNA. TriMix is a 
mixture of 3 mRNAs, encoding CD40-ligand, a constitutively active form of TLR4 and CD70 (a 
co-stimulatory molecule required for effective CD8+ T cell priming)8. Co-delivery of these 3 
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nucleic acid sequences was already shown to modulate the DCs’ functionality, resulting in 
APCs that display a more mature, T cell activating phenotype9. Previous studies have 
demonstrated the superiority of TriMix over other, more conventional, maturation stimuli after 
intranodal injection of TAA and TriMix mRNA in tumor-bearing mice10. Also in a clinical setting, 
vaccination with DCs electroporated with TAA and TriMix mRNA lead to the induction of durable 
antitumor responses in a chemorefractory melanoma patient11, 12. On the basis of these results, 
we evaluated the potential of simultaneous delivery of TAA mRNA and TriMix via microbubbles 
and ultrasound to induce potent antitumor immune responses in mice, as schematically 
depicted in Figure 1A.  
 
Figure 1. mRNA sonoporation of DCs using mRNA-loaded microbubbles and 
ultrasound.  
(A) Schematic representation of the use of mRNA-loaded microbubbles, which implode 
upon exposure to ultrasound and sonoporate the DCs. As a result, both antigen and DC 
modulating proteins are produced by the DC, which can lead to antigen presentation and 
T cell activation. (B) Schematic representation of the production of mRNA-loaded 
microbubbles. Antigen and TriMix mRNA are premixed and complexed to biotinylated 
cationic liposomes. The resulting mRNA-lipoplexes can then be attached to the surface of 
avidinylated lipid microbubbles. 
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MATERIALS AND METHODS 
Cell culture and mice  
Primary murine bone marrow-derived DC (BM-DC) cultures were generated from 
C57BL/6 mice. Female C57BL/6 mice were purchased from Harlan (Gannat, France) and 
housed in an SPF facility according to the regulations of the Belgian law and the local Ethical 
Committee. Mice were sacrificed and bone marrow was flushed from the hind limbs. After red 
blood cell lysis (Pharm Lyse Buffer, BD Biosciences, Erembodegem, Belgium), the collected 
cells were seeded in 100 mm not TC-treated polystyrene culture dishes (Corning®, Amsterdam, 
The Netherlands) at 2x106 cells ml-1 in 15 ml. The cell culture medium used was RPMI 1640 
(Gibco-Invitrogen, Merelbeke, Belgium) supplemented with penicillin/streptomycin/L-glutamine 
(1%, Gibco-Invitrogen), β-mercaptoethanol (50 µM, Gibco-Invitrogen), 5% FetalClone™ I (FCI, 
5%, HyCloneTM) and recombinant murine GM-CSF (20 ng ml-1, Peprotech, Rock Hill, NJ). On 
day 3 of the culture, an additional 15 ml complete culture medium containing GM-CSF (40 ng ml-
1) was added. On day 5, all cells were collected by centrifugation (5min at 300g), resuspended 
in the appropriate culture medium at 5x105 cells ml-1 and seeded per 10 ml in OptiCellsTM (Nunc, 
Thermo Scientific, Aalst, Belgium) for sonoporation the next day. 
The mouse melanoma cell line MO4 (kindly provided by K. Rock, University of 
Massachusetts Medical Center) and the T cell lymphoma E.G7-OVA (obtained from the 
American Type Culture Collection, Rockville, MD, USA) were cultured at 37°C in a humidified 
5% CO2 atmosphere in RPMI 1640 medium (Sigma-Aldrich, Diegem, Belgium) supplemented 
with 5% FCI, 100 U ml-1 penicillin, 100 µg ml-1 streptomycin, 2 mM L-glutamine, 1 mM sodium 
pyruvate and nonessential amino acids (Sigma-Aldrich).  
C57BL/6 and OT-I mice for in vivo experiments were ordered from Charles River 
(L'Arbresle, France) and housed in SPF facilities according to the regulations of the Belgian law 
and the local Ethical Committee.  
Messenger RNA 
The vector, pST1 was provided by U. Sahin (Johannes-Gutenberg University, Mainz, 
Germany). The vectors pGEM-Ii80tOVA, pST1-eGFP-bis, pST1-caTLR4, pST1-mouse CD40-
L and pST1-mouse CD70 were previously described8, 10, 13. Before in vitro transcription, pGEM 
and pST1 vectors were linearized with the restriction enzymes Spe I and Sap I, respectively. 
All enzymes were purchased from Fermentas (Vilnius, Lithuania). The in vitro transcription of 
mRNA and its subsequent quality control were performed as previously described13. 
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In vitro mRNA sonoporation 
Lipid microbubbles loaded with mRNA-lipoplexes were prepared as described 
previously4. A schematic representation of the material production is shown in Figure 1B. 
Briefly, perfluorobutane (F2 chemicals, Preston, UK) microbubbles stabilized by a lipid coat 
consisting of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) (Lipoid, Ludwigshafen, 
Germany) and DSPE-PEG-biotin [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[biotin(polyethylene glycol)-2000] (Avanti Polar Lipids, Alabaster, AL) in a 85:15 molar ratio 
were prepared. These biotinylated microbubbles were subsequently coated with avidin (Cell 
Sciences, Canton, USA), to allow coupling to biotin-containing mRNA lipoplexes. The mRNA 
lipoplexes were prepared by mixing mRNA with cationic liposomes consisting of 48.75% 
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane), 48.75% DOPE (1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine) and 2.5% DSPE-PEG-2000-biotin [1,2-distearoyl-sn-glycero-3-
phosphoethanol-amine-N-[biotinyl(polyethylene glycol)-2000] (all Avanti Polar Lipids), at a 
cationic lipid-to-mRNA charge (N/P) ratio of 8 in OptiMem® (Gibco Invitrogen). When multiple 
mRNAs were used, these were first pre-mixed in a 1:1 ratio prior to complexation to the cationic 
liposomes. The resulting mRNA-lipoplexes (corresponding to 10 µg mRNA when GFP or OVA 
were used alone, or 40 µg when co-sonoporations with TriMix were performed) were incubated 
with the microbubbles for 5 min prior to use. After injection of mRNA lipoplex-loaded 
microbubbles in the OptiCellsTM, ultrasound was applied using a Sonitron 2000 (Artison, Inola, 
USA) (1 MHz, 2 W cm-² corresponding to a peak negative pressure of 800 kPa, 20% duty cycle 
(2ms on, 8ms off), 30s total insonation time per OptiCellTM).  
BM-DC antibody staining and flow cytometric analysis 
To evaluate the impact of mRNA sonoporation on the transfection efficiency and DC 
phenotype, the mRNA sonoporated cells were collected 24h or 48h after ultrasound application. 
The cells were washed and surface stained with anti-CD11c-APC (BM-DC marker, Affymetrix 
eBioscience, Vienna, Austria) and anti-CD40-PE (Affymetrix), anti-CD86-PE (BD biosciences) 
or anti-CD70-PE (Affymetrix) for 45min at 4°C in the dark. After washing, the cells were 
resuspended in FACS buffer (phosphate buffered saline (PBS, Gibco-invitrogen), 
supplemented with 5% bovine serum albumin (BSA, Sigma-Aldrich)) and analyzed using a 
FACSCaliburTM (BD) equipped with CellQuestTM software.  
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Vaccination of mice with mRNA sonoporated DCs 
After in vitro mRNA sonoporation, the DCs were incubated for 2h at 37°C in the 
OptiCellsTM. Then, all the cells (both the cells in suspension as well as the cells that grow 
adherent to the OptiCellTM membranes) were collected, and washed twice with PBS. Finally, 
the cells were resuspended at 2x106 cells ml-1 in PBS, of which 50 µl was injected 
subcutaneously into the flank of the mice.  
In vivo T cell proliferation assay 
In order to assess the potential of mRNA sonoporated DCs to efficiently induce 
proliferation of antigen-specific T cells, an in vivo OT-I proliferation assay was performed. This 
assay uses OVA as a model antigen, and is based on adoptive transfer of OT-I cells, which 
carry a transgenic CD8 T cell receptor which specifically recognizes the MHC-I restricted OVA 
peptide SIINFEKL. For this, spleens from OT-I mice were processed into a single-cell 
suspension. After red blood cell lysis, CD8+ T cells were isolated via magnetically activated cell 
sorting, using a MACS CD8a T cell isolation kit (MACS Miltenyi, Leiden, The Netherlands) 
according to the manufacturer’s instructions. The collected CD8+ T cells were fluorescently 
labeled using carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular probes, 10 µM 
in PBS supplemented with 0.1% BSA) for 15min at 37°C. After washing the cells with RPMI 
medium, the cells were resuspended at 1x108 cells ml-1 in PBS. All mice received 200 µl of this 
CFSE-labeled OT-I cell suspension i.v. via tailvein injection. The next day, the mice received 
subcutaneous injections with PBS (negative control) or mRNA sonoporated DCs, as described 
previously. 5 days after vaccination, the mice were sacrificed and the inguinal lymph nodes 
were collected. After 30min digestion of the nodes in liberase TL (100 µl, Roche, Vilvoorde, 
Belgium), a single-cell suspension was prepared. Half of the cells were used for flow cytometric 
analysis of proliferation (using a FACSCanto flow cytometer with FACSDivaTM software, BD 
Biosciences). On the other half of the suspension, a CD8+ T cell sort was performed. The 
resulting cells were resuspended at 2x106 cells ml-1 in RPMI medium and seeded per 100 µl in 
a round-bottom 96 well plate for restimulation. To this extent, day 6 BM-DCs were loaded with 
1 µg ml-1 SIINFEKL peptide (Eurogentec, Seraing, Belgium) for 30min at 37°C. After washing, 
100 µl SIINFEKL-pulsed DCs, suspended at 2x105 cells ml-1 were added to the OT-I cells in the 
96 well plates for 24h at 37°C.  
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In vivo cytotoxic T lymphocyte assay 
To investigate the potential of mRNA sonoporated DCs to induce antigen-specific 
cytotoxic T lymphocyte (CTL) responses, an in vivo CTL assay was performed using an OVA 
model. For this, 5 days after vaccination with mRNA sonoporated DCs, the vaccinated mice 
were challenged i.v. with both target cells and control cells in a 1:1 ratio. The injected cells were 
splenocytes of untreated C57BL/6 mice that were either labeled with CFSE at low intensity 
(CFSElo control cells, 5x106 cells per injection), or labeled with CFSE at high intensity and 
additionally pulsed with the peptide SIINFEKL (CFSEhi target cells, 5x106 cells per injection). 
The next day, the mice were sacrificed, inguinal lymph nodes were collected, processed into a 
single-cell suspension, and analyzed for CFSE staining via flow cytometry using a BD 
FACSCanto. Mice injected subcutaneously with PBS served as non-immunized controls. The 
percentage specific lysis of target cells was calculated using the following formula: 
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 = 1 −  
(%𝐶𝐹𝑆𝐸
ℎ𝑖
%𝐶𝐹𝑆𝐸𝑙𝑜
⁄ )𝑖𝑚𝑚𝑢𝑛𝑖𝑧𝑒𝑑
(%𝐶𝐹𝑆𝐸
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%𝐶𝐹𝑆𝐸𝑙𝑜
⁄ )𝑛𝑜𝑛−𝑖𝑚𝑚𝑢𝑛𝑖𝑧𝑒𝑑
 × 100% 
 
In vivo therapeutic vaccination experiments 
The therapeutic potential of mRNA sonoporated DCs to reduce tumor growth was 
evaluated by performing therapeutic vaccinations in tumor-bearing mice. For this, C57BL/6 
received a subcutaneous injection of 3x105 MO4 or E.G7-OVA tumor cells (suspended in PBS) 
in the flank. 10 days after tumor inoculation, when the lesions were palpable, the mice were 
randomized in different treatment groups based on tumor volume, and vaccinated with mRNA 
sonoporated DCs. A second therapeutic vaccination was performed at day 13 or 14 after tumor 
cell injection. Tumor growth was measured every other day using a caliper. When the tumor 
volume exceeded 1500 mm³, the mice were euthanized via cervical dislocation. Animals that 
completely rejected their tumors were rechallenged with 3x105 E.G7-OVA tumor cells, and 
subsequently with 3x105 MO4 cells. As controls for the rechallenge study, naïve (non-
vaccinated) C57BL/6 were used.  
ELISA measurements 
Supernatants of mRNA sonoporated DCs were screened for the presence of IL-10 and 
IL-12p70. Supernatants of DC and T cell co-cultures were assayed for IFNγ. Cytokine 
measurements were performed via ELISA (all Ready-SET-Go!® ELISA kits, Affymetrix) 
according to the manufacturer’s instructions. 
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Statistical analysis 
A one-way ANOVA followed by a Bonferroni multiple comparison test, was carried out 
(GraphPad software, la Jolla, CA, USA). Sample sizes and number of times experiments were 
repeated are indicated in the figure legends. The results are shown in column graphs as mean 
 standard deviation. The number of asterisks in the figures indicates the statistical significance 
as follows: *p<0.05; **p<0.01; ***p<0.001. Survival was visualized in a Kaplan-Meier plot. 
Differences in survival were analyzed by the log-rank (Mantel-Cox) test. 
RESULTS 
Transfection efficiency and phenotype of mRNA sonoporated DCs 
In our previous report, we demonstrated that sonoporation could be used for ultrasound-
triggered transfection of primary DCs with mRNA in vitro. In addition, the sonoporation 
procedure as such, without the use of additional maturation stimuli, was shown to readily induce 
a small but significant shift in the expression of the DC maturation markers CD40 and CD864. 
However, compared to a positive control where the DCs’ TLR4 was stimulated by incubation 
with bacteria-derived lipopolysaccharide (LPS), this maturation was merely partial. As complete 
DC maturation is warranted for effective immunostimulation, this prompted us to include 
additional stimuli to further increase the expression of co-stimulatory markers. Therefore, we 
included TriMix mRNA in the antigen mRNA-containing lipoplexes. We evaluated the effect of 
TriMix inclusion on the transfection efficiency as well as the DC phenotype, by analyzing the 
expression of 3 molecules involved in T cell activation by DCs 24h after sonoporation with either 
reporter mRNA alone (GFP) or in combination with TriMix (GFP+TriMix).  
In accordance with our previous report, the results in Figure 2 indicate satisfactory 
transfection with GFP mRNA, resulting in 19% GFP-expressing DCs 24h after sonoporation. 
Inclusion of TriMix results in a decrease in transfection efficiency to 11%. With regards to the 
DC phenotype, we observed a significant up-regulation of CD86 and CD40 expression in the 
GFP group compared to blank. The effects on CD70 expression are less pronounced. 
Sonoporation with GFP+TriMix, lead to a slight but significant additional increase in the 
expression of CD40, CD86 and CD70 over sonoporation with GFP mRNA alone. However, the 
expression levels of these surface molecules after GFP+TriMix sonoporation are still 
significantly lower in comparison to an LPS-stimulated positive control.  
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Figure 2. Transfection efficiency and phenotypical analysis of DCs after mRNA 
sonoporation.  
24h after treatment of the DCs by sonoporation with GFP mRNA alone (GFP) or in 
combination with TriMix (GFP+TriMix), the cells were analyzed for the expression of GFP 
and different maturation markers (CD40, CD86 and CD70). DCs were gated based on 
CD11c staining. Untreated cells and LPS-stimulated cells served as negative and positive 
controls, respectively (n=3). 
Similar observations can be made when looking at the levels of immune stimulating (IL-
12p70) and immune suppressive (IL-10) cytokines that are produced by the mRNA sonoporated 
DCs 24h after treatment (Figure 3). Sonoporation with GFP mRNA alone resulted in a 
significant increase in IL-10, but not IL-12p70 secretion. For both cytokines, inclusion of TriMix 
into the mRNA lipoplexes surrounding the microbubbles results in higher cytokine production. 
But still, the concentrations are significantly lower than when LPS was applied to induce 
maturation of the DCs.  
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Figure 3. Cytokine production by mRNA sonoporated DCs.  
The amounts of cytokines produced by untreated DCs (blank), DCs sonoporated with GFP 
mRNA alone, or in combination with TriMix (GFP+TriMix) and DCs that were matured with 
LPS were measured 24h after cell treatment. Figures show graphical representations of 
the levels of (A) IL-12p70 and (B) IL-10. Graphs are summaries of 2 independent 
experiments at n=3, **p<0.01, ***p<0.001. 
In vivo induction of antigen-specific T cell proliferation by mRNA sonoporated DCs 
To assess the impact of mRNA sonoporation on the capacity of DCs to prime antigen-
specific CD8+ T cells, we performed an in vivo T cell proliferation study using chicken ovalbumin 
(OVA) as a model antigen. This makes use of an adoptive transfer of OT-I cells, which are 
transgenic T cells that carry a CD8 T cell receptor that specifically recognizes the OVA-derived 
peptide SIINFEKL when presented in MHC-I. 24h after adoptive OT-I cell transfer, tumor-free 
mice were vaccinated with mRNA sonoporated DCs, and the percentage proliferating OT-I cells 
was evaluated 5 days later. Results were normalized to the background signal in mice that 
received PBS instead of DCs. As demonstrated in Figure 4A, no unspecific OT-I proliferation 
was observed in the negative control group that received DCs sonoporated with GFP mRNA 
(3 ± 3%). When vaccination was performed with DCs sonoporated with antigen mRNA alone 
(OVA), this resulted in 31 ± 16% proliferation of OVA-specific CD8+ T cells, indicating efficient 
intracellular processing and presentation of OVA by the mRNA sonoporated DCs without 
additional stimulation of maturation. When OVA sonoporation was combined with phenotype-
modulating stimuli, either by 2h incubation of the sonoporated DCs with LPS (OVA/LPS as a 
positive control) or by sonoporation with OVA and TriMix mRNA (TriO), antigen-specific T cell 
proliferation increased to respectively 41 ± 15% and 48 ± 19%. Although there is a trend towards 
more extensive proliferation in the OVA/LPS and TriO groups, the observed differences were 
not statistically significant (p>0.05).  
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Figure 4. In vivo proliferation of antigen-specific T cells.  
1 day after adoptive OT-I transfer, mice were vaccinated with DCs sonoporated with GFP 
mRNA (negative control), OVA mRNA alone (OVA) or in combination with TriMix (TriO), or 
OVA-sonoporated DCs that were matured with LPS (OVA/LPS). Read-out was performed 
24h later. Graphs show (A) percentages proliferating OT-I cells normalized to the 
background that was detected in mice that received a PBS injection. (B) levels of IFNγ 
measured 24h after restimulation of proliferated OT-I cells with peptide-pulsed DCs. 
Graphs are summaries of 2 independent experiments at n=3, *p<0.05, ***p<0.001. 
Representative histograms for the percentage proliferating OT-I cells are provided in (C). 
In addition, we evaluated the functionality of the proliferating T cells, by performing a re-
stimulation with peptide. For this, a fraction of the proliferated OT-I cells were co-cultured in a 
10:1 ratio with DCs that were pulsed with SIINFEKL peptide. 24h later, the response of these 
restimulated T cells to the antigen-presenting DCs was evaluated by measuring the levels of 
IFNγ, an important mediator of CTL responses, in the co-culture supernatant. The results in 
Figure 4B display a similar trend to the proliferation results: T cells activated by DCs that 
received OVA mRNA via sonoporation produce significantly larger amounts of IFNγ compared 
to those stimulated with DCs sonoporated with GFP mRNA. After additional maturation by LPS 
incubation or sonoporation with TriMix, a trend towards higher IFNγ levels was observed.  
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In vivo cytotoxic T cell response induction by mRNA sonoporated DCs 
 
Figure 5. In vivo cytotoxic T cell assay.  
5 days after vaccination of mice with DCs sonoporated with GFP mRNA (negative control), 
OVA mRNA alone (OVA) or in combination with TriMix (TriO), or OVA-sonoporated DCs 
that were matured with LPS (OVA/LPS), mice were challenged with target cells and non-
target cells in a 1:1 ratio. The next day, the percentage of antigen-specific lysis of target 
cells compared to non-target cells was measured. (A) Graphs are summaries of 3 
independent experiments at n=3, *p<0.05. Representative histograms showing the relative 
distribution of target to non-target cells (as used for the calculation of the percentage 
target-specific lysis) are provided in (B).  
 
Besides the capacity to stimulate antigen-specific T cells to proliferate, mRNA 
sonoporated DCs should be able to activate CD8+ T cells to cause antigen-specific lysis of 
target cells. To evaluate this, an in vivo CTL assay was performed, again using OVA as a model 
antigen. For this, tumor-free mice were vaccinated with mRNA sonoporated DCs and 5 days 
later, the animals were challenged with allogenic splenocytes that were either untreated (non-
target cells) or pulsed with SIINFEKL peptide (target cells). The next day, the ratio of target 
cells versus non-target cells was studied as a measure for antigen-specific lysis. The results, 
as represented in Figure 5, show 41 ± 31% OVA-specific lysis of target cells when mice were 
vaccinated with DCs sonoporated with OVA mRNA. LPS-induced maturation of the DCs after 
sonoporation (OVA/LPS), could not further increase this percentage (39 ± 23%). Unexpectedly, 
DCs sonoporated with TriO were markedly less efficient in inducing antigen-specific lysis 
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(25 ± 18%). Based on the proliferative potential of TriO DCs as well as on their capacity to 
stimulate IFNγ-producing CD8+ T cells, more extensive CTL responses were expected.  
Therapeutic vaccinations with mRNA-sonoporated DCs 
Immune induction is a complex orchestrated response that relies on numerous synergistic 
components of both cellular and humoral immunity. Moreover, tumor-mediated suppression of 
immune responses, regulated by various immunosuppressive cell types such as myeloid-
derived suppressor cells and regulatory T cells (Tregs) that reside in the tumor microenvironment, 
could potentially limit the therapeutic benefits of DC-based immunotherapy14, 15. Therefore, the 
impact of cancer vaccines can only truly be evaluated when all these different players are taken 
into account. For that reason, we assessed the potential of DCs sonoporated with antigen and 
TriMix mRNA in a therapeutic setting. For this, we examined the effect of vaccination with ex 
vivo mRNA sonoporated DCs in mice with pre-existing tumors. We initially opted for an OVA-
expressing B16 melanoma model (MO4). 10 days after tumor inoculation in the flank, tumors 
were palpable and the animals were randomized into 3 treatment groups based on the tumor 
volume (as shown in Figure 6A).  
Subsequently, the animals were given a subcutaneous injection with either DCs 
sonoporated with GFP mRNA (DC GFP, negative control, n=9), OVA mRNA (DC OVA, n=9), 
or sonoporated with TriMix and OVA mRNA (DC TriO, n=8). A second vaccination was 
performed 3 days later. When measuring tumor growth as a function of time, we observed a 
significant slow-down of tumor outgrowth in the DC OVA, and especially in the DC TriO group 
compared to the DC GFP group (Figure 6). This was translated in a prolongation of median 
survival of 41% and 82% for DC OVA and DC TriO respectively. This indicates that antigen 
mRNA sonoporated DCs can induce potent antitumor immune responses in vivo, which can 
further be boosted by sonoporation with DC-modulating TriMix mRNA.  
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Figure 6. Therapeutic vaccination of MO4-bearing mice with mRNA sonoporated 
DCs.  
10 and 13 days after inoculation with MO4 melanoma cells, mice were randomized in 
three treatment groups based on tumor volume as shown in (A) Then, the animals 
received therapeutic vaccinations with mRNA sonoporated DCs. Graphs show tumor 
growth as a function of time for mice vaccinated with DCs sonoporated with (B) GFP 
mRNA (control), (C) OVA mRNA and (D) OVA mRNA and TriMix (DC TriO). A Kaplan-
Meier survival curve is shown in (E). 
These therapeutic vaccination experiments were repeated in a different tumor model, 
expressing the same antigen. For this, mice were inoculated with E.G7-OVA, which are OVA-
expressing lymphoma cells. Randomization was done based on tumor volume at day 10 after 
tumor inoculation (as shown in Figure 7A). Once more, two therapeutic vaccinations were 
performed at 10 and 14 days after tumor inoculation. In addition to the three treatment groups 
described in the previous experiment, we included a group that received OVA mRNA 
sonoporated DCs that were additionally matured with LPS for 2h prior to injection (DC 
OVA/LPS) (n=6 in all groups). This way, we aimed to compare the therapeutic effects of TriMix 
sonoporation to the use of a known and potent maturation inducer.  
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Figure 7. Therapeutic vaccination of E.G7-OVA-bearing mice with mRNA 
sonoporated DCs.  
10 and 14 days after inoculation of mice with E.G7-OVA lymphoma cells, mice were 
randomized in three treatment groups based on tumor volume as shown in (A) Then, the 
animals received therapeutic vaccinations with mRNA sonoporated DCs. Graphs show 
tumor growth as a function of time for mice vaccinated with DCs sonoporated with (B) 
GFP mRNA (control), (C) OVA mRNA, (D) OVA mRNA and TriMix (DC TriO) and (E) OVA 
mRNA followed by a 2h maturation with LPS (DC OVA/LPS). A Kaplan-Meier survival 
curve is shown in (F). 
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In accordance to the previous experiment, the tumor growth curves in Figure 7 indicate 
that sonoporation with antigen results in a significant delay of tumor outgrowth, resulting in a 
58% increase in median survival. Interestingly, the slow-down of tumor growth was markedly 
shorter-lived in the DC OVA/LPS group compared to their unstimulated counterparts (DC OVA). 
This resulted in merely 35% prolongation of median survival of animals in the DC OVA/LPS 
group compared to the DC GFP group. In contrast, stimulation of antigen presentation by 
sonoporation with OVA and TriMix mRNA, resulted in a pronounced effect on tumor growth: 
median survival was more than doubled (212% increase), and complete tumor regression was 
observed in 2/6 animals in the DC TriO group.  
 
Figure 8. Rechallenge of tumor-free DC TriO treated mice.  
The two E.G7-OVA challenged mice that showed complete tumor regression after two 
vaccinations with DC TriO, were rechallenged with E.G7-OVA and MO4 tumor cells on 
day 42 and day 80 after initial tumor inoculation, respectively. As controls, naïve, non-
vaccinated mice were injected with the same tumor load. 
These surviving animals, as well as two naïve control mice, were rechallenged with E.G7-
OVA tumor cells 42 days after the first tumor inoculation. This to evaluate whether durable 
antitumor immunity was induced by the vaccinations. Indeed, in comparison to the control mice 
where rapid tumor growth was observed, the DC TriO vaccinated mice were protected against 
a second injection with the same tumor (Figure 8). To prove that this protective immunity is 
antigen-specific, we challenged these animals with a different tumor (MO4 melanoma instead 
of the initial lymphoma) that expresses the same antigen. Once more, no tumor growth could 
be detected in the DC TriO vaccinated animals in contrast to 3 naïve control mice. Thus, 
vaccination with DC TriO can induce antigen-specific immunological memory that is capable of 
protecting tumor-free survivors against tumor recurrence.  
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DISCUSSION 
In continuation of our previous report on the use of mRNA-loaded microbubbles and 
ultrasound for the transfection of DCs in vitro4, we further investigated if antigen transfer into 
DCs via mRNA sonoporation could result in the induction of antitumor immune responses. For 
this, it is crucial to not only deliver antigen mRNA to the DCs, but also to induce a shift in activity 
of these cells, in order to make them more effective in antigen presentation to naïve T cells. 
This should in turn result in protection against tumor growth. To allow this antigen-loading and 
maturation to occur simultaneously, we included TriMix into the mRNA-lipoplexes that surround 
the microbubbles, and performed sonoporations with four mRNA sequences in total.  
First of all, we were able to show that sonoporation with multiple mRNAs is feasible. Upon 
sonoporation with GFP mRNA and TriMix, both GFP expression as well as a slight but 
significant up-regulation of maturation marker expression by DCs were observed. However, 
sonoporation with TriMix leads to a reduction in the percentage of GFP-expressing cells, which 
is probably due to limitations in the amount of mRNA that can be loaded onto the microbubble 
surface. For sonoporation with TriMix, a four-fold increase in total amount of mRNA, and 
therefore in amount of mRNA-lipoplexes is required. However, the number of binding spaces 
on the bubble surface is limited16. Therefore, it is likely that in the TriMix conditions, complete 
microbubble saturation occurs, resulting in the presence of a substantial portion of free mRNA-
lipoplexes in the medium. In our previous reports, we demonstrated that the highest transfection 
efficiencies could be reached when the lipoplexes are physically attached to the microbubbles 
and not just co-delivered17, 18. For that reason, sonoporation with multiple mRNAs could lead to 
a lower protein expression. In addition, there is the possibility that the co-transfection with 
multiple RNAs results in competition for mRNA translation. This theory is supported by the 
observations of Chen et al., who also reported a drop in transfection efficiency when two 
mRNAs were co-electroporated in DCs compared to electroporation of each of these mRNAs 
alone19. This was also reported by Bonehill and colleagues who showed that upon 
electroporation of DCs with TriMix the number of mRNA-expressing DCs was always slightly 
decreased when two or three mRNAs were co-electroporated, in comparison to the 
electroporation of each mRNA alone8. This might indicate that there is a limit to the amount of 
mRNA that can be transferred into the cells. This raises the question whether this reduced 
transfection efficiency could limit the use of antigen mRNA and TriMix sonoporation. To answer 
this, it is important to take the therapeutic studies performed with TriO sonoporated DCs into 
account. These confirm that a higher transfection efficiency does not necessarily result in more 
potent immune responses. Indeed, DCs sonoporated with antigen mRNA alone, which allows 
higher antigen expression, result in less powerful immune responses, even after additional 
LPS-maturation, compared to TriO sonoporated DCs, where the amount of antigen that is 
produced by the DCs is lower. This discrepancy between transfection efficiency and 
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immunogenicity was previously reported by Grünebach et al., who postulated that it is important 
to realize that T cell receptors can detect antigens at much higher sensitivity than any routinely 
used analytical instrument in the lab20. In addition, T cell activation does not only depend on the 
presence of the antigen. Only when the antigens are presented to T cells by fully functional and 
mature DCs, can this result in effective T cell activation6.  
Thus, it is crucial to obtain antigen-loaded DCs with a mature phenotype. In accordance 
to our previous reports, mRNA sonoporation as such, without incorporation of additional 
immune stimulants, readily results in a distinct up-regulation of maturation marker expression 
at the DC surface. This in contrast to mRNA electroporation, which is considered the golden 
standard for mRNA transfer into DCs in vitro, where no effects on the DC maturation status 
were observed8, 13. Two possible mechanisms might explain this sonoporation-induced 
maturation. First of all, sonoporation is a physical transfection method, where pores are created 
as a result from shear forces and violent microbubble movements21. DCs are known to be 
sensitive to shear forces, and can already up-regulate maturation markers upon stress due to 
pipetting and centrifugation22. Thus, the shear stress induced by sonoporation could contribute 
to the observed phenotypical changes. In addition, sonoporation was reported to influence Ca2+ 
signaling within cells21, 23. Importantly, increased intracellular Ca2+ concentrations were also 
reported as one of the early events after LPS stimulation of mouse bone marrow-derived DCs24. 
Another possibility is direct triggering of innate immune responses by the cationic lipids (in this 
case DOTAP) within the mRNA lipoplexes, via TLR4 ligation. This, charge-related TLR 
activation was previously reported for DOTAP-containing lipoplexes as well as for various 
cationic polymers that are routinely used as transfection reagents25, 26. Likely, the observed 
effects are caused by a combination of these different mechanisms.  
Much to our surprise, this limited maturation induced by antigen sonoporation alone 
already rendered the cells capable of inducing potent T cell proliferation, CTL responses and 
antitumor immune effects in tumor-free animals in vivo. Therefore, it was crucial to evaluate 
whether or not sonoporation with TriMix had an added value on the induced immune responses. 
By looking at the relative maturation marker expression and cytokine production by mRNA 
sonoporated DCs in vitro, it would appear that the contribution of TriMix is limited, especially in 
comparison to maturation by LPS as a positive control. A possible explanation for this could be 
the transfection efficiency that can be obtained with mRNA sonoporation. Although this 
technique allows substantial transfection of DCs, its efficiency is still relatively low in comparison 
to electroporation, where over 90% of the DCs can be transfected with mRNA. Indeed, with 
mRNA electroporation, TriMix does cause a significant up-regulation of maturation markers and 
cytokine expression, as previously reported by Bonehill et al.9. In addition, based on the results 
obtained in the OT-I proliferation assay and the in vivo CTL assay, it would appear that TriO 
sonoporation works fine to enhance the quantity of antigen-specific CD8+ T lymphocytes (i.e. 
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numbers of proliferating cells), but at a first glance, their quality (i.e. cytolytic activity) is not as 
good as when OVA or OVA/LPS are used. However, it should be noted that these experiments 
were performed in naïve, healthy mice and not in tumor-bearing animals. In the latter, it was 
obvious that TriO sonoporation was superior and resulted in the most pronounced slowdown of 
tumor outgrowth and prolongation of median survival. Importantly, TriO DCs could even induce 
complete regression in 30% of the vaccinated animals, resulting in long-lasting protection 
against (re)challenges with tumor cells that express the vaccine antigen (in this case OVA).  
A possible explanation for this discrepancy between immune responses observed in 
healthy versus tumor-bearing animals, is the existence of pre-vaccination antitumor immune 
responses. It was shown by Germeau and colleagues that large numbers of antitumor T cells 
are already present within melanoma patients prior to vaccination with tumor antigens. 
However, these natural pre-vaccine immune responses are often too weak to result in tumor 
rejection or even a reduction in tumor growth, due to the various immune suppressive 
mechanisms that occur within the tumor microenvironment27. Vaccination can then aid in 
boosting these spontaneous immune responses, either by aiding to overcome tumor-induced 
immune suppression, by re-activating anergic tumor-reactive T cells at the tumor site, or by 
inducing new antitumor CTL clonotypes (probably due to additional antigen release from 
attacked tumor cells)2, 28. This priming of the immune system by a growing tumor could explain 
why the immunogenicity of the mRNA sonoporated DCs was more pronounced in a therapeutic 
setting.  
As to the question what could explain the superiority of TriMix over LPS in the therapeutic 
vaccination experiment, there are a number of possible causes. In essence, it is important to 
always keep in mind that immune responses are regulated in a complex manner, involving 
numerous different cell types. As discussed earlier, the effectiveness of a DC vaccine is not 
only determined by its capacity to induce effector CD8+ T cells. Major factors that limit the 
potency of cancer vaccines are the hostile tumor microenvironment and the presence of Tregs 
that counteract CTL activity29. Therefore, undermining these immunosuppressive mechanisms 
might be the key to successful cancer vaccines. Interestingly, previous research by Pen et al. 
exposed TriMix as a potential tool in subverting Treg effects. They demonstrated that CD8+ T 
cells that were preactivated by TriMix electroporated DCs were protected against Treg 
suppression. What was more, TriMix electroporated DCs could reprogram Tregs towards a Th1 
phenotype, thus reinforcing cellular immunity against the tumor30. Based on these observations, 
it is quite likely that in the therapeutic vaccination setting, the superior antitumor effects of TriO 
DCs could be, at least partially, attributed to a reduction of Treg-mediated immune suppression. 
Of course, many other cell types are involved in the regulation of antitumor immunity, and the 
effects of TriMix on these different cells is not yet known. For instance, it might be possible that 
TriMix transfected DCs could stimulate natural killer (NK) cells, which act synergistically with 
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CTLs and were recently reported to mount antigen-specific responses that can lead to long-
term memory31-34.  
We reported that the transfection efficiencies that can be reached with mRNA 
sonoporation are significantly lower than when mRNA is electroporated into DCs, however it 
should be noted that the importance of mRNA sonoporation as a transfection technique lies 
within its possible in vivo applicability35, 36. Commercially available microbubble contrast agents 
were shown to migrate to the tumor-draining lymph nodes upon intradermal injection around 
the tumor of breast cancer patients37. This makes them useful to identify and localize sentinel 
lymph nodes in a non-invasive manner, using contrast-enhanced ultrasound imaging (CEUS). 
In addition, their lymphatic uptake is particularly interesting, since lymph nodes harbor large 
numbers of immune cells, including a substantial fraction of DCs38, 39. Therefore, microbubbles 
could be used for image-guided in vivo vaccination. The immunotherapy could then consist of 
a subcutaneous injection of mRNA-loaded microbubbles, of which the migration to the draining 
lymph nodes could be visualized using CEUS. Once the microbubbles and hence the mRNA 
are localized within the lymph nodes, higher intensity ultrasound pulses could induce localized 
microbubble implosion, resulting in spatiotemporally controlled delivery of both antigen mRNA 
and immunomodulating TriMix to intranodal DCs. This could allow a minimally invasive 
vaccination procedure that could substantially reduce the costs and laborious procedures that 
are currently associated with the production of ex vivo generated DC vaccines. Of course, this 
will require a thorough optimization of microbubble and mRNA dosages and ultrasound 
parameters, as these greatly influence the transfection efficiency with microbubbles and 
ultrasound in vivo40.  
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CONCLUSIONS 
Taken together, DCs that were sonoporated with antigen mRNA via mRNA loaded 
microbubbles and ultrasound can induce potent antigen-specific immune responses in vivo. 
Sonoporation with TriMix, to further modulate the DC’s antigen-presenting functionality, could 
be used to further augment immunity. Especially in a therapeutic setting, vaccination with 
antigen and TriMix mRNA sonoporated DCs resulted in a significant reduction in tumor growth, 
leading to a marked increase in overall survival and long-lasting antigen-specific protection 
against tumor recurrence. Therefore, sonoporation could be a useful tool in the future 
development of in vivo DC vaccines.  
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ABSTRACT 
Microbubbles have shown potential as intralymphatic ultrasound contrast agents while 
nanoparticle-loaded microbubbles are increasingly investigated for ultrasound-triggered drug 
and gene delivery. To explore whether mRNA-nanoparticle loaded microbubbles could serve 
as theranostics for detection and mRNA transfer to the lymph nodes, we investigate the 
behavior of unloaded and mRNA-loaded microbubbles using contrast-enhanced ultrasound 
imaging after subcutaneous injection in dogs. Our results indicate that both types of 
microbubbles are equally capable of rapidly entering the lymph vessels and nodes upon 
injection, and novel, valuable and detailed information on the lymphatic structure in the animals 
could be obtained. Furthermore, additional observations were made regarding the dynamics of 
microbubble lymph node uptake. Importantly, neither the microbubble migration distance within 
the lymphatics, nor the observed contrast signal intensity was influenced by mRNA-loading. 
Although further optimization of acoustic parameters will be needed, this could represent a first 
step towards ultrasound-guided, ultrasound-triggered intranodal mRNA delivery using these 
theranostic microbubbles.  
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INTRODUCTION 
Over the years, microbubbles have gained popularity as contrast agents for ultrasound 
imaging, as described in Chapter 1. When injected intravenously, these microbubbles remain 
within the vasculature where they increase the echogenicity of blood. In this way, enhanced 
contrast between blood and soft tissues can be achieved. This has led to the FDA and EMA 
approval of various microbubble contrast agents for echocardiography (e.g. Definity®, 
SonoVue®, Sonazoid® and Optison®)1. Ever since, new applications for these contrast agents 
are under investigation, including their potential to enhance contrast in the lymphatics. For this, 
the microbubbles are injected intradermally (i.d.) or subcutaneously (s.c.), after which they drain 
to the lymphatics and accumulate in the lymph nodes. This is particularly interesting, since 
studies in tumor-bearing animals as well as in human breast cancer patients showed that 
peritumoral i.d. and s.c. injection of microbubbles results in their drainage to the sentinel lymph 
node (SLN)2-7. This lymph node is especially important, as it is the first node to come in contact 
with tumor material, making it most vulnerable to metastasis. Therefore, SLN detection, biopsy 
and removal are routine procedures in oncology to detect and remove disseminated tumor 
cells8, 9. Currently used standard methods for SLN detection are the injection of blue dyes which 
aid to localize the SLN visually during surgery, or via scintigraphy after injection of radiolabeled 
dyes8, 10. However, these procedures both come with their limitations, resulting in an ongoing 
search for novel SLN mapping modalities, such as microbubble contrast-enhanced ultrasound 
imaging (CEUS), which could represent a non-radioactive, non-invasive and potentially more 
patient-friendly alternative11, 12.  
In addition to these clinical applications, microbubbles are also under preclinical 
investigation as potential drug- and gene-delivery agents. When microbubbles are exposed to 
ultrasound, their gas core starts cavitating, i.e. continuously expands and shrinks. When the 
amplitude of the applied ultrasound waves is augmented, this cavitation can become unstable, 
eventually causing the microbubbles to implode. Both stable cavitation as well as microbubble 
implosion can affect neighboring cells, by either stimulating endocytosis or by the formation of 
temporary pores in the cell membranes13. Both mechanisms can be used for ultrasound-
triggered delivery of drugs and genes in vitro and in vivo14-16.  
In the previous chapters, we reported on the design of microbubbles that can be loaded 
with mRNA-nanoparticles and therefore have potential applications in cancer immunotherapy17. 
The results in Chapter 4 indicated that it is indeed possible to induce ultrasound-triggered 
transfection of dendritic cells (DCs) in vitro, without interfering with their potential to respond to 
maturation stimuli17. Furthermore, in Chapter 5 we expanded this concept by loading the 
microbubbles with lipoplexes containing both antigen as well as adjuvant mRNA. When mRNA-
sonoporated DCs were injected as vaccines, we showed the onset of potent antitumor immune 
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responses and the induction of long-term immunological memory18. However, for these mRNA-
loaded microbubble vaccines to have potential for in vivo transfection of DCs, it is crucial that 
they can be present within the anatomical locations where large numbers of DCs are present: 
the lymph nodes.  
Therefore, we investigated if these nucleic-acid loaded bubbles can reach the lymph 
nodes after s.c. injection, and if this can be monitored with CEUS. For this, we performed a 
crossover study where both unloaded and mRNA-loaded microbubbles were injected s.c. in 
dogs. Using CEUS, we determined (a) which injection site resulted in optimal lymphatic 
microbubble appearance, (b) if there were differences in kinetics and lymph node contrast-
enhancement for both types of microbubbles and (c) to what extent the nucleic acid-loaded 
microbubbles could have potential as intralymphatic theranostics.  
MATERIALS AND METHODS 
mRNA and mRNA-lipoplexes 
Luciferase mRNA was produced by in vitro transcription from pBlue-Luc-A50 plasmids. 
The plasmids were purified using a QIAquick PCR purification kit (Qiagen, Venlo, The 
Netherlands) and linearized using Dra I restriction enzymes (Promega, Leiden, The 
Netherlands). Linearized plasmids were used as templates for the in vitro transcription reaction 
using the T7 mMessage mMachine kit (Ambion, Life Technologies, Ghent, Belgium). The 
resulting capped and polyadenylated mRNAs were purified by DNase I digestion, LiCl 
precipitation and washed with 70% ethanol. The mRNA concentration was determined by 
measuring the absorbance at 260 nm. mRNA was stored in small aliquots at -80°C at a 
concentration of 1 µg µl-1.  
mRNA lipoplexes were prepared by complexing the mRNA to cationic liposomes. For this, 
liposomes were prepared consisting of 48.75% DOTAP (1,2-dioleoyl-3-trimethylammonium-
propane), 48.75% DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, both Avanti Polar 
Lipids) and 2.5% DSPE-PEG3400-biotin [1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-
N-[biotinyl(polyethylene glycol)-3400] (Laysan Bio Inc., Arab, Alabama). Fluorescently labeled 
mRNA-lipoplexes were prepared by incorporating 1% CholEsteryl-BODIPY® FL C12 (Avanti 
Polar Lipids). The appropriate amounts of lipids (dissolved in chloroform) were transferred to a 
round-bottom flask, and the chloroform was evaporated under nitrogen. Subsequently, the 
resulting lipid film was hydrated in RNase-free water (Ambion) to obtain a final lipid 
concentration of 1 mg ml-1. The resulting cationic liposomes were sonicated for 15min in a bath 
sonicator (Branson Ultrasonics, Dansbury, USA). Then, the cationic liposomes were mixed with 
mRNA in OptiMem® (Gibco Invitrogen) to obtain mRNA-lipoplexes at a cationic lipid-to-mRNA 
charge (N/P) ratio of 8. 
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Unloaded and mRNA-loaded microbubbles 
Lipid microbubbles loaded with mRNA-lipoplexes were prepared as described 
previously17. Briefly, perfluorobutane (F2 chemicals, Preston, UK) microbubbles stabilized by a 
lipid coat consisting of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) (Lipoid, 
Ludwigshafen, Germany) and DSPE-PEG3400-biotin [1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotin(polyethylene glycol)-3400] in a 85:15 molar ratio were 
prepared as follows. Appropriate aliquots of both lipids, dissolved in chloroform, were 
transferred to a round-bottom flask. After chloroform evaporation, the lipids was dissolved in a 
1:2:7 glycerol-propyleneglycol-H2O mixture to obtain a clear solution with a final concentration 
of 4.6x10-4 mmol ml-1. Aliquots of this lipid solution were transferred to 2.5 ml chromatography 
vials and the vial headspace was filled with perfluorobutane gas (F2 chemicals, Preston, UK). 
In order to form microbubbles, the vials were shaken at high-frequency in a Capmix™ device 
(3M-ESPE, Diegem, Belgium) for 15s. Microbubbles were avidinylated by first performing 
washing steps to remove excess lipids, after which the microbubbles were incubated with avidin 
(Cell Sciences, Canton, USA) for 5min. Then, the bubbles were washed to remove excess 
avidin and the final bubble cake was redispersed in a sterile, endotoxin- and nuclease-free 5% 
glucose solution (Sigma-Aldrich, Diegem, Belgium). 5min prior to injection, 150 µl avidinylated 
bubbles were mixed with either 100 µl OptiMem® (for the unloaded bubbles) or 100 µl mRNA-
lipoplexes (for the mRNA-loaded microbubbles, corresponding to 10 µg mRNA per injection).  
Microbubble characterization 
The size distribution and concentration of mRNA-loaded microbubbles was determined 
via coulter counter measurements using a Beckman-coulter Multisizer 4 (Analis SA, Suarlée, 
Belgium). Confocal microscopy was performed to evaluate the loading of the microbubbles with 
fluorescently labeled mRNA-lipoplexes. This was done using a Nikon C1si confocal laser 
scanning module attached to a motorized Nikon TE2000-E inverted microscope (Nikon, 
Brussels, Belgium), and a Plan Apo 60X 1.4 NA oil immersion objective lens (Nikon). 
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Dogs 
Six healthy research beagles (3 spayed females, 1 intact female and 1 castrated male 
and 1 intact male) were used in this experiment. All procedures were performed in accordance 
with the Ethical committee guidelines of Ghent University (2014/31). The mean age of the 
animals was 7 years, and body weight ranged from 9.7 kg to 15.4 kg with a mean of 10.8 kg. 
Dogs were healthy based on physical findings and routine laboratory data. 
Contrast-enhanced ultrasound imaging 
For CEUS experiments, the animals were sedated by intravenous injection of a 
combination of Butorphanol (Dolorex, 0.4 mg kg-1) and Acepromazine (Placivet, 0.04 mg kg-
1). Once sedated, the animals were manually restrained in dorsal recumbency and received a 
s.c. injection of microbubbles. First, different injection sites in the caudal abdomen and inguinal 
region were evaluated based on contrast migration to choose the optimal location for further 
experiments. After injection of 250 µl microbubbles, the contrast timer was started and the 
injection site was massaged during 1min. After this, continuous CEUS imaging was performed 
with contrast-specific software using a 12-5 MHz linear transducer (L12-5) of a Philips iU-22 
US scanner (Philips Medical systems, Bothell, Wa) for at least 6min. Mechanical index (MI) was 
set at a low level (MI=0.08) to achieve microbubble resonance with production of harmonic 
frequencies. Machine settings such as overall gain (80%), time gain compensation, depth 
(2.5 cm), frame rate (10 Hz) persistence (off) and dynamic range were set at the same value 
for every examination. Only one focal spot was used, set at the lowest level of the image. 
Destruction of intranodal microbubbles was performed at the end of the imaging period by 
setting the acoustic power at the highest level (MI=0.61). Multiple subsequent bursts were 
delivered until the echo intensity stabilized.  
This study was performed using a crossover design, with all dogs receiving 2 injections 
of both unloaded and mRNA-loaded microbubble formulations, on 2 injection sites (in the left 
and right abdominal region) at 2 different time points separated by a 2 week wash-out period, 
resulting in a total of 24 injections (12 with unloaded bubbles and 12 with mRNA loaded 
bubbles, Table 1).  
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Table 1. Design of the crossover CEUS study.  
Day Dogs Microbubble injections 
Week 1, day 1 1, 2, 3 
Left: unloaded microbubbles 
Right: mRNA-loaded microbubbles 
Week 1, day 2 4, 5, 6 
Left: mRNA-loaded microbubbles 
Right: unloaded microbubbles 
2 week wash-out 
Week 3, day 1 1, 2, 3 
Left: mRNA-loaded microbubbles 
Right: unloaded microbubbles 
Week 3, day 2 4, 5, 6 
Left: unloaded microbubbles 
Right: mRNA-loaded microbubbles 
 
Image analysis 
Image analysis was performed using QLAB quantification software (Philips) and ImageJ. 
Microbubble migration distances were calculated as a linear distance between the injection site 
and the most distant microbubble contrast signal. Measurements were performed by 2 
independent, blinded observers. Maximal echo intensities were measured using ImageJ at 
different timepoints after injection on a region of interest (ROI) within the lymphatics (i.e. within 
the enhanced lymph nodes or within the lymph vessels when no lymph node enhancement 
could be observed). Analysis of burst destruction of intranodal microbubbles was performed by 
drawing a ROI over the lymph node of interest, after which the mean echo intensity was studied 
as a function of time using the QLAB quantification software. In the figures, time is indicated in 
min:s on the CEUS images, and the depth scale bar is shown at the right-hand side of the 
corresponding B-mode images (the distance between two ticks is 5 mm in all images). In the 
figures, time is indicated in min:s on the CEUS images, and the depth scale bar is shown at the 
right-hand side of the corresponding B-mode images (the distance between two ticks is 5 mm 
in all images). 
Statistical analysis 
The migration distance and the maximal echo intensity was compared between the 
loaded and unloaded bubbles by a mixed model with dog as random effect and period and 
bubble type as categorical fixed effects, using the F-test at the 5% significance level. The 
contrast echo intensity over time was compared between the loaded and unloaded bubbles by 
a mixed model with dog as random effect and period, time, bubble type and the interaction 
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between time and bubble type as categorical fixed effects, using the F-test at the 5% 
significance level. 
Within and between observer variability was determined by estimating the within and 
between observer variances for a same assessment (i.e., the same dog, side, bubble type and 
period) by the restricted maximum likelihood procedure (REML). These estimated variances 
were next used to determine the range in which 95% of the differences between two 
measurements of the same observers and two different observers are contained. SAS version 
9.3 was used for all analyses. 
RESULTS  
Characterization of unloaded and mRNA-loaded microbubbles 
 
Figure 1. Characterization of mRNA-loaded microbubbles.  
(A) Graphical representation of the mRNA-loaded microbubble composition. (B) Confocal 
micrographs of microbubbles loaded with fluorescently labeled mRNA-lipoplexes: (B1) 
transmission, (B2) green fluorescent mRNA-lipoplexes, (B3) overlay.  
mRNA-lipoplex loaded microbubbles were prepared by first complexing the mRNA to 
cationic liposomes, to form mRNA-lipoplexes in which the mRNA is protected against 
degradation. These mRNA-lipoplexes are then attached to the surface of avidinylated lipid 
microbubbles, as shown in Figure 1A. To demonstrate effective loading, we performed confocal 
microscopy on microbubbles that were loaded with fluorescently labeled mRNA-lipoplexes. As 
demonstrated in Figure 1B, the mRNA-lipoplexes are clearly present around the microbubble 
surface, and we did not observe any aggregation. The size and concentration of the 
microbubble preparations was determined via coulter counter measurements. The unloaded 
microbubbles had a mean number diameter of 2.48 ± 1.57 µm. Attachment of mRNA-lipoplexes 
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did not significantly alter the mean diameter (1.93 ± 1.25 µm). The concentration of the 
microbubble preparations was 2.68 ± 0.86 x 109 bubbles ml-1.  
Factors influencing intralymphatic CEUS 
Based on previous experiments studying the lymphatic drainage of SonoVue® 
microbubbles by Goldberg et al.7, we performed s.c. injections of both unloaded and mRNA-
loaded microbubbles in dogs. When performing these experiments, we observed a number of 
factors that influenced the observed CEUS signals.  
First of all, we noticed important differences in the migration of the microbubbles 
depending on the injection site. When the microbubbles were injected in the groin, close to the 
inguinal lymph node, no lymphatic uptake of the contrast agents could be observed. The 
reasons for this are probably dual. First of all, lymphatic uptake occurs through a passive 
process that depends on the interstitial pressure at the injection site. Hence, regions such as 
the groin, where the skin is loose and the interstitial pressure is low, are not preferable19. In 
addition to pressure-related differences, some tissues such as the mammary regions of female 
dogs, contain a more developed lymph vessel network. In accordance to this, initial s.c. 
injections of the contrast agents in the loose skin of the abdominal region, did not result in 
migration of the contrast agents from the injection site. This despite the fact that the 
microbubbles were injected at a distance of merely 20 mm from the inguinal lymph node, as 
indicated by palpation and B-mode ultrasound imaging. On the other hand, injection around the 
dog’s nipple resulted in extensive microbubble drainage in all female dogs, as shown in 
Figure 2. Migration from the injection site was seen for all injections with both unloaded (8/8) 
and mRNA-loaded (8/8) microbubbles in the female dogs, and after most of the injections 
around the nipples of the male dogs (4/4 for the unloaded bubbles and 2/4 for the mRNA-loaded 
bubbles). This is not unexpected, as the mammary regions accommodate a vast network of 
lymph vessels that lead to multiple clusters of lymph nodes close to the mammary glands, as 
well as more distant gastric and mesenteric lymph nodes, depending on the location of the 
mammary gland (e.g. axillary versus inguinal mammary glands)20. Based on these 
observations, further injections were performed s.c. around the left and right nipple of the 
inguinal mammary gland. 
Besides the effects of the injection site, inter-animal variation in the mammary gland 
lymphatic network also played a role. In male dogs, the mammary glands are markedly less 
developed compared to females, which also results in a less dense lymphatic network and 
fewer intramammary nodes. Moreover, the male dogs clearly showed a less thick subcutaneous 
fat layer (i.e. where the lymph vessels and nodes are located) compared to all females, as 
evidenced by the B-mode images in Figure A2, B2 and C2. As a result, contrast agent migration 
after injection was less pronounced in the males compared to the females. In the intact male, 
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injection next to the testicles resulted in more distant microbubble migration when compared to 
injection around the mammary glands, which therefore represented a valuable alternative to 
injection around the mammary glands. Beside these gender-related factors, we also observed 
differences between spayed and intact females. After microbubble injection in the intact female, 
the lymphatic structures were visible as a vast network with multiple nodes and vessels 
extending more deeply into the subcutaneous fat pad (Figure 2C, observed for all injections 
with both unloaded and mRNA-loaded microbubbles). Such a branched lymph network could 
not be observed in any of the 3 spayed females.  
 
Figure 2. Influence of animal properties on the lymphatic CEUS images.  
CEUS images obtained after s.c. injection of unloaded microbubbles around the mammary 
glands of a male dog (A1), a spayed female dog (B1) and an intact female dog (C1). 
Respective B-mode images are shown in A2, B2 and C2. The injection site is indicated as 
“i.s.” (The injection site for images C1 and C2 is out of the field-of-view), arrows indicate 
the accumulation of microbubbles in the lymph nodes and lymph vessels are pointed out 
with asterisks. Time after microbubble injection is noted on the CEUS images (in min:s).  
Of course, this inter-animal variation makes it more difficult to fully exclude anatomical 
bias when comparing the lymphatic drainage of unloaded and mRNA-loaded microbubbles. 
The crossover design used for this study, where all dogs receive s.c. injections with both 
unloaded and mRNA-loaded microbubbles in the nipples of both the left- and the right caudal 
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mammary gland, was used to take this variability into account and allow a better comparison of 
both microbubble types.  
Lymphatic network visualization 
 
Figure 3. Contrast agent migration from the injection site into the lymph vessels and 
nodes.  
Upon microbubble injection, unidirectional transport of microbubbles away from the 
injection site, through an afferent lymph vessel into a draining lymph node can be 
observed with CEUS (A1). Image (B1) shows the trafficking of microbubble contrast signal 
through branched lymph vessels. In (C1), the CEUS image shows a lymph node 
connected to one afferent lymph vessel and 3 efferent lymph vessels that take the contrast 
agents further away from the injection site. Corresponding B-mode images are shown in 
(A2), (B2) and (C2), respectively. Images were obtained after injection of mRNA-loaded 
microbubbles in different female dogs. The injection site is marked as “i.s.” (unless outside 
of the field-of-view), arrows indicate lymph nodes and asterisks point out lymph vessels. 
Time after microbubble injection is noted in min:s. 
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After microbubble injection and massaging of the injection site, the migration of the 
contrast agent was observed unidirectional, with the contrast agents leaving the injection site 
at only one end in the spayed females and the males, as exemplified in Figure 3A. In the intact 
female, microbubble migration occurred both cranially as well as caudally. The migrating 
contrast agents were followed through the lymph vessels towards draining lymph nodes (Figure 
3B and 3C). Importantly, in none of the injections (0/24) was blood pool contrast enhancement 
observed, indicating that the microbubbles were restricted to the interstitium, the lymph vessels 
and the lymph nodes. Moreover, when the contrast agents were injected on one side (either left 
or right) of the animal, contrast signal was only observed on that same side of the animal. No 
contrast crossing over the midline of the dogs was noted in any of the cases. One or multiple 
lymph nodes could be identified using CEUS after 9/12 injections of both unloaded and mRNA-
loaded microbubbles, and the size of the enhanced lymph nodes ranged from 1.6 to 7.0 mm.  
Interestingly, CEUS imaging revealed detailed information on the lymphatic anatomy: in 
accordance to previous reports, CEUS could pinpoint the location of the lymph nodes, and 
provide information on the number of afferent and efferent lymph vessels5. In addition, we could 
observe different patterns of contrast agent presence with the nodes. Some lymph nodes, such 
as the one shown in Figure 4A, are completely filled with contrast agent, whereas others rather 
exhibit a “hollow” appearance, with contrast material only appearing at the outer rim of the node, 
as shown by the yellow arrows in Figure 4B and 4C. This can be explained by the fact that 
afferent lymph vessels can either directly discharge their content into the draining lymph nodes, 
or the afferent lymph vessels run through or over the nodes, without effectively discharging the 
lymph within the node21.  
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Figure 4. Lymph node anatomy observed by CEUS.  
CEUS can be used to identify the relation between afferent lymph vessels and draining 
lymph nodes. Lymph vessels either distribute their content within the lymph node (“filled” 
nodes, A1-A2) or they go around the lymph nodes without discharging its contents into the 
node (“hollow” nodes, B1-B2 and C1-C2). In the latter scenario, we always observed a 
node with a “hollow” appearance (indicated as “H”), followed by a more distant “filled” 
node (indicated as “F”). Images were obtained from 3 different animals. Where possible, 
the injection site is pointed out as “i.s.”. Time after microbubble injection is noted on the 
CEUS images (in min:s). 
Lymphatic CEUS using mRNA-loaded microbubbles versus unloaded microbubbles.  
In this study, we compared the CEUS images after s.c. injection of unloaded and mRNA-
loaded microbubbles, using three main scoring criteria: (a) the migration distance of the contrast 
agents from the injection site within the lymphatics, (b) the maximal intensity of the contrast 
signal and (c) the stability of the contrast agents in the lymph vessels and nodes over time.  
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Figure 5. Maximal migration distance and maximal echo intensity of mRNA-loaded 
and unloaded microbubbles.  
Scatterplots show (A) the linear migration distance of unloaded and mRNA-loaded 
microbubbles from the injection site and (B) the maximal echo intensity within the 
lymphatics for both microbubble types. For both parameters, no statistically significant 
differences between unloaded and mRNA-loaded microbubbles could be detected.  
With regard to the first parameter, the migration distance, we could detect microbubble 
migration from the injection site for all injections with unloaded microbubbles (12/12), and in 
10/12 cases after mRNA-loaded microbubble injections. The two injections that did not result 
in contrast agent drainage were observed in the male dogs (one in the castrated male and one 
in the intact male). The microbubble migration distance (calculated linearly from the injection 
site) was on average 24.7 ± 13.7 mm for unloaded microbubbles and 29.0 ± 19.0 mm for mRNA-
loaded microbubbles (Figure 5A). No significant differences could be observed between for 
migration distances of loaded and unloaded bubbles, with a mean difference equal to 4.33 (95% 
CI: [-4.55; 13.22]). It should be noted that even though these results were analyzed based on 
injections of unloaded and mRNA-loaded microbubbles within the same mammary gland, 
variation based on the exact injection site cannot be excluded, even though injections were 
always performed caudally from the nipple by the same person. For instance, it was shown by 
Goldberg et al. that injection sites that were merely 1 cm apart in distance, could result in 
drainage to a different lymph node, which can obviously impact the microbubble migration 
distance that was observed6. As the exact injection site was not marked at the time of the first 
imaging session, variation related to the injection site location cannot be fully excluded. The 
variation between repeated measurements of the same observer was 23.9, and the extra 
variation due to different observers was 9.0 for loaded bubbles, leading to somewhat larger 
95% intervals for differences between two measurements of two different observers as 
compared to the same observer. On the other hand, for the unloaded microbubbles, the 
variation due to repeated observations of the same observer was 16.7, and there was no extra 
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variation due to different observers, resulting in the same 95% intervals for differences between 
two measurements of two different observers as compared to the same observer. 
In addition to migration distance measurements, we compared the maximal echo intensity 
that we could obtain within the lymphatics after injection of unloaded and mRNA-loaded 
microbubbles. As for the migration distance, we could not observe significant differences in 
lymphatic contrast enhancement between both types of bubbles (Figure 5B), with a mean 
difference between loaded and unloaded bubbles equal to -2.56 (95% CI: [-15.04; 9.91]). 
Moreover, when the contrast echo intensity was evaluated as a function of time, we could 
observe relatively long-term contrast agent stability within the lymphatics. In all cases where 
contrast migration was observed, the microbubbles could still be clearly detected 6 min after 
microbubble injection. There was merely a slight decay of the echo intensity over this period, 
and we could not detect significant differences between both types of microbubbles (Figure 6).  
 
Figure 6. Intralymphatic stability of unloaded and mRNA-loaded microbubbles.  
The maximal echo intensity was followed as a function of time for both unloaded and 
mRNA loaded microbubbles. A slow reduction in maximal echo intensity was observed 
over the 6min imaging period. No significant differences could be detected between 
unloaded and mRNA-loaded microbubbles.  
Keeping in mind the final aim of the mRNA loaded microbubbles, namely the ultrasound-
triggered delivery of mRNA to DCs that reside within the lymph nodes, we tested whether 
intranodal mRNA-loaded microbubbles could indeed be imploded by applying higher-intensity 
ultrasound bursts. For this, we used the scanner’s preset burst function (at a MI of 0.61), and 
looked at the decrease in mean echo contrast intensity within the lymph node. As shown in 
Figure 7, with each burst, the microbubble echo intensity was reduced, reaching a minimum 
after 6 bursts.  
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Figure 7. Burst destruction of intranodal microbubbles.  
After visualization of microbubble drainage, the scanner’s burst function was used to 
destroy the microbubbles within the lymphatics. Images show (A) a CEUS image with a 
ROI around a lymph node filled with mRNA-loaded microbubbles and (B) the 
corresponding B-mode image. Burst analysis is represented in (C) where each burst is 
visible as a peak in echo mean (in dB), followed by a reduction of the contrast echo mean. 
Time after microbubble injection is noted on the CEUS images (in min:s). 
DISCUSSION 
In recent years, drug- and gene loaded microbubbles emerged as interesting theranostics 
after intravenous injection. This, however, is the first report on the development of theranostic 
mRNA-loaded microbubbles for lymphatic imaging and lymph node detection after s.c. injection. 
When taken together with our previous research on transfections with these microbubbles, this 
paves the way for ultrasound-guided microbubble-assisted drug delivery to intranodal cells. To 
explore this, we aimed to compare unloaded and mRNA-loaded microbubbles with respects to 
the lymphatic uptake and contrast enhancement in the lymph nodes upon s.c. injection in dogs.  
The lipid microbubbles used in this study could be loaded with mRNA-lipoplexes, and had 
mean diameters around 2.5 µm, which is comparable to the size of commercially available 
microbubbles. Lipoplex-loading did not significantly alter the mean microbubble diameter. Our 
imaging results indicated that despite animal-related variation, both types of microbubbles could 
be detected within the lymph nodes within 1min after s.c. injection around the mammary glands.  
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How exactly the microbubbles are transported from the interstitium to the lymph vessels 
remains controversial, as it goes against the current view of ideal particle properties for 
lymphatic uptake. It is generally considered that particles between 10 and 100 nm in size result 
in the best lymphatic uptake19. Although the appearance of 1 µm particles in the draining lymph 
nodes was also observed, their uptake efficiency and speed was significantly reduced, and a 
large fraction of the injected particles was retained at the injection site22. In the case of our 
microbubbles we could observe fast and extensive microbubble uptake into the lymph vessels 
and draining nodes, despite their larger size. The rapid uptake of microbubbles into the 
lymphatic system is not well understood. A first explanation could be found within the other 
physicochemical properties of the microbubble contrast agents we injected. Besides particle 
size, lipophilicity and the presence of surface modifications that give stealth properties to 
injected particles, were also reported to positively impact their lymphatic drainage22. Therefore, 
the presence of the lipid coat in both the microbubbles and the mRNA-lipoplexes could aid to 
promote microbubble uptake into the lymph vessels. In addition, the microbubbles as well as 
the mRNA lipoplexes contain lipids that are conjugated to polyethylene glycol (PEG, 15 mol.% 
and 2.5 mol.% for bubbles and lipoplexes, respectively), which is known to protect the particles 
against uptake by phagocytes. Thus, their premature clearance is reduced, resulting in 
enhanced drainage to the lymphatics. On the other hand, Goldberg et al. proposed a cell-
mediated uptake mechanism after s.c. injection of Sonazoid® in pigs6. They performed electron 
microscopy on isolated lymph nodes after contrast agent injection, and observed the presence 
of vacuoles in the intranodal phagocytic cells, which could imply that the microbubbles are first 
ingested by cells, which then transport them from the interstitium to the lymph vessels and 
draining lymph nodes. However, this cellular transport through the lymphatics is only likely for 
microbubbles that are easily phagocytosed. A study by Yanagisawa et al. pointed out that 
microbubble phagocytosis by primary liver cells was highly dependent on the microbubble 
composition. Indeed, the authors demonstrated that over 99% of the Sonazoid® microbubbles 
were rapidly phagocytosed by primary liver cells, which can likely be attributed to their shell 
composition23. Sonazoid® consists of egg phosphatidyl serine, which is recognized by 
macrophages and thus enhances phagocytic uptake24, 25. In contrasts, anionic Imavist® 
microbubbles (where the anionic charges reduces microbubble contact with cell membranes) 
and PEGylated SonoVue® microbubbles were merely for 0% or 7.3% phagocytosed, 
respectively. As our microbubbles are also PEGylated (by inclusion of 15% DSPE-PEG(3400)-
biotin), and no specific targets for macrophage recognition are present, it is unlikely that our 
microbubbles were carried into the lymphatics inside of cells. (For an overview of the shell 
composition of commercially available microbubbles, we refer to Table 4 in Chapter 1.) 
Upon s.c. injection, we could observe clear migration of unloaded and mRNA-loaded 
microbubbles from the injection site into the lymph vessels and the draining lymph nodes. 
Moreover, our CEUS images nicely correspond to previous reports on the lymphatic drainage 
164 | C h a p t e r  6  
of microbubbles, which indicates that the observed structures were indeed lymph nodes5-7, 26, 
27. The imaging options that are associated with these mRNA-loaded microbubbles could have 
implications for mRNA delivery as well as for diagnostic purposes. Firstly, the mRNA-loaded 
microbubbles could provide information on the anatomical features of draining lymph nodes. To 
our knowledge, this is the first report where CEUS was shown to discriminate between the two 
different types of connection of lymph vessels to lymph nodes (i.e. the “hollow” nodes and the 
“filled” lymph nodes)21. The impact of this might be dual. First of all, from our perspective of 
future mRNA delivery to intranodal DCs, it would be a major advantage to be able to 
discriminate between situations where the afferent lymph vessels discharge the mRNA-loaded 
bubbles within the core of the lymph node (“filled” nodes) versus lymph vessels that merely run 
over the surface of the lymph nodes, thus bypassing the actual node, resulting in the absence 
of a microbubble signal in the center of the node (“hollow” nodes). Only in the first scenario will 
the mRNA-loaded bubbles be able to reach the intranodal DCs, and is DC transfection with 
mRNA via sonoporation possible. Therefore, delivery of high-intensity ultrasound pulses to 
induce microbubble implosion and mRNA delivery, should only be performed in the lymph 
nodes that exhibit the “filled” appearance. Other than for ultrasound-guided drug delivery, this 
anatomical information could also have benefits with regards to SLN detection. In a tumor 
setting, the SLN will be the first lymph node that encounters material that directly originates 
from the tumor, such as disseminating tumor cells. However, if the first lymph node after the 
tumor has the “hollow” characteristics, this means that the tumor cells do not enter within the 
node, making it less likely that this node would be populated with tumor cells21. Therefore, lymph 
node biopsies to detect lymph node metastasis could best be performed in the first node in 
which the content of the tumor-draining lymph vessels are actually discharged. CEUS-guided 
identification of the first “filled” SLN could therefore have an added value to reduce the chance 
of false negatives in SLN biopsies. Of note, other imaging possibilities such as 3D CEUS 
imaging, could enable improved visualization of the lymphatic drainage and improve variability 
in measurements. 
When comparing mRNA-loaded microbubbles with unloaded microbubbles, we could not 
observe statistically significant differences with regards to migration distance, mean contrast 
intensity and the stability of both contrast agents in the lymphatics. As the size distribution of 
both types of bubbles did not significantly differ, this was not entirely unexpected. In addition, 
experiments on similar nanoparticle-loaded lipid microbubbles by Luan et al. demonstrated that 
the shell elasticity of individual unloaded and liposome-loaded microbubbles was nearly the 
same28. The effects of liposome-loading that was observed by the authors were mainly on the 
microbubble shell viscosity (which was higher for liposome-loaded microbubbles) and thus on 
the ultrasound-induced microbubble vibrations. Taken together, the impact on these acoustical 
differences between both types of bubble populations is expected to be limited with respect to 
contrast-enhancement. However, it is likely that for molecular imaging and therapeutic 
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purposes, which often involve only a single microbubble or a few microbubbles in a given 
volume, these differences will need to be addressed: liposome-loaded microbubbles exhibited 
a higher pressure threshold for microbubble vibration, which might indicate that the pressures 
that will be needed to implode these bubbles in order to locally deposit the mRNA, also need 
to be higher. This could already be expected based on the burst-destruction of the intranodal 
mRNA-loaded microbubbles. Using the preset “burst” function on the clinical scanner, the 
microbubble contrast signal is maximally reduced by 50%, indicating an incomplete intranodal 
microbubble destruction. Only after 6 bursts the mean echo reaches a minimum. On this basis, 
the transducer that was used in this study (12-5 MHz linear) is probably not ideal for 
microbubble destruction that could allow effective sonoporation and mRNA transfection. Other 
clinical transducers that can emit lower frequencies, which are closer to the resonance 
frequency of the microbubbles and can emit higher powers (and thus higher MIs), could be 
better suited. In any case, in vivo optimization of the various ultrasound parameters such as 
acoustic pressure, pulse duration and number of pulses, will be required for this purpose13.  
CONCLUSION 
In conclusion, we were able to show that homemade unloaded as well as mRNA-loaded 
microbubbles efficiently reach the lymph vessels and nodes upon s.c. injection in dogs. Loading 
of the microbubbles with mRNA-lipoplexes had no significant effect on the distance of 
microbubble migration from the injection site, nor on the intensity of the observed contrast 
signals. This shows that theranostic mRNA-loaded microbubbles could have potential for the 
ultrasound-guided, ultrasound-triggered intranodal delivery of mRNA. However, further 
research is needed for the optimization of acoustic parameters to most effectively sonoporate 
target cells of interest. 
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Summary, conclusions & future 
perspectives 
 
SUMMARY 
In the early 1970’s, Ralph M. Steinman discovered a novel cell type in the lymphoid 
organs of mice: the dendritic cells (DCs). This was quickly regarded a scientific breakthrough, 
as these cells were identified as the missing link between antigens and antigen-specific T cell 
responses. This crucial finding not only resulted in a (posthumous) Nobel Prize in Medicine for 
Ralph M. Steinman in 2011, it also ushered in a new era in cancer immunotherapy. From then 
on researchers started exploiting DCs by loading them with tumor antigens in vitro to turn them 
in to cellular vaccines that could aid to harness our immune system in the battle against cancer. 
Chapter 1 comprises two main sections that explain the key principles of this thesis. 
Firstly, it provides an overview of how DCs can trigger antitumor immunity, and how they can 
be utilized in DC-based vaccination. Unfortunately, several drawbacks associated with these 
patient-specific, laborious and costly vaccines have moderated the initial enthusiasm. Hence, 
researchers started shifting their focus: instead of collecting cells and modifying them ex vivo, 
it would be beneficial to target DCs in situ as this could allow the production of off-the-shelf 
vaccines. This change in strategy has brought material scientists and immunologists closer 
together in their joint search for biomaterials (e.g. nano- and microparticles or implantable 
scaffolds) that could deliver tumor antigens to DCs in vivo. One of the most important pitfalls in 
particulate vaccine developments that the exclusive delivery of tumor antigens to DCs will not 
suffice to evoke powerful and durable antitumor immunity in vivo. In order to transform antigen-
laden DCs into potent antigen-presenting cells, they require additional stimuli that are ideally 
co-delivered with the antigenic material. Therefore, we presented an overview of different nano- 
and micromaterials that fulfill this requirement. In the second part of this chapter, we focused 
on an interesting group of biomaterials that merge therapy and diagnostic imaging into a single 
compound. These theranostics are a hot topic these days, as they provide real-time feedback 
on the treatment effects. We briefly highlighted two diagnostic imaging techniques that do not 
require the use of ionizing radiation: fluorine magnetic resonance imaging (19F MRI) and 
ultrasonography. For both techniques, the development of theranostic particles is on the rise. 
In case of 19F MRI, highly fluorinated perfluorocarbons can be imaged at a negligible tissue 
background. Alternatively, ultrasonography is an inexpensive imaging technique in which 
enhanced contrast can be obtained by using microbubbles. Interestingly, their unique response 
to ultrasound waves not only makes them interesting contrast agents. Their potential use 
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reaches far beyond imaging alone. In response to higher intensity ultrasound waves, these 
microbubbles can implode, which temporarily permeates neighboring cell membranes. Thus, 
by designing theranostic microbubbles loaded with drugs or genes, ultrasound-guided, 
ultrasound-triggered enhanced drug and gene delivery may be established. When combining 
the insights from the immunotherapy point of view and the multifunctionality of theranostics, the 
aim of this thesis is to design immunotheranostics: imageable carriers that could assist in DC-
mediated cancer vaccination.  
In the development of agents for therapeutic imaging, the initial screening of novel 
materials is performed in vitro, on model DCs that are often derived from the bone marrow of 
mice. However, there is a large variety in the protocols that are used to obtain these bone 
marrow-derived DCs (BM-DCs). Chapter 2 investigates the impact of 2 variables on the BM-
DC immunobiology and the cells’ response to nanoparticlulate vaccines. We showed that 
different combinations of bovine serum and cytokines can result in cultures with extensive 
differences in purity, yield and phenotype. Especially the maturation status of the DCs was 
affected, as indicated by maturation marker expression and cytokine production. This is crucial, 
since more mature cells have a reduced endocytic capacity. Indeed, the uptake of mRNA-
lipoplexes, as a model particulate vaccine, was clearly reduced in more mature BM-DC models. 
When looking more deeply into transfection efficiency and T cell activation, we also observed 
extensive model-related variation despite the use of identical nanoparticles. In this way, we 
were able to expose an important bias of the model cells on the functional outcome of a 
particulate vaccine.  
In Chapter 3, we reported on the design and evaluation of a first particle for therapeutic 
imaging that allows the simultaneous loading of DCs with antigenic protein and a 19F MRI 
contrast agent. For this, we developed a layer-by-layer particle consisting of a liquid 
perfluorocarbon core, surrounded by multiple alternating layers of cationic lipids and negatively 
charged antigenic protein. These particles were rapidly ingested by BM-DCs in vitro, resulting 
in efficient antigen presentation and activation of antigen-specific T cells. Besides this capacity 
to deliver antigens to DCs, the particle-loaded DCs could be imaged via 19F MRI at low detection 
limits (down to 103 cells µl-1). This strategy could be interesting in the development of ex vivo 
generated DC vaccines, as one of the hurdles in these vaccines is the poor migration of the 
antigen-containing cells from the injection site to the draining lymph nodes, where antigen-
presentation to T cells occurs. Using these particles, selective and non-invasive tracking of DCs 
that have taken up the antigen and are able to induce antitumor immune responses, could be 
possible.  
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This strategy, however, still requires DC precursor isolation, ex vivo antigen-loading and 
injection of DCs as vaccines. In order to address this, we explored other paths that could allow 
targeting antigens towards DCs in vivo. For this, we developed mRNA-loaded microbubbles as 
immunotheranostics for ultrasonography. As described in Chapter 4, we designed lipid 
microbubbles that could be loaded with mRNA-lipoplexes via avidin-biotin linkages. When these 
microbubbles were exposed to ultrasound in the presence of BM-DCs in vitro, this resulted in 
transfection efficiencies up to 24%. Of note, ultrasound-triggered transfection did not affect the 
DCs’ potential to respond to maturation stimuli, making these microbubbles a promising tool for 
the safe transfer of antigen-mRNA to DCs.  
Based on this proof of concept, we further improved the potential of these 
immunotheranostics (Chapter 5). As we already highlighted in Chapter 1, it is important to co-
deliver antigen and immune stimuli to DCs in order for a cancer vaccine to be truly effective. In 
case of the mRNA-loaded microbubbles, this was achieved by loading them with multiple 
mRNAs. On the one hand, we used mRNA that is translated into tumor associated antigens, 
and on the other hand, we used TriMix, an mRNA cocktail that will modulate the DCs’ 
functionality. Co-sonoporation with these four mRNAs resulted in acceptable transfection 
efficiencies and moderately increased the expression of maturation markers and the production 
of cytokines by the DCs. When these sonoporated DCs were injected as a vaccine, we 
observed extensive proliferation of antigen-specific T cells, which led to specific lysis of antigen-
expressing target cells. Most importantly, in a therapeutic setting where tumor-bearing mice 
were vaccinated with sonoporated DCs, we observed a significant reduction in tumor outgrowth 
in the animals that were vaccinated with antigen mRNA, but especially in the animals that 
received both antigen and TriMix mRNA. In the latter group, complete tumor regression could 
even be observed in 30% of the vaccinated animals. Moreover, these animals displayed long-
term antigen-specific immunological memory. These results clearly show the potential of mRNA 
sonoporation for cancer vaccination, especially when it is used to co-deliver antigen and 
immunostimulatory mRNA. 
The results above illustrate that the way DCs are modulated using immunotheranostics 
results in the generation of highly immunogenic cells. However, the full potential of these 
mRNA-loaded microbubbles lies within the possibility to directly deliver the antigen and 
immunostimulatory mRNA to DCs in vivo. The ideal location where this should occur, are the 
lymph nodes, as these harbor large numbers of immature DCs and these are the anatomical 
sites where antigen presentation to T cells occurs. Therefore, in Chapter 6, we performed a 
study in dogs, to investigate whether mRNA-loaded microbubbles are capable of reaching the 
lymph nodes after subcutaneous injection. Using contrast-enhanced ultrasound imaging 
(CEUS), we observed that already within 1min after injection, mRNA-loaded microbubbles can 
be detected within the lymph nodes. The ultrasound contrast provided by these microbubbles 
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provided detailed information on the lymph node anatomy, which could be of value for further 
in vivo sonoporation experiments.  
GENERAL CONCLUSIONS 
Taken together, the results in this thesis show that therapeutic imaging can indeed be 
used for cancer immunotherapy and, as such, gained the status of “immunotherapeutic 
imaging”. We developed two different biomaterials that could deliver antigens to DCs in vitro. 
Moreover, using the microbubble approach, we showed the simultaneous delivery of antigen 
and immunostimulating mRNA, which markedly improved the therapeutic outcome in tumor-
bearing mice. Lastly, and most importantly, mRNA-loaded microbubbles can reach the lymph 
nodes of larger animals, which brings them to the key anatomical site of interest for 
immunotherapy. The image feedback information provided by these contrast agents on the 
lymphatic anatomy underpins their interesting role as immunotheranostic agents.  
FUTURE PERSPECTIVES 
Are we there yet? Unfortunately, the answer is no. We have merely made our first steps 
towards a potentially potent immunotherapeutic strategy. The promising results that we were 
able to show here, definitely warrant further investigation. Firstly, although we have collected 
convincing evidence that theranostics such as microbubbles can be used to transfect DCs in 
vitro, generate highly immunogenic DC vaccines, and that they can reach the DCs within the 
lymph nodes in vivo, we still need to investigate whether in vivo ultrasound-guided and 
ultrasound-triggered delivery of antigen and adjuvant mRNA is feasible. Without a doubt, the 
key challenge there will be to identify the ideal ultrasound parameters needed to burst the 
mRNA-loaded bubbles and deliver the mRNA to the DCs intranodally.  
An additional feature that will certainly need to be addressed, is immune suppression. It 
should be kept in mind that immunotherapy does not end with the induction of an antitumor T 
cell response. Increasing evidence indicates that during tumor development, a growth-
supporting micro-environment is created, harboring a plethora of immune suppressive cell 
types (e.g. regulatory T cells and myeloid-derived suppressor cells) which allow the tumor to 
escape from immune recognition and block effector immune cells at the tumor site. Therefore, 
even if using intelligent antigen- and adjuvant-delivery strategies results in the effective 
proliferation of antitumor CTLs, in all likelihood, a major fraction of these cells might become 
trapped within the tumor microenvironment without exerting their tumor-killing effects. Finding 
ways to overcome this tumor-mediated immune suppression will likely become a leading topic 
of investigation.  
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Lastly, it is probably safe to say that the future lies in the art of combining. Several 
established cancer treatments, such as chemotherapy and thermal tumor ablation have been 
shown to induce immunogenic cell death. In this process, tumor antigens and additional 
immunostimulatory signals (e.g. danger-associated molecular patterns, DAMPs) are released 
from the dying tumor cells. This, in turn, attracts and activates DCs. Thus, in a way, the 
stimulation of immunogenic cell death can turn tumor cells into an auto-vaccine. Hence, by 
merging these established treatments with immunotherapy, we could tackle the tumor from 
different angles.  
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Samenvatting, besluiten & 
toekomstperspectieven 
 
SAMENVATTING 
In het begin van de jaren ’70 ontdekte Ralph. M. Steinman een nieuw celtype in de 
lymfeweefsels van muizen: de dendritische cellen (DC’s). Al snel werd dit beschouwd als een 
belangrijke wetenschappelijke doorbraak. DC’s vormen immers de missing link tussen 
antigenen en antigen specifieke T-cel responsen. In 2011 werd Ralph M. Steinman voor deze 
ontdekking geëerd met een (postume) Nobelprijs. Het ophelderen van de werking van DC’s en 
hun cruciale rol in het opwekken van immuniteit kondigden een nieuw tijdperk aan in het domein 
van kanker immunotherapie. Door DC’s in vitro te beladen met tumor antigenen, en deze zo 
om te vormen tot cellulaire vaccins, slaagden wetenschappers er in ons immuunsysteem in te 
schakelen in de strijd tegen kanker.  
Hoofdstuk 1 bestaat uit twee delen die de belangrijke thema’s die in dit werk aan bod 
komen, toelichten. Het eerste deel focust op immunotherapie, meer specifiek op de werking 
van DCs en hoe ze kunnen gemodificeerd worden tot krachtige antikanker DC-vaccins. 
Ondanks de succesverhalen gepubliceerd werden, blijft DC-vaccinatie te kampen hebben met 
een aantal nadelen. Zo zijn deze ex vivo gegenereerde vaccins steeds patiënt specifiek en het 
omslachtige en arbeidsintensieve productieproces leidt tot een hoge kost per vaccin. Om dit te 
verbeteren, is men sinds kort beginnen zoeken naar methodes om DC’s in vivo te moduleren 
en zo een kant-en-klaar vaccin te maken dat bij een grotere patiëntenpopulatie kan worden 
gebruikt. Deze koerswijziging bracht al snel wetenschappers van verschillende achtergronden, 
materiaalkundigen en immunologen, samen in een vereende zoektocht naar biomaterialen 
(bijv. nano- en micropartikels of implantaten) die tumorantigenen kunnen aanleveren aan DC’s 
in vivo. De belangrijkste valkuil bij het ontwikkelen van dergelijke partikelvaccines is dat het 
uitsluitend afleveren van tumorantigenen niet zal volstaan om een effectief kankervaccin te 
ontwikkelen. Naast de belading met antigen, moet de DC er namelijk ook toe worden aangezet 
het antigeen materiaal efficiënt te gaan presenteren om zo antigen specifieke T-cellen te 
activeren. Voor deze omvorming van antigen opnemende naar antigen presenterende cellen 
zijn extra stimulansen nodig die idealiter simultaan met de antigenen worden afgeleverd. De 
verschillende nano- en micromaterialen die aan deze vereisten voldoen, worden hier 
samengevat. Het tweede deel van dit hoofdstuk legt de focus op een bijzonder interessante 
groep biomaterialen die therapeutische en diagnostische eigenschappen samenbrengen in één 
enkel partikel. Deze theranostische materialen hebben het voordeel dat ze via medische 
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beeldvorming real-time feedback verschaffen tijdens en/of kort na de behandeling. We lichten 
specifiek twee beeldvormingstechnieken uit waarbij geen ioniserende straling wordt gebruikt, 
en waarvoor steeds meer theranostica worden ontwikkeld: fluor magnetische resonantie 
beeldvorming (19F MRI) en echografie. Als contraststoffen voor 19F MRI worden sterk 
gefluorineerde perfluorocarbonen gebruikt, gezien deze aan hoge signaal-ruisverhouding in 
beeld kunnen gebracht worden. Een andere techniek is de echografie, een goedkope medische 
beeldvormingsmethode waar microbubbels voor verbeterd contrast kunnen zorgen. De unieke 
trillingsrespons van microbubbels op ultrasone golven, maakt ze uiterst geschikt als 
contraststoffen en biedt tegelijk nog heel wat andere mogelijkheden. Wanneer de amplitude 
van de ultrasone golven toeneemt, kunnen microbubbels imploderen, wat via verschillende 
mechanismen kan zorgen voor een tijdelijke porievorming in naburige celmembranen. Hier kan 
gebruik van worden gemaakt door de microbubbels te beladen met geneesmiddelen of genen 
en zo ultrasound-geleide ultrasound-geïnduceerde gen- of geneesmiddelafgifte rechtstreeks 
doorheen de poriën tot in het cytoplasma van de cel, mogelijk te maken. Door de nieuwste 
inzichten op vlak van kanker-immunotherapie en de multifunctionaliteit van theranostica te 
bundelen, kwam het idee om immunotheranostica te ontwerpen. Dit zijn biomaterialen die niet-
invasief gevolgd kunnen worden via medische beeldvorming en een rol kunnen spelen in DC 
vaccinatie tegen kanker.  
Tijdens de ontwikkeling van deze immunotheranostica wordt steeds eerst een in vitro 
screening uitgevoerd op model-DC’s die veelal verkregen worden uit het beenmerg van 
muizen. Er bestaan echter erg veel verschillende protocollen om deze beenmerg-afgeleide 
DC’s (BM-DC’s) te verkrijgen. Daarom onderzoekt Hoofdstuk 2 wat de impact is van twee 
variabelen op de BM-DC immunobiologie en de respons van deze cellen op nanopartikel-
vaccins. We konden aantonen dat wanneer verschillende combinaties van kalfsserum en 
cytokines werden gebruikt, dit leidde tot BM-DC culturen die sterk verschillend waren op vlak 
van zuiverheid, opbrengst en fenotype. Het effect was het meest uitgesproken op de 
maturatiestatus van de cellen. Dit is van cruciaal belang, aangezien meer mature cellen 
doorgaans een verminderde endocytose-capaciteit vertonen. Zo werd wanneer mRNA-
lipoplexen (als model partikelvaccins) werden gebruikt, een beduidend lagere partikelopname 
vastgesteld in de BM-DC modellen met een meer matuur fenotype. Door dieper in te gaan op 
de transfectie-efficiëntie en de capaciteit van de antigen-beladen BM-DC’s om T-cellen te 
activeren, konden we ook hier een uitgesproken modelgerelateerde variatie waarnemen, 
ondanks het feit dat telkens identieke nanopartikels werden gebruikt. Deze resultaten toonden 
aan dat het type model BM-DC dat wordt gebruikt, een belangrijke invloed kan hebben op de 
functionele uitkomst van een partikelvaccin.  
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Hoofdstuk 3 beschrijft het ontwerp en de evaluatie van een eerste immunotheranostisch 
partikel voor de simultane belading van DC’s met antigenen en met een 19F MRI contraststof. 
Deze partikels bestaan uit een kern van vloeibaar perfluorocarbon die omgeven wordt door 
meerdere afwisselende lagen kationische lipiden en negatief geladen antigene eiwitten. De 
antigen-beladen perfluorocarbonpartikels werden snel opgenomen door BM-DC’s in vitro wat 
leidt tot efficiënte antigenpresentatie en activering van antigen specifieke T-cellen. Tegelijk met 
de afgifte van antigenen aan de DC’s, werden de cellen gemerkt met het perfluorocarbon, wat 
toelaat de partikel-beladen DC’s via 19F MRI in beeld te brengen aan een lage detectielimiet 
(tot 103 cellen µl-1). Deze strategie kan mogelijk interessant zijn voor het ontwikkelen van ex 
vivo aangemaakte DC-vaccins. Het is immers zo dat de beperkte migratie van de antigen-
beladen DC’s vanuit de injectieplaats naar de lymfeknopen, waar antigenpresentatie aan T-
cellen plaatsvindt, een gekend probleem is bij dergelijke cellulaire vaccins. Deze 
immunotheranostische partikels kunnen het mogelijk maken om selectief en niet-invasief de 
antigen-beladen DC’s die in staat zijn een antitumor immuunrespons op te wekken, te traceren 
in vivo.  
Deze aanpak blijft echter steunen op de isolatie van DC precursoren, ex vivo 
antigenbelading en injectie van de gemodificeerde cellen als vaccins. Om dit aan te pakken, 
werd onderzocht of het mogelijk is een detecteerbaar materiaal te ontwikkelen dat de antigenen 
naar de DC’s kan brengen in vivo. Hiervoor werden mRNA-beladen microbubbels aangemaakt 
als immunotheranostica voor contrast-echografie. Hoofdstuk 4 beschrijft de ontwikkeling van 
lipide-gestabiliseerde microbubbels die konden beladen worden met mRNA-lipoplexen via 
avidine-biotine bruggen. Wanneer deze microbubbels bestraald werden met ultrasound in de 
nabijheid van BM-DC’s in vitro, leidde dit tot expressie van het mRNA in 24% van de cellen. 
Belangrijk hierbij is dat de ultrasound-geleide transfectie geen impact heeft op de 
maturatiecapaciteit van de DC’s, wat van deze microbubbels een veelbelovend materiaal maakt 
voor de veilige afgifte van antigen-mRNA aan DC’s.  
Op basis van deze proof of concept wordt de mogelijke toepassing van deze 
immunotheranostica verder uitgewerkt in Hoofdstuk 5. Zoals eerder aangehaald in 
Hoofdstuk 1, kan een DC-vaccin pas echt efficiënt zijn wanneer het antigen tegelijk met de 
nodige immuunadjuvantia aan de cellen wordt aangeleverd. Voor de mRNA-beladen 
microbubbels wordt dit mogelijk gemaakt door de bubbels te beladen met meerdere mRNA 
sequenties. Zo wordt enerzijds mRNA gebruikt dat codeert voor tumorantigenen, en anderzijds 
TriMix mRNA, een mRNA cocktail die de werking van de DC’s zal moduleren. Co-sonoporatie 
met deze vier mRNA’s resulteert in een aanvaardbare transfectie-efficiëntie en een matig 
maturatie-effect. Wanneer de gesonoporeerde DC’s als vaccin worden geïnjecteerd, 
veroorzaakt dit een duidelijke proliferatie van antigen specifieke T-cellen, wat leidt tot specifieke 
vernietiging van antigen-expresserende doelwitcellen. Nog belangrijker is het effect in een 
178 | S a m e n v a t t i n g ,  b e s l u i t  &  t o e k o m s t p e r s p e c t i e v e n  
therapeutisch kader. Wanneer tumordragende muizen worden gevaccineerd met 
gesonoporeerde DC’s, stellen we een significante vertraging van de tumorgroei vast wanneer 
werd gesonoporeerd met antigen mRNA. Wanneer tegelijk gesonoporeerd werd met antigen 
en TriMix mRNA, is dit effect nog meer uitgesproken. In deze laatste groep resulteert dit zelfs 
in volledige tumorregressie en langdurig antigen specifiek immunologisch geheugen in 30% 
van de gevaccineerde dieren. Deze resultaten leveren bewijs van het potentieel van mRNA 
sonoporatie voor immunotherapie, in het bijzonder wanneer het wordt gebruikt om tegelijk 
antigen mRNA en immuunstimulerend mRNA af te leveren.  
Bovenstaande resultaten tonen dat DC-modulatie m.b.v. microbubbels als immuno-
theranostica aanleiding geeft tot sterk immunogene cellen in vitro. Het grote voordeel van deze 
mRNA-beladen microbubbels ligt echter in de mogelijkheid om het antigen en 
immuunstimulerend mRNA rechtstreeks in te brengen in DC’s in vivo. De locatie bij uitstek waar 
dit zou moeten gebeuren, is in het lymfeklierweefsel. Hier zijn namelijk grote aantallen DC’s 
aanwezig en dit zijn tevens de anatomische regio’s waar antigenpresentatie aan T-cellen zich 
voordoet. Daarom wordt in Hoofdstuk 6 een studie uitgevoerd om na te gaan of mRNA-
beladen microbubbels tot in de lymfeknopen geraken na subcutane injectie in honden. Op 
contrast-echografie kan amper 1 minuut na injectie al een groot aantal mRNA-beladen 
microbubbels gedetecteerd worden in de lymfeknopen. Het contrastsignaal van de 
microbubbels levert tegelijk gedetailleerde informatie over de anatomie van het lymfesysteem, 
wat van belang kan zijn voor verdere in vivo sonoporatie-experimenten.  
ALGEMENE BESLUITEN 
De resultaten die in dit doctoraal onderzoek werden behaald wijzen er op dat theranostics 
effectief kunnen gebruikt worden voor kankerimmunotherapie. Ze kunnen dus de status krijgen 
van immunotheranostics. Er werden twee verschillende biomaterialen ontwikkeld die antigenen 
kunnen afleveren aan DC’s in vitro. De techniek op basis van microbubbels maakt het 
bovendien mogelijk om tegelijk antigen en immuunstimulerend mRNA af te leveren, wat 
duidelijk een positief therapeutisch effect heeft in tumordragende muizen. Een laatste en erg 
belangrijke vaststelling is dat de mRNA-beladen microbubbels de lymfeknopen kunnen 
bereiken in grotere proefdieren. Dit brengt ze naar de optimale anatomische regio voor 
immunotherapie. Daarenboven leveren de gedetailleerde beelden van de contrast 
echografieën extra bewijs van het mogelijk belang van mRNA-beladen microbubbels als 
immunotheranostica.  
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TOEKOMSTPERSPECTIEVEN 
Betekent dit dat we de oplossing gevonden hebben? Helaas niet… Dit zijn slechts de 
eerste stappen in een lange zoektocht naar een mogelijk interessant immuno-therapeuticum. 
De resultaten in deze thesis vragen zeker om verder en meer diepgaand onderzoek. Een eerste 
belangrijke punt hierbij is dat de resultaten die we hier konden voorleggen, werden behaald na 
het in vitro sonoporeren van de DC’s. We moeten dus nog steeds onderzoeken hoe we dit 
kunnen vertalen naar een in vivo setting. Zonder twijfel wordt het optimaliseren van de 
ultrasoundparameters om de microbubbels te imploderen en zo het mRNA af te leveren aan 
intranodale DCs in vivo, een van de belangrijkste uitdagingen in dit verder onderzoek.  
Een belangrijke stoorzender in elke vorm van immunotherapie is immuun-onderdrukking. 
Immunotherapie eindigt namelijk niet bij het opwekken van een antitumor T-cel respons. 
Integendeel, er zijn steeds meer aanwijzingen van het ontstaan van een immunosuppressieve 
en tumor bevorderende micro-omgeving binnenin het tumorweefsel. Deze herbergt een grote 
diversiteit aan onderdrukkende immuuncellen (bijv. regulatoire T-cellen en myeloid-derived 
suppressor cellen) die de tumor helpen te ontkomen aan vernietiging door het immuunsysteem 
en die effector antitumor immuuncellen lamleggen t.h.v. de tumor. Dus zelfs wanneer 
intelligente antigen- en adjuvant-afgiftesystemen ontwikkeld worden die een sterke activering 
van antitumor T-cellen induceren, zal een groot deel van deze cellen naar alle waarschijnlijkheid 
vastgehouden worden in de tumor micro-omgeving zonder dat ze hun tumor dodende functie 
kunnen uitoefenen. Het zoeken naar manieren om deze tumor gemedieerde 
immuunsuppressie tegen te gaan, wordt zeker een belangrijk onderzoeksonderwerp in de 
toekomst.  
Ten slotte kunnen we met zekerheid stellen dat er toekomst zit in combinatietherapie. Bij 
vaak toegepaste kankerbehandelingen zoals chemotherapie en hitte-ablatie, werd al 
aangetoond dat ze immunogene celdood veroorzaken. Tijdens dit proces worden 
tumorantigenen en bijkomende immuunstimulerende signalen (zoals danger-associated 
molecular patterns, DAMP’s) vrijgesteld vanuit de stervende tumorcellen. Deze zorgen op hun 
beurt voor de aantrekking en activering van DC’s. Zo zal het induceren van immunogene 
celdood de tumorcellen als het ware omvormen tot een auto-vaccin. Door deze 
standaardbehandelingen te combineren met een extra stimulatie van het immuunsysteem via 
immunotherapie, zou het mogelijk kunnen worden de tumor tegelijk vanuit verschillende hoeken 
aan te vallen.  
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Appendix A 
 
Report on experiments performed at 
the University of Virginia (UVa): 
 
The potential of doxorubicin-loaded 
microbubbles for ultrasound-guided, 
ultrasound-triggered tumor treatment  
in vivo 
 
 
 
 
 
 
 
 
These experiments were performed at the Lab of Prof.dr. Alexander Klibanov, during a 1 month 
research visit (June 2011) to the University of Virginia (UVa), Charlottesville, Virginia, USA.   
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ABSTRACT  
Theranostic microbubbles have previously shown potential for various applications. 
Recently, a formulation where liposome-loaded microbubbles were produced through a self-
assembly process was developed. In this study we aimed to evaluate this formulation in vivo. 
Experiments performed in tumor-bearing mice indicate that these doxorubicin (DOX)-liposome 
loaded microbubbles can be used to obtain detailed information on the tumor perfusion by 
contrast-enhanced ultrasound imaging. Moreover, when therapeutic ultrasound was applied to 
locally burst the microbubbles and allow enhanced DOX delivery, a trend towards a reduction 
in tumor outgrowth was observed. Although further research is warranted to fully assess the 
theranostic features of this microbubble formulation, these experiments already provide a first 
indication of their potential in vivo.  
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INTRODUCTION 
In 2011, a strategy for the production of self-assembled liposome-loaded microbubbles 
was developed in our group1. The formulation, as shown in Figure 1 makes use of maleimide-
containing liposomes that are added to a microbubble precursor solution. The latter consists of 
the basic lipid component of the microbubbles, DPPC, and DSPE-PEG-SPDP, a lipid that is 
equipped with a PDP moiety via a polyethylene glycol (PEG) spacer. When this resulting 
solution is mixed in the presence of perfluorobutane gas, liposome-loaded microbubbles are 
formed. Such an in vial formulation abrogates the washing steps that are needed for avidin-
biotin linking of liposomes to microbubbles. As a result, this type of formulations could be an 
important step forward in bringing drug-loaded microbubbles from bench to bedside.  
 
Figure 1. Schematic representation of self-assembly liposome-loaded 
microbubbles.  
(A) Doxorubicin (DOX)-loaded maleimide-liposomes were added to a solution of 
microbubble lipids that contain DSPE-PEG-SPDP. The vial’s headspace was filled with 
perfluorobutane gas. (B) By mechanical agitation, lipid-coated microbubbles are formed, 
that are loaded with DOX-loaded liposomes as schematically depicted in (C). In (D), the 
chemical reaction between the maleimide on the liposomes and the PDP on the 
microbubbles is clarified. Image adjusted from Geers et al.1 
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After extensive in vitro characterization of the microbubbles, the aim of these experiments 
was to evaluate the potential of this new liposome-loaded microbubble formulation in vivo. More 
specifically, we prepared microbubbles loaded with doxorubicin (DOX)-containing liposomes, 
and tested whether intravenous injection of these microbubbles, followed by local ultrasound 
application at the site of the tumor, could result in enhanced antitumor effects. For this, we 
collaborated with Prof.dr. Alexander Klibanov at the University of Virginia (UVa, Charlottesville, 
Virginia, USA), who has extensive experience with the in vivo application of ultrasound-assisted 
microbubble therapeutics2-4.  
MATERIALS AND METHODS 
Doxorubicin containing liposomes 
Liposomes were loaded with DOX via an active loading system, as previously described 
by Haran and colleagues5. Briefly, liposomes were prepared via the proliposome technique6, 
by first dissolving DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids, 
Alabaster, AL, USA), Cholesterol (Sigma, St. Louis, MO) and DSPE-PEG3400-maleimide 
(Shearwater, Mill Creek, WA, USA) in a 50:35:15 molar ratio in absolute ethanol (at 60°C). 
Then, ammonium citrate (0.5 M, at 60°C) was added to obtain a weight ratio 100:80:200 of 
lipids:EtOH:ammonium citrate. The so formed pre-liposomes are rapidly diluted with pre-heated 
ammonium citrate while vortexing, resulting in a final lipid concentration of 16 mg ml-1. Then, 
the liposomes were sized via extrusion through a 200 nm polycarbonate filter, and 
unencapsulated ammonium citrate was removed in three washing steps. Active loading of DOX 
into the liposomes was performed by adding DOX (10 mg ml-1 in saline, Bedford LaboratoriesTM, 
Bedford, OH, USA), and allowing overnight loading at 60°C. Excess DOX was again removed 
in three washing steps. The resulting DOX-loaded liposomes were resuspended in saline and 
the final DOX concentration was measured via absorbance spectroscopy.  
Liposome-loaded microbubbles 
Microbubbles were prepared starting from a solution of a mixture of 65 mol.% DPPC (1,2-
dipalmitoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and 35 mol.% DSPE-PEG2000-
SPDP (Avanti Polar lipids) in a 1:2:7 glycerol-propyleneglycol-H2O solvent. For this, appropriate 
aliquots of both lipids, dissolved in CHCl3, were transferred to a round-bottom flask. After CHCl3 
evaporation, the lipid film was dissolved in a 1:2:7 glycerol-propyleneglycol-H2O mixture to 
obtain a clear solution with a final lipid concentration of 2x10-4 mmol ml-1. 500 µl aliquots of this 
lipid solution were transferred to 2.5 ml chromatography vials, the headspace of which was 
filled with C4F10 gas (F2 chemicals, Lancashire UK). Then, TCEP (Tris(2-
carboxyethyl)phosphine hydrochloride, a thiol-free reducing agent) and DOX-liposomes 
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(corresponding to 355 µg DOX) were added per vial. Finally, DOX-liposome loaded 
microbubbles were obtained by high-frequency shaking of the lipid solution in a Vialmix™ 
device (Lantheus Medical Imaging, Billerica, MA, USA) during 15s. The concentration of the 
microbubbles in the dispersion were determined with a Beckman-coulter Multisizer 3 
(Beckman-coulter, Brea, CA). 
Cells and mice 
MC38 murine colon carcinoma cells were provided by Dr. J. Schlom (National Institute of 
Health), and maintained in DMEM with 10% Fetal Calf Serum, 1% Penicillin/Streptomycin and 
1% sodium pyruvate.  
All animal experiments were conducted in accordance with the animal guidelines of the 
Animal Care and Use Committee (ACUC) of the UVa. Female C57BL/6 mice (weight ~30 g) 
were anesthetized using isoflurane, and the hair of the left hind leg was removed using Nair 
shaving crème. After this, they were inoculated subcutaneously with 5x104 MC38 cells in the 
left hind leg. Treatment was started 5 days after tumor inoculation. Tumor growth was monitored 
at least every other day.  
Therapeutic regimen 
5 and 8 days after tumor inoculation, the mice received treatments with either DOX-
liposome loaded microbubbles and ultrasound or free DOX-loaded liposomes. For this, the mice 
were anesthetized using isoflurane and placed on a heating pad. Their tumor-bearing hind leg 
was placed over an absorbing rubber pad to avoid reflection of the ultrasound waves. The 
center of the tumor was marked as the starting point for ultrasound application. Mice receive a 
retro-orbital injection of 100 µl of either the in vial prepared DOX-liposome loaded microbubbles, 
washed DOX-liposome loaded microbubbles (to remove unattached DOX-liposomes) or free 
DOX-liposomes (without bubbles). Then, ultrasound application and contrast-enhanced 
ultrasound imaging (CEUS) were performed as depicted in Figure 2.  
Briefly, the rushing in and ultrasound-triggered destruction of DOX-loaded microbubbles 
was visualized using an Acuson Sequoia clinical scanner (Siemens medical solutions, Malvern, 
PA, USA) equipped with a 15L8-S (linear array transducer, 15-8 MHz operating frequency) in 
cadence pulsed sequencing (CPS) mode (Figure 2B). All images were recorded at a frequency 
of 14 MHz at low mechanical index (MI=0.19). Under US imaging, higher intensity ultrasound 
pulses were given to locally burst the microbubbles within the tumor, using a therapy and 
imaging probe system (TIPS, Philips Research, Briarcliff, NY, USA), which has a focused 
transducer consisting of an eight element linear array (Figure 2C)7. Pulses of 10,000 cycles 
were given at a frequency of 1.2 MHz, a wave amplitude of 2 MPa (corresponding to a MI=1.8) 
186 | A p p e n d i x  A  
and at a pulse repetition frequency (PRF) of 10 Hz. During ultrasound application, the TIPS 
scanned over the tumor area, following 8 coordinates that form a square spiral of 6x6 mm, for 
a total of 13 loops (Figure 2D). The duration of one loop was about 15s, followed by a 10s 
period where the ultrasound was switched off to allow replenishment of the tumor vasculature 
with microbubbles.  
 
Figure 2. Experimental set-up.  
(A) Photograph of the experimental set-up where the mouse is positioned on a heating 
pad, with the tumor-bearing hind leg placed on an absorbing rubber. The tumor is imaged 
in CEUS mode via an imaging probe connected to an Acuson Sequoia scanner (B). 
Simultaneously, higher intensity therapeutic ultrasound is applied using a TIPS therapy 
probe as shown in (C). Therapeutic ultrasound was applied at 8 different points over the 
tumor area. The treatment scan plan is depicted in (D). Image (C) was reproduced from 
Seip et al.7 
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After two days of treatment (at day 5 and day 8 after tumor inoculation), tumor growth 
was followed as a function of time. Animals were euthanized when tumor volumes reached 
1500 mm³ or when humane end-points were reached.  
RESULTS 
Preparation and characterization of DOX-liposome loaded microbubbles 
After preparation of the DOX-liposomes, as described in the materials and methods 
section, the DOX content was measured via absorbance spectroscopy. This revealed a DOX 
encapsulation of 0.71 mg DOX per ml liposomes. These liposomes were added to a 
microbubble-precursor solution in order to prepare liposome-loaded microbubbles. The 
resulting DOX-LPS loaded microbubbles were allowed to float for 1min to remove the fraction 
of larger microbubbles in the vial. If needed, washing steps were performed to remove unbound 
DOX-liposomes. An overview of the DOX and microbubble concentrations that were 
administered this way, is provided in Table 1. 
Table 1. Overview of DOX and microbubbles doses for injection.  
Days after tumor 
inoculation 
In vial formulation Washed microbubbles Free DOX-liposomes 
5 
82 µg DOX 18.9 µg DOX 82 µg DOX 
3.9x106 bubbles 8x106 bubbles No microbubbles 
8 
86 µg DOX 21 µg DOX 86 µg DOX 
8.6x108 bubbles 5.37x108 bubbles No microbubbles 
 
CEUS imaging during tumor treatment 
The theranostic DOX-liposome loaded microbubbles were imaged prior and during 
ultrasound treatment via CEUS. B-mode images recorded prior to microbubble injection show 
the outline of the tumor, and the presence of a region where the echogenicity is lower. When 
switching to the CPS CEUS mode, only reflections at the skin surface are visible. Rapidly after 
retro-orbital injection of the DOX-liposome loaded microbubbles, their rushing in at the tumor 
site was detected. Here too, a dark region where no microbubble contrast appears is observed, 
at the same anatomical location as in the previous B-mode images. Likely, this poorly 
vascularized region is a necrotic core within the tumor volume. 1min after microbubble injection, 
the therapeutic ultrasound was applied, which resulted in immediate and complete destruction 
of the microbubbles within the tumor. After one full round of ultrasound expose, partial 
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replenishment of the tumor volume with microbubbles could be observed during the 10s delay 
period. However, due to the relatively low concentrations of microbubbles used in these 
experiments, this only occurred until after the second therapeutic ultrasound application. After 
this, no further replenishment could be detected in the CEUS images. An example of ultrasound 
B-mode and CEUS images that could be obtained during animal treatment, is provided in 
Figure 3. Notably, due to the lower microbubble concentrations in the washed microbubble 
preparations, a less intense CEUS signal was received from the intratumoral washed 
microbubbles.  
 
Figure 3. Ultrasound imaging of the DOX-liposome loaded microbubbles.  
Prior to injection with DOX-liposome loaded microbubbles, the tumor was imaged with in 
B-mode (A) and CPS mode (B). Microbubbles were injected during imaging, and one 
maximal tumor enhancement was reached (C), the therapy probe was used to burst the 
bubbles at the tumor site. As a result, the non-linear echoes derived from the DOX-
liposome loaded microbubble contrast agents disappeared, as shown in (D).  
Effect of DOX-liposome loaded microbubble treatment on tumor growth 
To assess the therapeutic potential of DOX-liposome loaded microbubbles, different 
treatment groups were compared. Firstly, we made a comparison between groups that received 
DOX-liposome loaded microbubble formulations where the excess free DOX-liposomes were 
washed away, either with or without ultrasound application. As shown in Figure 4A, the delivery 
of these washed formulations results in a reduction in tumor growth compared to control. 
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Additional application of ultrasound to enhance local DOX delivery at the tumor site resulted in 
a more pronounced slowdown of tumor outgrowth. However, none of the differences observed 
were statistically significant, which is likely the result of the low dosage of DOX that could be 
delivered in this way.  
 
Figure 4. Therapeutic effect of DOX-liposome loaded microbubbles and ultrasound 
application.  
The antitumor effects of washed and unwashed (in vial) formulations of DOX-liposome 
loaded microbubbles were compared in the presence or absence of ultrasound 
application. (A) provides a graphical representation of tumor growth as a function of time 
for animals treated with washed DOX-liposome loaded microbubbles with or without 
ultrasound application. In (B), the tumor growth for the in vial, unwashed DOX-liposome 
loaded microbubble formulation with therapeutic ultrasound is shown compared to an 
equal dose of free DOX-liposomes (without microbubbles). Untreated tumor-bearing 
animals served as controls. Results are shown as mean ± standard error mean.  
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When microbubbles were injected straight from the vial, without additional washing steps, 
there is still a fraction of free DOX-liposomes present. Therefore, we compared the effects of 
the delivery of equal doses of DOX, either via DOX-liposome loaded microbubbles and 
ultrasound or via free DOX-liposomes (without microbubbles or ultrasound). As shown in 
Figure 4B, delivery of a DOX dose of ~2.7 mg kg-1 body weight packaged in liposomes, did not 
result in an improved outcome when compared to untreated mice. However, when an equal 
dose of DOX was delivered via DOX-liposome loaded microbubbles and ultrasound, a slight 
reduction in tumor growth could be observed. Although the DOX doses that were delivered with 
the in vial formulation were about four times higher than in the experiments with the washed 
microbubbles, the observed differences were not statistically significant.  
DISCUSSION & CONCLUSIONS 
In the described experiments, we were able to show that theranostic DOX-liposome 
loaded microbubbles could indeed be detected intratumorally by means of CEUS imaging after 
intravenous injection. However, there are a number of limitations that need to be reported with 
respect to this study, that make it difficult to interpret the therapeutic effects of the different 
formulations.  
Firstly, the first aim of this research visit was to inject DOX-liposome loaded microbubble 
formulations that were prepared in Ghent. This would allow optimal comparison to previously 
obtained in vitro results. However, transportation from Ghent to the USA clearly affected the 
quality of the microbubble preparations, resulting in a significantly lower microbubble 
concentration, and substantial leakage of DOX from the liposomes. This prompted the in situ 
preparation of new samples at UVa, where not all the materials and instruments were present 
to prepare these samples in optimal conditions. This resulted in lower DOX-encapsulation 
efficiencies in comparison to the formulations prepared in Ghent, as well as in substantially 
reduced microbubble quality (lower concentrations and a relatively larger size distribution). This 
way, the DOX doses were 10 times lower (for the washed microbubble formulations) and about 
4 times lower (for the in vial formulation) than the 10 mg kg-1 doses that are normally required 
for effective treatment8. Although intratumoral DOX delivery via microbubbles and ultrasound 
triggering could be more efficient in comparison to intravenous injection of free DOX, the ability 
to deliver higher doses of DOX at the tumor site would surely augment the therapeutic effects.  
Secondly, the time we had to perform these experiments was limited, and it only allowed 
us to perform two experiments in tumor-bearing mice. Due to sample instability during the first 
experiment, we could not combine the results of multiple experiments to enlarge the overall 
sample number and increase statistical power.  
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Overall, these experiments do point towards improved delivery of the chemotherapeutic DOX 
by attaching DOX-loaded liposomes to microbubbles and locally applying therapeutic 
ultrasound. However, to fully assess their potential as theranostics in cancer treatment, further 
experiments are necessary.  
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“In this world, there are things you can only do alone,  
and things you can only do with somebody else.  
It's important to combine the two in just the right amount.”  
Haruki Murakami, After Dark 
 
 
Als ik één iets met 100% zekerheid kan zeggen op het einde van deze 4 jaar, is het wel 
dat een doctoraat één van de dingen is die enkel maar in dichte samenwerking met andere 
mensen tot stand kunnen komen. En ik heb geluk gehad: de lijst met “te bedanken mensen” is 
lang. 
Stefaan, als student was ik al onder de indruk van je begeesterde manier van lesgeven, 
waarbij je ons meetrok in je enthousiasme en continue verbazing over hoe alles ineen zit, en je 
ons leerde om alles in vraag te stellen en steeds kritisch na te denken. Net diezelfde manier 
van werken maakt je zo’n goeie promotor. Na elke Mondaymeeting (die overigens maar zelden 
echt op een maandag plaatsvond) had ik weer stof om over na te denken, soms 
wetenschappelijk, soms eerder filosofisch. Ik herinner me nog een moment in mijn eerste jaar, 
toen ik bubbels aan het maken was in het lab. Je kwam bij me staan, nam mijn vialtje bubbels 
over, hield dat tegen het licht en zei: “Als je er eens bij stil staat hoe lang het duurt om zo’n 
kleine microbubbel te karakteriseren, probeer je dan maar eens voor te stellen hoe lang het 
zou duren om de hele wereld te karakteriseren”. En inderdaad... Het mysterie van de bubbels 
is nog niet helemaal opgehelderd, en toegegeven, ook de wereld snap ik nog niet helemaal, 
maar ik ben er wel mee bezig…  
Karine, in je rol als hoofdondervrager op mijn IWT-verdediging was onze eerste 
ontmoeting er eentje van stress en angstzweet. Enkele maanden later kruisten onze wegen 
nog eens: na weken vruchteloos wachten op een recombinante T cel lijn waren we bij jullie 
gaan aankloppen. We kregen niet alleen de cellen, maar meteen ook een berg advies, en de 
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mogelijkheid om een in vivo assay bij jullie te komen doen. Al snel werd dat ene assay een hele 
reeks experimenten en zaten we tijdens incubatietijden te koffiekletsen, of gingen we na een 
lange dag in het lab iets eten (en drinken, uiteraard) in de Bibitor. In alle labs die ik intussen 
heb gezien, zie je maar zelden een prof nog hands-on dirty labwork doen, maar jij slaagde er 
altijd in tijd vrij te maken om samen miltjes te pletten, muizen te injecteren en FACS analyses 
te doen. Ik ben je enorm dankbaar voor alles wat je me hebt geleerd, je onuitputtelijke 
enthousiasme en wetenschappelijke kennis, de snelle en vrolijke e-mails met antwoorden op 
al mijn vragen, alle weekendwerk om tumoren te gaan opmeten, alle leuke momenten en 
gezellige babbels aan de VUB en op congres, en alle kansen die ik dankzij jou heb gekregen. 
Ik ben dan ook niet minder dan vereerd dat je bereid was om naast Stefaan ook mijn promotor 
te worden. Bedankt! 
Ine, je was al mijn mentor tijdens mijn thesis en je passie voor bubbels is extreem 
besmettelijk. Je gaf me toen al de vrijheid om mijn project zelf in handen te nemen en al snel 
was er geen ontsnappen aan de bubblebug (de goeie variant, gelukkig). Je creativiteit in het 
bedenken van projecten en experimenten, en het vinden van niet-alledaagse oplossingen voor 
al even weinig alledaagse problemen is indrukwekkend. Je was er altijd om me advies te geven, 
knopen door te hakken, me op te peppen als dat nodig was, nieuwe contacten te leggen, of om 
leuke momenten te beleven op congres: celebrities spotten op Broadway, stoffenwinkels 
plunderen (tot grote ergernis van Bart en Roel die ongeduldig buiten stonden te wachten), 
gedeelde hotelkamers met een glazen badkamerdeur (blij dat je braaf aan de veilige kant van 
de kamer bleef)… Die ene keer bij je presentatie in Egmond aan Zee toen je hoogzwanger was 
van Janne en Stefaan al ongerust op zijn stoel aan het schuiven was in ’t geval je hulp nodig 
zou hebben, sloeg iemand de nagel op de kop toen ze je een “heroic woman” noemde, want 
dat ben je, geen twijfel mogelijk. Ook op persoonlijk vlak zorgde die creatieve geest voor 
vonken. Onze gemeenschappelijke interesses in naaien, patronen tekenen, laser cutten en 3D-
printen zorgden dat je al snel veel meer werd dan “zomaar” co-promotor. Bedankt voor de raad, 
de motivatie, de rondvliegende muizenpootjes, je eeuwige enthousiasme, de verhuishulp, de 
gezellige patroontekenavonden (in de les en nadien op café of bij jou thuis) en de inspiratie. Ik 
kan niet anders zeggen dan dat ik met mijn gat in de boter ben gevallen met een begeleider/co-
promotor/mentor/vriendin als jij. Merci! 
Ook de andere professoren in het lab in Gent, Jo, Kevin en Katrien zou ik graag 
bedanken voor de steun en raad, voor de wetenschappelijke input en voor het creëren van een 
lab waar ik zo veel ondersteuning en kansen heb gekregen.  
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Voor zij die het nog niet zouden weten: Labo Biochemie rules! Er zijn niet alleen de 
creatieve lunchpauzes (op een dag komen daar patenten uit voort, mark my words), cel lab 
meezingmomenten of helpende handen links en rechts, maar ook de (foute) lab party’s en 
bijhorende verkleedsessies, lab weekendjes, uitstapjes, after-work feestjes en Fun on Friday 
die zorgden dat deze periode in het lab onvergetelijk is.  
In elk lab zit één iemand op wie iedereen kan rekenen, die – soms zelfs in het bezit is van 
een Fiat multipla, maar dan moet je al érg veel geluk hebben – een draaiende kracht is binnen 
een lab en die voor al je kleine of grote, praktische of onnozele problemen altijd wel een 
oplossing vindt. Bart, je was altijd al een redder in nood, in het lab en daarbuiten. Bedankt voor 
de multi-multipla-verhuis samen met Ine, de pootjesleveringen, de vaste 3 Lousbergs en een 
portie kaas op maandagavond, de vers-van-de-kip eitjes, de tips, goeie raad en vooral om je 
eeuwige en geduldige bereidheid om mij en alle andere mensen in het lab altijd met de glimlach 
te helpen.  
Ook jullie, Katharine en Ilse, zijn mee verantwoordelijk voor het logistiek en administratief 
smooth sailing tijdens mijn doctoraat. Bedankt voor alle hulp, het scheppen van orde in de 
chaos en voor de gezellige babbels over reizen en andere leuke dingen.  
Werken in een bureau waar je elke dag opgevrolijkt wordt door 3 fantastische vrouwen 
met wie je alles – soms zelfs té veel – kan delen, ervaringen kan uitwisselen (over wetenschap 
en andere dingen), kan discussiëren maar vooral veel stoom kan aflaten en onnozel mee kan 
doen, maakte van dit doctoraat een fantastische ervaring. Lynn, jij zat al in de bureau toen die 
nog bevolkt werd door dinosaurussen uit een ver vervlogen tijd. Je had altijd wel wat 
“spetterende” verhalen of gekke trucjes klaar, bent verantwoordelijk voor het introduceren van 
een aantal niet mis te verstane gebaren, was mijn melige partner in crime (“Zeg dat je niet hoeft 
te gaan schat. Nee, nee nee!”) en doet er altijd nog nét dat schepje bovenop. Op onze eerste 
werkuitstap samen kochten we uit pure miserie in Dessel (want noch daar, noch in Mol was 
een open frietkot te vinden) een slaatje en een zak chips in de Delhaize als avondeten. Gelukkig 
was er “thuis” om de zeden te verzachten… Laura, bedankt voor de etentjes na een lange dag 
experimenteren in het lab, voor de Moulin Rouge zangstonde in de straten van Versailles, de 
überdeskundige hulp met de T cellen, je vrolijkheid, je fantastische verkleed-outfits en collectie 
pruiken, en het aanzetten tot office-planking. Joke, de nieuwe en volledig door Ine DC 
democratisch verkozen vice-CPO, je bent een enorme aanwinst voor het lab én voor de bureau. 
Sfeer gegarandeerd! Sangram, I wish you all the best in your work and life. It must be a little 
tough to be the only man in an office filled with women, but hang on in there! 
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Ine, samen met “grote Ine” staan we intussen op het jaarlijkse ultrasoundcongres in 
Rotterdam gekend als “The girls from Ghent”, en je bent een fantastische bubbelcollega! 
Jammer dat ik nog niet de eer gehad heb om door jou “kaasgunstig” verklaard te worden, maar 
wat niet is, kan natuurlijk nog komen…  
Rein(tje), dankzij jouw sappig accent merkt niemand nog dat ik stiekem ook uit Brugge 
afkomstig ben. Je was al een crème van een thesisstudent, maar nu ook nog een fantastische 
collega, bierconnaisseur en opschenker van 70-jarige ex-playboybunny’s met blauw haar. 
Kunnen samenwerken met iemand als jij is pure luxe. 
Karen, Sosuke, je enthousiasme is grenzeloos, of het nu over octopi, whaaaalllles, 
hemelkijkers, koeienogen of autofagie gaat. Je dansmoves zijn té groovy voor woorden, je bent 
keistrak in je gouden morphsuit, je bent – dat geef ik grif toe – mijn meerdere in CTR en met 
jou en de Patron nieuwe bands spotten op pukkelpop is gewoon de max. Voor eens en voor 
altijd en speciaal voor jou: Totoro Sosuke suki!!!  
Freya, je bent een superonesie, de ideale persoon om mee in een doos te kruipen of om 
samen een GSM mee te zoeken in de struiken, een dansmirakel en de indrukwekkendste Mega 
Mindy die ik ken!  
Stephan, de experimenten die ik samen met jou gedaan hebben waren ongetwijfeld bij 
de plezantste die ik al gedaan heb (flow cytometrie was nog nooit zo plezant). Het feit dat je 
voor mij onlosmakelijk verbonden bent met een combinatie van kriek, wc-papier en de 
bijhorende dansmoves (met inbegrip van je overtuigende Harlem Shake interpretatie), kan daar 
natuurlijk ook wel voor iets tussen zitten.  
Koen, met jou als Chief Party Officer is er nogal wat afgefeest binnen het lab. Afhankelijk 
van de situatie was je Zorro, schuurtalent Geordie, een topatleet, grote broer of zomaar een 
marginaal met nekmat en en/of movembermoustache.  
Thomas en Katrien, jullie worden gemist… En hard… Bedankt voor de fotosessies en 
fotoshops (sommige staan voor eeuwig in mijn geheugen gegrift), het delen van gênante 
mascaramomenten, het niet zomaar opgeven toen we niet in de laserkaraoke binnen mochten, 
en alle hulp en tips over “how to defend your PhD”, ik had me geen betere adviseurs kunnen 
wensen. Het moet gezegd: You are The Hague.  
Koen, Lotte, Eline, Elisa, Oliwia, Hua, George, Rita, Bart G, Broes, Dries, bedankt 
voor: de schuine mopjes, de droge mopjes, de naturelle radioreclamestem, baking chips in the 
oven like a cake, je kletterende lach, being our very own biochemistry lab version of Psy, 
elucidating the liposome-mysteries, being a splendid & fun office-buddy, de korte en lange-
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afstandshulp bij het bubbelen, het blijven organiseren van de traditionele burger & movie 
avonden, en de immer toevallige ontmoetingen op de gekste plaatsen.  
I’ve been lucky to have a great number of collaborators in other universities in Belgium 
and beyond who’ve helped me with experiments, gave me the opportunity to expand my view 
and to get acquainted with new assays and techniques, or who’ve brightened up the evenings 
at conferences (Leeds, Rotterdam…). Prof.dr. Uwe Himmelreich, Prof.dr. Sasha Klibanov, 
Prof.dr. Katrien Vanderperren, Roos, Sandra, Cleo, Emmelie, Hendrik, Sunil, Tim, Tom, 
Guillaume, Ying, Verya, Ilya, and many, many more… Thanks!! 
Zonder de steun van vrienden en familie, was dit boekje er wellicht nooit gekomen. Ik kon 
altijd op jullie rekenen, jullie waren altijd te vinden voor goeie raad, hulp, een gezellige avond 
na een lange dag, het maken van een fantastische illustratie bij dit boekje, of overheerlijk 
comfort food. Mama en papa, ik kan jullie niet genoeg bedanken voor alle kansen die ik van 
jullie gekregen heb. Jullie interesse en trots was altijd een enorme motivatie tijdens mijn studies 
en gedurende de afgelopen vier jaar. Jullie gaven me de mooiste cadeaus die ik ooit had 
kunnen krijgen: een warm, creatief, avontuurlijk nest, aangeboren nieuwsgierigheid, een passie 
voor reizen en een gezonde dosis relativeringsvermogen. Bedankt voor alles.  
“Luck is what happens to you when fate gets tired of waiting”. En er is een goeie dosis 
geluk nodig geweest om jou eerst op de trein en daarna op de reismarkt in Brugge tegen het 
lijf te lopen. Bart, ik wist meteen al dat ik met jou mijn avonturier gevonden had, en ik had gelijk. 
Elke dag weer verras je me, vul je me perfect aan, breng je het beste in mij naar boven en 
maak je van mij het gelukkigste kieken ter wereld. Bedankt om de platen op te leggen waarvan 
je weet dat ik er gelukkig van word, bedankt om met me te dansen in de keuken en te zingen 
op de fiets, bedankt voor de fantastische reis in Myanmar, het vrolijk mingulaba’en en de liefde 
in tijden van Dengue, bedankt om me mijn chaos te gunnen en me tegelijk ook een beetje 
structuur te geven, bedankt om altijd jezelf te zijn, maar bovenal: bedankt om samen met mij 
nieuwe plannen te maken en te dromen. Ik zie je graag, Bart, en ik kijk al uit naar onze volgende 
avonturen samen…  
 
 
-Heleen- 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
  
